Western University

Scholarship@Western
Canadian Journal of Surgery

Digitized Special Collections

11-1-1988

Volume 31, issue 6
Canadian Medical Association

Follow this and additional works at: https://ir.lib.uwo.ca/cjs
Part of the Surgery Commons

Recommended Citation
Canadian Medical Association, "Volume 31, issue 6" (1988). Canadian Journal of Surgery. 190.
https://ir.lib.uwo.ca/cjs/190

This Book is brought to you for free and open access by the Digitized Special Collections at Scholarship@Western.
It has been accepted for inclusion in Canadian Journal of Surgery by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

The Canadian Journal of Surgery
Le journal canadien de chirurgie
Vol. 31, No. 6, November 1988 Novembre

• Soft-Tissue Sarcomas
• Peritoneovenous Shunts
• Incidental Appendectomy

Published by the Canadian Medical Association
Sponsored by the Royal College of Physicians and Surgeons of Canada

A logical first choice
for serious
polymicrobial
infections...

Dalacin C
Phosphate
Sterile Solution

(clindamycin phosphate)

Sustained effectiveness against:
• Bacteroides fragilis and other
anaerobes
...common pathogens in poly
microbial infections

• Staphylococcus aureus
...the most common organism in
post-op wound infections

A

to reduce the
threat o f
post-surgical
complications

* w

r-

For prescribing information see page 380

The Canadian Journal of Surgery
Le journal canadien de chirurgie
Vol. 31, No. 6, November 1988 Novembre
ISSN 0008-428X

QUILL ON SCALPEL

Diabetes and the Surgeon
D.M. Grace

377

SURGEONS’ UPDATE

Researchers Seek Improved Treatment for Patients Requiring Hip
Replacement; New Director of Training and Evaluation at Royal College;
CJS Coeditor Named 1988 Sims Travelling Professor; Ontario’s Health
Ministry Awards Annual Research Grants; Multiorgan Transplant Unit
Opens in Vancouver
L. Williamson

381

HOW I DO IT

Surgeon-Administered Local Anesthesia for Forefoot Surgery
A.A. Giachino

383

ROYAL COLLEGE SYMPOSIUM

Symposium on Current Perspectives in the Management of Soft-Tissue
Sarcoma. 1. Incidence, Investigations and Staging of Soft-Tissue Sarcoma
M.G. Rock

385

2. The Role of Chemotherapy in Multimodality Therapy
V.H.C. Bramwell

390

3. Limb-Sparing Management in Extremity Soft-Tissue Sarcomas in the
Adult: the Radiation Oncologist’s Viewpoint
B. O’Sullivan

397

4. Role of the Pathologist in the Management of Soft-Tissue Sarcomas
A.J. Worth

404

5. Definitive Surgical Management for Soft-Tissue Sarcomas
H.R. Shibata

407

Guidelines for the Surgical Management of Soft-Tissue Sarcoma. Report
of the Canadian Sarcoma Group
W.J. Temple, V. Bramwell, E. Eisenhauer, R.D.T. Jenkin, F. Langer,
A.J. Worth

410

Unusual Gastric Foreign Body: a Case Report
W.M. Kuzon, Jr., C.A. McFadyen, F.L. Moffat

413

ORIGINAL ARTICLES

VOL. 31. NO. 6 NOVEMBER 1988/CJS

375

U terin e L e io m y o sa rc o m a W ith Cardiac M eta sta ses

418

F . H o y , R . B o u c h e r , A . B ro d y

N o r m o g ly c e m ia A fte r Im p la n ta tio n o f P u rified I s le t C e lls in D o g s

421

G .L . W a r n o c k , M .S . C a tt r a l , R .V . R a jo t t e

O o p h o r o v e s ic u la r -C o lo n ic F istu la : a R are C o m p lica tio n o f C ro h n ’s

A

427

D ise a se

/■

S .D . G o ld b e r g , R .R . G r a y , K .I. C a d e s k y , R .L . M a c k e n z ie

F in e -N e e d le A s p ir a tio n B io p s y o f an I s le t C ell T u m o u r S im u la tin g

429

P a n crea tic C arcin om a
A .H . Z a le v , H .J . K a h n , W . H a n n a

R esid u a l H y p o th e r m ia in P a tie n ts R e c o v e r in g in th e I n te n s iv e Care U n it

434

F rom Cardiac S u r g e r y
<

D . M a re lli, R .C - J . C h i u , D .M . F le is z e r , R .A . B r o w n

C o m p lic a tio n s im m e d ia te s d e la r e s e c tio n tr a n su re tra le d e la p ro sta te:

438

e tu d e de 1 0 0 0 c a s c o n s e c u tifs
J-M . P a q u in , J - P . P e r r e a u l t , R . F a u c h e r , F . M a u f f e tte , L . V a l i q u e t t e ,
S . L a p o in te

A c u te P a n c o a s t’s S y n d r o m e C au sed by F u n g a l In fec tio n

44 1

F .M . S h a m ji, J .R . L e d u c , J . B o r m a n is , H .J . S a c h s

P e r ito n e o v e n o u s S h u n t s — D e v ic e s o f L ast R eso rt

444

*

K .E . S h e p h e r d , B .J . M ille r

I s In cid en ta l A p p e n d e c to m y a S afe P ractice?

448

A .J . V o itk , J .B . L o w r y

HISTORY OF SURGERY

D o c to r or M ister (th e C orrect A p p e lla tio n o f B r itish S u r g e o n s )

P.

452

E ib e l

N o tic e o f C h a n g e o f A d d r e s s /A v is de c h a n g e m e n t d ’a d r e sse

379

B o o k R ev iew s

382

S E S A P V Q u e stio n

396

B o o k s R eceiv ed

403

S E S A P V C ritiq ue

426

C o v er p ic tu r e

A d v e r tis e r s ’ Index

454

Nickels and magnets — a mass
swallowed deliberately to alleviate
epigastric discomfort (see page 413)

C la ssifie d A d v e r tisin g

454

\/w
<4 *

•« A

376

VOL. 31, NO. 6 NOVEMBER 1988/CJS

QUILL ON SCALPEL

This section provides a medium through which
Canadian surgeons can declare themselves,
briefly and informally, on the day-to-day affairs of surgery.

/

> ►

Diabetes and the Surgeon
D. Michael Grace, MD, FACS, FRCSC
Member, Editorial Board, Canadian Journal o f Surgery. Associate Professor o f Surgery,
University o f Western Ontario, University Hospital, London, Ont.
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n this issue (pages 421 to 426),
Warnock and colleagues describe
a technique of pancreatic islet isola
tion, purification and implantation
which can produce normoglycemia
in dogs for prolonged periods. This
work is important because it has
tens that day when successful islet
transplantation may be used to
fight the devastating long-term ef
fects of insulin-dependent diabetes
mellitus.
Diabetes mellitus of both types is
a common problem in both medical
and surgical patients. Efforts to
control blood sugar levels may com
plicate routine surgical procedures,
and infection or emergency opera
tion makes management of the dia

I

The Canadian Journal of S urgery
1867 Alta Vista Dr.
Ottawa, Ont. K1G 3Y6

betic even more difficult. Abdominal
pain may be difficult to assess in a
patient with ketoacidosis. Surgeons
may also be called to treat compli
cations of diabetes, such as foot
infection or ulceration resulting
from diabetic vascular disease or
neuropathy. In spite of aggressive
conservative treatment, diabetes
and its associated complications are
the most common cause of nontraumatic limb amputation. Diabetic
renal disease is now a common
cause of chronic renal failure. In
such patients, it is a challenge to
establish an arteriovenous fistula or
graft for hemodialysis because the
rate of atherosclerosis is accelerated
and the arterial wall is of poor
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Telex: 053-3152
Fax: (613) 731-9013
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vertising costs for advertis
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restricted by Section 19 of
the Canadian Income Tax
A c t'
"Advertisers who file Cana
dian tax returns can claim
the advertising costs of
this publication as a busi
ness expense "

quality. Renal transplantation car
ried out by surgeons for end-stage
renal failure in diabetes can present
a moral and technical dilemma. The
results are improving, but chronic
immunosuppression can further
complicate the management of a
“brittle” diabetic. Diabetes is also
the most common cause of blind
ness in Canada and ophthalmolo
gists must often treat retinal disease
and cataracts in diabetics. Non
insulin-dependent diabetes mellitus
occurs later in life but may produce
similar complications. The role of
gastroplasty in the treatment of
morbid obesity remains controver
sial, but there is no doubt that
substantial weight loss in obese

Coeditors

L.D. MacLEAN, Montreal, PQ
C.B. MUELLER, Hamilton, Ont.

C o nsu ltin g E d ito r

The Canadian Medical Association
President
I . O'BRIEN-BELL, MB, BS

D.D. CURRAN

Secretary General

Associate E d ito r

D ire cto r o f P ublications

LEO-PAUL LANDRY, MD

G. PANC1ROV

BARBARA DREW

E d ito ria l Assistant

A d ve rtisin g Sales Representative,
Canadian Jo urna l o f S urgery
McGOWN & ASSOCIATES INC.

L. WILLIAMSON

(514)735-5191
E d ito ria l Researchers

P ro du ction Manager

K. BEAUDOIN
M. McCART

KATHRYN A. FREAMO
Assistant P rodu ction M anager

NANCY POPE
E d ito ria l A dvisory Board

P.J.E. CRUSE, Calgary, Alta.
A.C.H. DURANCEAU, Montreal. PQ
G.A. FARROW, Toronto, Ont.
D.M. GRACE, London. Ont.
J.F. JARRELL, Hamilton, Ont.
R.G. KEITH, Toronto, Ont.
N. SCHMIDT. Vancouver, BC
N.M. SHEINER, Montreal, PQ
C. SORBIE, Kingston, Ont.
C.F.O. TYERS, Vancouver, BC
C.J. WRIGHT, Saskatoon, Sask.

Manager, Classified A d ve rtisin g

VIOLET SHAW
The Royal College of Physicians
and Surgeons of Canada
President

D.R. WILSON, MD, FRCSC
E xecutive D ire cto r

J.H. DARRAGH, MD, FRCPC

377

GRACE

diabetics corrects the condition and
may reduce the frequency and se
verity of subsequent problems.
The prevention of complications
in insulin-dependent diabetics re
mains insoluble in spite of world
wide research efforts. Genetic coun
selling may prevent some cases, and
better understanding of the immu
nologic causes of diabetes may help
to prevent the disease or result in
the early treatment of others. Rec
ognition of the autoimmune nature
of diabetes mellitus in rats led to
the demonstration that cyclosporine
could prevent the disease.1 Trials of
cyclosporine in insulin-dependent
diabetics have demonstrated that
the condition may be prevented or
severity reduced if cyclosporine is
started early.2 However, the number
of children who can be treated is
small and treatment is expensive.
Moreover, it remains to be proven
whether the complications are in
deed prevented. Cyclosporine car
ries its own set of complications,
including renal damage, which may
be nearly as serious as the ne
phropathy one is trying to prevent.
Tight control of blood sugar levels
by regular insulin injection or use
of insulin pumps has resulted in an
increased number of hypoglycemic
reactions but has not decreased the
retinopathy, nephropathy, neuropa
thy or peripheral vascular disease.
A national trial is attempting to
answer this question with certain
ty.3
To surgeons, transplantation of
the whole pancreas has usually
made more sense than it has to
endocrinologists. Our emphasis has
been on improved techniques, graft
survival and freedom from insulin
requirement when we should be
striving for normal metabolism and
freedom from diabetic complica
tions. We were also encouraged by
the success of other transplants.
Renal transplantation proved more
effective in humans than in animals,
378

it improved the quality of life and
saved money. Liver and heart trans
plants were dramatic, effective and
lifesaving. The technical problems
of pancreatic transplantation are no
more challenging than those of
renal transplantation, although
management of the pancreatic duct
has been controversial. When the
pancreatic duct was drained to the
peritoneal cavity, pancreatic ascites
resulted and gave way to enteric
anastomosis or occlusion of the
duct with polymers. Now drainage
of the duct to bladder has achieved
better results and has allowed clos
er monitoring of rejection by mea
surement of urinary amylase levels.
Surgeons familiar with the potential
for pancreatitis or pancreatic cysts,
abscesses or fistulas after pancreat
ic surgery have respect for this
organ and the potential complica
tions of transplantation. The results
in transplantation of the pancreas
have improved so that, currently, an
average of 50% of grafts are func
tioning after 1 year and most pa
tients survive.4 Between 1966 and
March 1988, 1394 pancreatic trans
plants were reported to the Pancre
as Transplant Registry at the Uni
versity of Minnesota.4 Results have
improved steadily due to better im
munosuppression and surgical tech
niques.
The questions that have not been
answered include the appropriate
indications for transplantation of
the pancreas, the timing of the
procedure and its effect on the
complications of diabetes. Trans
plantation of the pancreas early in
the course of diabetes in rats can
prevent nephropathy.5 Therefore,
pancreatic transplantation carried
out early in the course of human
diabetes makes sense; however, not
all diabetics have complications,
and the long-term risks of im
munosuppression and rejection are
substantial. It, therefore, makes
more sense to transplant the pan

creas in diabetics with renal failure
who receive a renal transplant and
are already on immunosuppression.
Simultaneous renal and pancreatic
transplantations appear not to harm
the kidney and may result in better
pancreatic survival.4 Unfortunately,
transplantation may not reverse dia
betic complications.67 It is not sur
prising that severe retinopathy,
neuropathy or nephropathy do not
improve with normoglycemia. Al
though pancreatic transplantation
should continue to be evaluated as
part of research protocols, it is
difficult to recommend its wide
spread use until immunosuppres
sion is free of side effects and it is
clear that the complications of dia
betes can be prevented or delayed.
Because many of the technical
complications of pancreatic trans
plantation are due to unnecessary
exocrine tissue, transplantation of
pancreatic islets has always been
more attractive. The dilemma is
that isolation techniques are espe
cially difficult in larger animals,
that prolonged function of trans
planted islets is poor and that islets
seem more susceptible to rejection
than whole pancreas. The best
route of injection has not been
established with certainty, although
portal injection via the umbilical
vein is easiest in humans. Vascular
complications in animals can be
prevented by islet transplantation,8
but islets appear not to function as
well or as long as whole pancreas,
even when rejection is not a factor.5
New techniques for decreasing pan
creatic islet immunogenicity include
prolonged culture at 24°C,9 use of
multiple donors10 and treatment of
islets with ultraviolet irradiation.11
Fetal islets from multiple donors
have been used in China with limit
ed success,12 but there are ethical
barriers to the use of such tech
niques in North America. Trans
plantation of islets encapsulated in
a membrane that prevents rejection
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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but allows diffusion of insulin is an
exciting technique developed in
Canada.13 This method has proven
effective in rodents, but fibrosis
around the capsules may limit its
long-term effectiveness in larger an
imals.
Isolation and purification of suffi
cient numbers of islets from one
donor to maintain blood sugar lev
els in a recipient increases the
chances of successful transplanta
tion in humans. This would be even
more likely if improved isolation
techniques could be combined with
methods to decrease islet immunogenicity. Unfortunately, destruction
of transplanted islets by autoim
mune reaction rather than rejection
is still a risk. Studies on the preven
tion of diabetes by immunosuppres
sion and on the relation between
control of diabetes and its complica
tions must continue. Canadian cen
tres should perform and closely
evaluate transplants of whole pan
creas and follow with interest the
results achieved around the world
and reported regularly by the Pan
creas Transplant Registry at the
University of Minnesota. However,
islet transplantation may be the best
hope for treating insulin-dependent
diabetes mellitus, so Canadian sur
geons must continue to follow and
contribute to this work.
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DS: Pancreas transplant registry results.
Diabetes (in press)
5. O rloff MJ, M acedo A, Macedo C, et al:
Comparison of whole pancreas and pan
creatic islet transplantation in control
ling nephropathy and metabolic disor
ders of diabetes. Ann Surg 1987; 206:
324-334
6. Ramsay RC, Goetz FC, S utherland DE,
et al: Progression of diabetic retinopathy
after pancreas transplantation for in
sulin-dependent diabetes mellitus. N
Engl J Med 1988; 318: 208-214
7. S olders G, W ilczek H, Gunnarsson R,
et al: Effects of combined pancreatic and
renal transplantation on diabetic neurop
athy: a two-year follow-up study. Lancet
1987; 2: 1232-1235
BN, W atkins E jr: Prevention of
vascular complications of diabetes by
pancreatic islet transplantation. Arch
Surg 1976; 111: 254-257

sal of diabetes in nude mice after trans
plantation of fresh and 7-day-cuitured
(24°C) human pancreatic islets. Trans
plantation 1988; 45: 994-996
10. Gotoh M, P orter J, K anai T, et al:
Multiple donor allotransplantation. A
new approach to pancreatic islet trans
plantation. Transplantation 1988; 45:
1008-1012
11. Hardy MA, Lau H, W eber C, et al:
Pancreatic islet transplantation. Induc
tion of graft acceptance by ultraviolet
irradiation of donor tissue. Ann Surg
1984; 200: 441-450

12. Hu YF, Z hang H, Z hang HD, et al:
Culture of human fetal pancreas and
islet transplantation in 24 patients with
type 1 diabetes mellitus. Chin Med J
1985; 98: 236-243

8. Gray

9. R icordi C, S charp DW, Lacy PE: Rever

13. O ’S hea GM, Goosen MF, S un AM: Pro
longed survival of transplanted islets of
Langerhans encapsulated in a biocom
patible membrane. Biochew Biophys
Acta 1984; 804: 133-136

NOTICE OF CHANGE OF ADDRESS/
AVIS DE CHANGEMENT D’ADRESSE
To ensure that you continue to receive the Canadian Journal o f Surgery
without interruption, please fill in this form before you move.
Avant de demenager, assurez-vous de recevoir sans interruption le Journal
canadien de chirurgie en completant le formulaire suivant.
Please print / en lettres moulees, svp
Name / n o m ................................................................................................................
Royal College member number / numero d’identite ............................................
Old address / ancienne adresse.................................................................................

References
New address / nouvelle adresse
1. Laupacis A, Stiller CR, Gardell C, et
al: Cyclosporin prevents diabetes in BB
Wistarrats. Lancet 1983; 1: 10-12
2. Bougneres PF, Carel JC, Castano L, et
al: Factors associated with early remis
sion of type I diabetes in children treat
ed with cyclosporine. N Engl J Med
1988; 318: 663-670
3. Are continuing studies of metabolic con
trol and microvascular complications in
insulin-dependent diabetes mellitus justi
fied? The Diabetes Control and Compli
cations Trial. Ibid: 246-250

VOL. 31, NO. 6 NO VEM BER 1988/CJS

Postal code / code postal...........................................................................................
Date ................................................................................................................................
Royal College fellows please mail to: Royal College of Physicians and
Surgeons of Canada, 74 Stanley Ave., Ottawa, Ont. KIM 1P4.
Membres du College royal, veuillez expedier a: College royal des medecins et
chirurgiens du Canada, 74 Stanley Ave., Ottawa, Ont. KIM 1P4.
Subscribers please mail to: Information Systems, Canadian Medical Associa
tion, PO Box 8650, Ottawa, Ont. K1G 0G8.
Abonnes, veuillez expedier a: Systeme de diffusion d’informations, l’Association medicale canadienne, CP 8650, Ottawa, Ont. K1G 0G8.

379

Dalacin C Phosphate Sterile Solution

(clindamycin phosphate)

Antibiotic
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and micro-aerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci)
when the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or
clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydrochloride) has not
been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn (in
fants below 30 days of age), or in pregnant women.
Warnings: Some cases of severe and persistent diarrhea have been reported during or after therapy
with Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, con
tinued only with close observation. Significant diarrhea occuring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes
may respondtosimpledrugdiscontinuance.Moderatetoseverecases.includingthoseshowingulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help in
persistent cases. Anticholinergics and antiperistalticagents may worsen the condition. Other causes
of colitis should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 -1 0 or more days, there was a rapid ob
served disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with
caution in atopic individuals. Dalacin C Phosphate must be diluted for intravenous administration.
(See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the
clinical situation.
As with all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored,during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not
effective means of removing the compound from the blood. Periodic serum levels should be deter
mined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin
phosphate) intramuscularly (with a solution containing 150 mg/ml), six (1.5%) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at
the injection site and two developed sterile absesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and
one patient developed both superficial and deep thrombophlebitis. The majority of these cases
developed in conjuction withthe use of indwelling I.V. cathetersand it isdifficultto knowhowmuchthe
drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either tbe intramuscular or intravenous routes developed systemic side effects as follows:
Number o f Patients
Rash......................................................................................................................................................
7
Urticaria.......................................................................................................................................................1
Pruritus........................................................................................................................................
1
Fever, Leucocytosis............................................................................................................................... 1
Nausea, with or without vomiting........................................................................................................... 1
Diarrhea (See also under ’Warnings").................................................................................................... 4
Hypotension.......................
Hypertension......................
Shortness of Breath...........
Superinfection*.................
Cardiac arrest* * .................
Bad or bitter taste in mouth.

**

Superinfection is a complication of antibiotic therapy in general and is not necessarily a true side
effect of clindamycin phosphate.
Due to underlying myocarditis in this patient.

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology,
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became
abnormal,during therapy. Overall evaluation of clinical laboratory values in these patients does not
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal
systems. Transient elevations of serum transaminases have occured in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and
there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No specific
antidote is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days
have been given without adverse effects.
DOSAGE AND ADMINISTRATION
Adults
Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2,3 or 4 equal doses. Intramuscular injections of more than
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to
I.V. administration to a dilution of 300 mg in 50 mL of diluent (6mg/mL) or more, and infused in not less
than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recommended.
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each
infused over 20 minutes or longer.
Severe Infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused over
20 minutes or longer. In life-threatening infections, doses of 2700to 4800 mg/day by’continuous drip or
in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose
Diluent
Time
300 mg
50 mL
10 min.
600 mg
100 mL
20min.
900 mg
l5 0 m L
30min
1200 mg
200 mL
45min.
Alternatively, drug may be administered in the form of asingle rapid infusion of thefirst dose followed
by continuous I.V. infusion as follows:
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
Above4mcg/mL
10mg/m in.for30min.
0.75mg/min.
Above5mcg/mL
15mg/m in.for30min.
1.00mg/min.
Above6mcg/mL
20mg/m in.for30m in.
1.25mg/min.
Children: (Over one month of age)
Intramuscular injection: 10 to 15 mg/kg/day in 2,3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration:
Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each
infused over 20 minutes or longer.
Severe infections: It is recommended that children be given no less than 300 mg/day regardless of body
weight. (Dilute Dalacin C Phosphate Sterile Solution in the same manner as for adults.)
Dilution and Compatibility:
4 mL (600 mg) Dalacin C Phosphate when diluted with 1000 mL of the following commonly used in
fusion solutions was found to be physically compatible and demonstrated no significant change in pH
or antimicrobial potency overa period of 24 hours:
Sodium chloride injection
Dextrose 5% in water
Dextrose 5% in saline
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 21/2% in Lactated Ringer's Solution (Hartmann's Solution)
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is
not recommended that Dalacin C Phosphate be mixed with any infusion solution containing B vitamins.
Supplied:
Dalacin C Phosphate contains the following per mL of sterile solution:
Clindamycin phosphate equivalent to clindamycin base 150 mg
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH
range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 mL and 4 mL ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request.

8704 REGISTERED TRADEMARK: DALACIN
TRADEMARK: DALACIN C CE 1377.1C

EE)

U p jo h n
antibiotic

— SCABC" ----- 1

TH E U P JO H N C O M PAN Y O F C A N A D A
8 6 5 Y O R K M IL L S R O A D /D O N M IL L S , O N T A R IO

PAAB
CCPP

SURGEONS’ UPDATE

Researchers Seek Improved
Treatment for Patients
Requiring Hip Replacement
A group of researchers at the Uni
versity of Waterloo, Waterloo, Ont.,
is searching for ways to improve
the results of surface replacement
of the hip, a procedure they believe
has advantages over the traditional
technique of hip replacement.
The group consists of Greg
McNeice, a civil engineer with ex
pertise in stress analysis and a
bioengineering background, John
Medley, a mechanical engineer with
a background in biotribology,
Wayne Brodland, a specialist in the
area of biomechanics, Martine LaBerge, a mechanical engineer
whose expertise includes clinical ex
perimentation with biomaterials,
particularly in surface replacement
for synovial joints, and several stu
dents.
Hip replacement, says one of the
researchers, has not always provid
ed a permanent solution since
“even under the best of circum
stances the implant-bone interface
may break down after a number of
years” , but surface replacement has
also presented difficulties. Says
McNeice, “We’ve heard of instances
where the cap slipped off the end of
the bone as early as one year after it
was implanted.”
The researchers believe that
some of the problems with the
surface replacement procedure are

Contributions to this column are welcome.
Please send your material to: Miss Laurel
Williamson, Canadian Journal of Surgery,
PO Box 8650, Ottawa, Ont. K1C 0C8
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caused by the material used. The
metal cap that is placed over the
shaved femoral head does not have
the same properties as the bone it
replaces, so when the bone is
capped “it may become stressshielded and when this happens, the
bone no longer carries normal
stress and...it disappears and you
get progressive failure”. The effect
of stresses on the femoral head is
one of the problems that will be
studied. Softer, more compliant ma
terial will be tested for use as the
cap or as a layer to be placed
between the cap and the bone. The
researchers also hope to develop
improved methods for cementing
the cap to the shaved bone.a

New Director of Training
and Evaluation at Royal
College

The Royal College of Physicians
and Surgeons of Canada has ap
pointed Jean-Pierre DesGroseilliers,
FRCPC, as its Director of Training
and Evaluation, succeeding Robert

F. Maudsley, FRCSC. Dr. DesGrosseilliers comes to the Royal College
from the University of Ottawa,
where he was Assistant Dean, Fac
ulty of Health Sciences, but has
in the past participated on several
College committees and survey
teams. ■

CJS Coeditor Named 1988
Sims Travelling Professor

Dr. Lloyd D. MacLean, who was
appointed the 1988 Sir Arthur Sims
Commonwealth Travelling Profes
sor by the Royal College of Sur
geons of England, begins his travels
this month. During the next 3
months Dr. MacLean will be visiting
various centres in New Zealand,
Australia, Malaysia and Hong
Kong; then in April he will be off
again — this time to the British
Isles. The Sims Professor’s role is
both academic — assisting in the
advancement of medical science by
lecturing, teaching or engaging in
research — and ambassadorial.■

Ontario’s Health Ministry
Awards Annual Research
Grants

FIG. 1 — J-P. DesGroseilliers.

The Ontario Ministry of Health re
cently awarded $5 million to fund
87 new and ongoing health care
research projects.
A group at the University of
Toronto hopes to improve the out
come of corneal transplant surgery;
20% of corneal transplants fail, the
majority during the first year. The
researchers will study data on 600
381
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patients, collected by the Corneal
Transplant Registry from 18 Ontar
io surgeons who perform corneal
transplants. Factors that can affect
success or failure of a transplant,
such as the interval between the
donor’s death and removal of the
eye, the interval before surgery and
method of storage of the eye be
tween removal and surgery, will be
analysed. The study is expected to
be completed by early 1991.
A Hamilton research group will
study geographic variation in can
cer rates across the province of
Ontario. They are asking the ques
tion — Is there more variation in
cancer incidence from one region to
another than one would expect by

chance? If a substantial variation is
found, the researchers will deter
mine if it is possible to link these
variations to environmental factors
such as water quality, air pollution,
terrestrial radiation, urbanization,
industrialization or occupation. The
study will be based on data collect
ed by the Ontario Cancer Treatment
and Research Foundation registry
from 1976 to 1985.■

Multiorgan Transplant Unit
Opens in Vancouver

General Hospital and the British
Columbia Transplant Society, was
opened recently by British Colum
bia Health Minister Peter Dueck.
Patients requiring transplant sur
gery will no longer be required to
travel to other provinces or coun
tries. Care will be provided both
before and after surgery in the
eight-bed unit equipped with stateof-the-art diagnostic and monitor
ing technology. A budget of
$3 680 000 will cover operating
costs for the first year and an
additional $350 000 will be used to
purchase new equipment.*

« V
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A multiorgan transplant unit, ad
ministered jointly by Vancouver

Laurel Williamson

BOOK REVIEWS

ANDROLOGY. John P. Pryor and
Larry I. Lipshultz. 340 pp. Illust.
Butterworth & Co. (Publishers) Ltd.,
London, 1987. $65.95 (US). ISBN
0-407-02361-5.

Andrology represents a current review
of 12 selected topics related to male
reproductive disorders. The subject-ori
ented format is of value not only to the
urologist-in-training but also to the
practising general urologist, because
this area of urology is taking up in
creasingly more clinical time.
The topics are well selected to pro
vide a state-of-the-art review of uncom
mon and specialized subjects, including
intersex, hypospadias and epispadias,
and the increasingly topical subjects of
impotence, infertility and vasectomy.
The material is directed primarily to the
clinician, giving a more basic discussion
of disorders of intersex, ejaculatory
disturbances, and hormone function
and regulation of the prostate. The
chapter on impotence is weak in the
area of diagnostic investigation; howev
er, the discussion on the treatment of
impotence is extensive and current. All
382

chapters are well referenced and the
text is extensively indexed.
This book is an excellent current
review of the subject of andrology, it
provides outstanding reference material
for further study and is presented in a
very readable format.
Grant Angus Farrow, MD, FRCSC,
FACS
Department o f Surgery,
University o f Toronto.
Ste. 14-214,
Eaton Wing,
Toronto General Hospital,
Toronto, Ont.

BENIGN STRICTURES OF BILE
DUCTS. Edward I. Galperin, Nikolai F.
Kuzovlev and Suren R. Karagiulian.
345 pp. Illust. International Universi
ties Press, Inc., Madison, Conn., 1987.
$60.00 (US). ISBN 0-8236-0494-2.

This book is written by experienced
Russian surgeons who have made bili

ary tract surgery their specialty. The
text is, therefore, a review of the treat
ment of benign biliary strictures, mostly
from their own experience. It includes
an overview of the literature on the
subject with an emphasis on the Rus
sian literature.
The problem with many translated
texts is that the awkwardness of the
language makes reading difficult as in
this case. The print is clear and there
are many excellent diagrams and draw
ings to supplement the text.
The content flows logically from eti
ology to clinical manifestations of be
nign biliary stricture, from there to
diagnostic maneuvers, preoperative
preparation and finally to principles and
practice of surgery for repair. The au
thors cover many different surgical
techniques and express personal prefer
ences. Some areas are controversial,
such as long-term stenting of biliary
anastomosis; however, in the authors’
hands, the results appear to be good. In
other parts of the book, such as that on

continued on page 384
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HOW I DO IT

Surgeon-Administered Local Anesthesia
for Forefoot Surgery
A.A. Giachino, MD, FRCSC
perating rooms are often not
put to full use because of a
shortage of anesthetists. However,
in certain circumstances the sur
geon can safely administer local
anesthesia and perform major sur
gery without complications as dem
onstrated in this paper.

O

Method
Eighty-seven patients underwent
147 procedures which were done on
100 feet.
In all patients history-taking was
thorough and physical examination
included specific questions regard
ing allergies to local anesthetic and
family history of malignant hyper
thermia. All procedures were per
formed in a regular hospital operat
ing room. In all patients, an intrave
nous line was established and elec
trocardiograms and blood pressure
monitoring were supervised by the
circulating nurse. Xylocaine was the
only local anesthetic used and the
dosage guidelines set forth in the
product monograph (Xylocaine Par
enteral Solutions; Astra Pharma
ceuticals Canada Ltd., Mississauga,
Ont.) were followed. The volume of

xylocaine without adrenaline did
not exceed 4.5 m g/kg and
xylocaine with adrenaline, 7
m g/kg.

dures a tourniquet is applied just
proximal to the malleoli and the
pressure adjusted to 100 mm Hg
above systolic pressure.

Technique

Results

Ankle blocks are performed, be
ginning on the posteromedial as
pect. A 25-gauge needle is posi
tioned posterior to the posterior
tibial artery until paresthesia is pro
duced in the region of the heel or
forefoot; then 5 ml of local anes
thetic is injected (Fig. 1). The sa
phenous nerve is next anesthetized
by palpating it next to the saphe
nous vein and injecting around it.
The deep peroneal nerve is blocked
by depositing a small amount of
xylocaine just superficial to the
ankle joint capsule by way of the
interval between extensor hallucis
longus and tibialis anterior tendons
(Fig. 2). The superficial peroneal
nerves are palpated and blocked in a
ring block fashion (Fig. 3). The
sural nerve is palpated next to the
peroneal tubercle and anesthetized
by a local injection (Fig. 4), except
in patients who are to undergo
bunion surgery. For most proce

Seventy-one ankle blocks and 21
local infiltrations or digital blocks
were performed for a variety of
procedures (Table I).
Only one patient, a hysterical
teenage girl with a gonococcal
infection of the great toe metatarso
phalangeal joint needed conversion
of the local anesthetic to a general
anesthetic. There were no medical
complications.
Use of an ankle tourniquet proxi
mal to the area of anesthesia was
not a problem. Major forefoot re
construction such as a combination
Fowler and Mayo metatarsal joint
excisional arthroplasty and proxi
mal joint fusions was carried out
with a tourniquet applied for more
than 1 hour and elicited no com
plaints from the patients.

From the Division o f Orthopedic Surgery, University o f Ottawa, Ottawa General Hospital,
Ottawa, Ont.
Presented at the annual meeting o f the Canadian Orthopaedic Association, Edmonton, Alta.,
June 1-5, 1986
Accepted for publication Feb. 2, 1988
Reprint requests to: Dr. A.A. Giachino, Ste. 206, 1929 Russell Rd., Ottawa, Ont. K1G 4G3
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Comment
The surgeon can safely and suc
cessfully administer local anesthesia
for forefoot surgery. A paresthesia
must be registered only from the
posterior tibial nerve, and once the
foot is prepared and draped and an
ankle tourniquet applied, access to
this nerve is markedly limited. To
limit the volume, and thus possible
383
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toxicity, of the xylocaine, the sural
nerve was not anesthetized in bun-

ion surgery, and the patients were
told that they would have sensation

on the lateral aspect of the foot.
When the sural nerve was blocked
it was easily palpated and well local
ized adjacent to the peroneal tuber
cle. Until the surgeon achieves a
high success rate in the administra
tion of the block, a standby anes
thetist should be available. ■
Table 1 -

F o re fo o t P ro c e d u re s P e rfo rm e d

Procedure

No.

U n ila te ra l
F o re fo o t re c o n s tru c tio n s
B u n io n p ro c e d u re s

FIG 1. — Paresthesia produced in heel
by injecting 5 ml of xylocaine posterior
to posterior tibial artery.

FIG. 2 — Injection of xylocaine super
ficial to ankle joint capsule will block
deep peroneal nerve.

M e ta ta rsa l o s te o to m ie s
B u n io n e tte e x c is io n s

16
13
17
3

P ro x im a l in te rp h a la n g e a l jo in t
fu s io n s
E x o s te c to m ie s
H a llu x rig id u s p ro c e d u re s
M ed ial s e s a m o id e c to m ie s

12
11
6
4

M e ta ta rso p h a la n g e a l jo in t
s y n o v e c to m ie s
M o rto n ’s n e u ro m a re s e c tio n s
G a n g lio n e x c is io n
R a d ic a l to e n a il e x c is io n s
M is c e lla n e o u s

4
2
1
11
21

B ila te ra l
F o re fo o t re c o n s tru c tio n s
M e ta ta rs a l o s te o to m y

are palpated then blocked.

FIG. 4 — Sural nerve is palpated and
blocked.

B u n io n p ro c e d u re s
C o m b in a tio n s

2
1
2
8

BOOK REVIEWS
continued from page 382

preoperative care, there are insights
into methods of treatment that would
be foreign to most Canadian readers.
One example of this is forced diuresis
for endotoxemia. One is left wishing to
know more about the results of such
treatment.
This book will appeal to the subspe
cialist surgeon or the general surgeon
with a particular interest in the bile
ducts. There is also a place for it on the
shelves of the reference library.
R.J. Fairfull-Smith, MB, ChB, FRCSC
Division o f General Surgery,
Ottawa General Hospital,
Ottawa, Ont.
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GENITOURINARY ULTRASOUND: A
TEXT/ATLAS. Edited by Beverly G.
Coleman. 542 pp. Illust. Igaku-Shoin
Medical Publishers, Inc., New York;
W.B. Saunders Company Canada Lim
ited, Toronto, 1988. $95.75. ISBN
0-89640-130-8.

Ultrasonography has become indispen
sable in diagnosing and treating benign
and malignant genitourinary disease as
a result of the great improvement over
the past decade in ultrasound tech
niques and equipment. This atlas docu
ments the various applications of ul
trasonography in urinary tract disease.
Each ultrasound image is accompanied

by a schematic anatomical reproduction
and a line drawing to aid in its descrip
tion and interpretation. The accompan
ying text is concise and makes for easy
viewing and, for the non-ultrasonographer, a remarkably informative teaching
tool.
The book covers all aspects of geni
tourinary disease, including benign and
malignant disease in both adults and
children and illustrations of interven
tional techniques. Although the images
are well reproduced and extensive, the
accompanying text is occasionally mis-

continued on page 412
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ROYAL COLLEGE SYMPOSIUM

Symposium on Current Perspectives in
the Management of Soft-Tissue Sarcoma
1. Incidence, Investigations and Staging of
Soft-Tissue Sarcoma
Michael G. Rock, MD, FRCSC

Soft-tissue sarcomas account for only 1% of all malignant lesions. The Canadian
Sarcoma Group encourages the investigation and management of these tumours at
tertiary institutions, where a multidisciplinary team can handle the complex
problems. Staging of these tumours implies accurate anatomic determination of the
extent of disease, the histogenesis and grade of the tumours and the presence of
regional or distant metastases. Arteriography, computed tomography and magnetic
resonance imaging can accurately define the tumour before biopsy. The biopsy
should be muscle-splitting to minimize contamination of additional compartments
and should allow inclusion of the biopsy site at definitive surgical resection. It
should be done at the institution where definitive management will be performed.
Regional lymph-node involvement can be detected using magnetic resonance
imaging or gallium scanning, whereas for distant metastases, specifically of lung,
computed tomography is the method of choice.
To date no one staging system for soft-tissue sarcomas has been universally
accepted. A hybrid, encompassing the advantages of each system, is being
formulated.

Les sarcomes des tissus mous comptent pour seulement 1% de tous les cancers. Le
Groupe canadien pour les sarcomes soutient la recherche et le traitement de ces
tumeurs dans des institutions de troisieme ligne, ou des equipes multidisciplinaires
peuvent prendre charge de problemes complexes. L’etablissement du stade evolutif
de la maladie suppose la determination anatomique precise de l’etendue de la
maladie, l’histogenese et le stade de la tumeur et la presence de metastases
regionales ou eloignees. L’arteriographie, la tomodensitometrie et la resonance
magnetique nucleaire permettent de definir clairement la tumeur avant la biopsie. La
biopsie doit etre faite par voie intermusculaire afin de minimiser les risques de
contamination de compartiments additionnels et doit permettre d’inclure le point de
biopsie lors de la resection chirurgicale definitive. Elle doit etre pratiquee dans
l’institution ou le traitement final sera prodigue. Une atteinte des ganglions
regionaux peut etre detectee par resonance magnetique nucleaire ou par scintigraphie au gallium, alors que la tomodensitometrie demeure la methode de choix
pour les metastases a distance, particulierement au poumon.
A ce jour, il n’existe pas de systeme universellement accepte pour determiner le
stade evolutif des sarcomes des tissus mous. Un systeme hybride, reunissant les
avantages de chacun, est en voie d’etre formule.
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lthough no accurate statistics
exist as to the incidence o f
soft-tissue sarcomas in Canada, it
has been estimated that in the Unit
ed States there are 5000 new cases
annually.
Because o f the need for specially
trained units to manage the com 
plex problems associated with these
tumours, 50 referral centres have
been identified in the United States.
Unfortunately, this arrangement is
not feasible in Canada. To manage
150 to 200 cases a year, quoted as
being the volume necessary to
maintain expertise in treating these

A

From the Division o f Orthopedic Surgery,
University Hospital, London, Ont.
Presented as part o f a symposium on current
perspectives in the management o f soft-tis
sue sarcomas, by the Royal College in coop
eration with the Canadian Oncology Society,
the Canadian Orthopaedic Association and
the Canadian Association o f Radiation On
cology, at the 56th annual meeting o f the
Royal College o f Physicians and Surgeons o f
Canada, Winnipeg, Man., Sept. 12, 1987
Accepted for publication Apr. 25, 1988
Reprint requests to: Dr. M.G. Rock, Division
o f Orthopedic Surgery, University Hospital,
PO Box 5339, 339 Windermere Rd., Lon
don, Ont. N6A 5A5
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tumours,1 all patients with soft-tis
sue sarcomas presenting in Canada
would have to be referred to three
or four major institutions. Realisti
cally, patients with these tumours
will continue to be managed in
university affiliated tertiary institu
tions and by capable staff in other
hospitals. Thus, all surgeons deal
ing with these problems must be
current in their knowledge of inves
tigation and staging.
At meetings dedicated to the sub
ject, the consensus has been that
these tumours should be treated by
a multidisciplinary team. Because
surgery is the mainstay of manage
ment, the surgeon should have the
cooperation of radiologists, special
ists in nuclear medicine, patholo
gists, chemotherapists and radiation
therapists. Before treatment, the
team should identify the anatomic
extension of the tumour, the histogenic type and grade, anticipated
response of the lesion to other
treatments and patient priority re
garding such plans.

Defining the Extent of Disease
Patients with soft-tissue tumours
usually present because of the mass
effect, which in itself may be
asymptomatic, painful, compromise
neurovascular structures, decrease
mobility of contiguous joints or
encroach upon or invade abdominal
or pelvic viscera. It is essential to
obtain a careful history since expo
sure to chemical carcinogens such
as phenoxyacids, chlorophenols,
phenylchloride gas, or long-stand
ing use of anabolic steroids have
been known to induce soft-tissue
sarcomas, especially hepatomas.2
Exposure to radiation from outmod
ed radiotherapy equipment or dur
ing administration of variable dos
age radiation can, after a long la
tent period, result in sarcomatous
transformation — as with the sec
386

ondary development of lymphangiosarcomas in long-standing lym
phedema after radical breast resec
tion (the Stewart-Trieves syn
drome). It is well recognized that
patients with von Recklinghausen’s
disease are predisposed to neurofi
brosarcomas.
Laboratory analysis should in
clude a complete blood count, mea
surement of sedimentation rate,
liver enzymes and alkaline phospha
tase levels. With large soft-tissue
sarcomas in which there is central
necrosis and at times local he
morrhage, it is not uncommon for
the patient to have a low hemoglo
bin value, slightly elevated leuko
cyte count and a significantly ele
vated blood sedimentation rate. Al
though the lung is the preferred
site of metastases for these tu
mours, the liver may be involved,
compromising heptic function. Al
kaline phosphatase determination is
necessary when the mass is close to
osseous structures, with the poten
tial to invade not only periosteum
but also underlying cortex. A bone
scan is mandatory in such cases as
the area involved must be included
in a definitive surgical excision.
Indium and gallium scans give
valuable information. The latter is
picked up predominantly by the
reticuloendothelial system, allowing
imaging of the liver and spleen and,
more importantly, regional lymph
nodes at the tumour site. Unlike its
bone counterpart, some soft-tissue
sarcomas, notably rhabdomyosar
coma, synovial sarcoma and malig
nant fibrous histiocytoma will dis
seminate to regional nodes in 20%
to 25% of cases. The indium scan is
much more selective for infection,
so any mass whose density on other
radiologic investigations appears
consistent with abscess or hemato
ma may be more effectively identi
fied.
Dual plain x-ray films are insuffi
cient to identify essential character

istics of the tumour (Fig. 1). Distor
tion of soft-tissue planes, compart
ment distortion or even scalloping
of underlying bony structures indi
cating invasion may be noted, but
these findings are inadequate when
deciding on treatment. Similarly,
ultrasonography, although effective
in identifying the presence of the
mass, will not determine its size,
extension or proximity to various
muscle groups or neurovascular
structures. The most useful infor
mation can be obtained from arteri
ography, computed tomography
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FIG. 1 — Plain x-ray film of thigh of
35-year-old woman, known to have
neurofibromatosis. Ill-defined soft-tis
sue mass is present medially.
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and magnetic resonance imaging.
Arteriography is indicated when
soft-tissue tumours adjoin major
vascular channels. The early phase
of the arteriogram will allow assess
ment of anatomic or vessel distor
tion and indicate the vascularity of
the lesion; if it appears to be highly
vascular it may be prudent to carry
out selective embolization of feed
ing vessels 24 to 48 hours before
resection of the mass. The late
venous phase allows appreciation of
tumour size and its reactive zone,
representing the host’s attempt to
wall off the rapidly growing lesion
with a zone of hypervascularity,
fibrous tissue and inflammatory
cells. This is important information
because satellite lesions, having
penetrated the pseudocapsule, will
sometimes extend into the reactive
layer from the principal tumour.
This appearance is erroneously con
ceived by many surgeons as an
effective barrier to tumour migra
tion. This surrounding contaminat
ed reactive zone may be left behind
in a marginal excision or shellingout procedure.
With computed tomography it is

possible to define the anatomical
extension, compromised tissue com
partments, consistency of the tu
mour and its proximity to vital
structures (Fig. 2). This is particu
larly true of intrapelvic and retro
peritoneal sarcomas that are ex
tremely difficult to define anatomi
cally by means other than computed
tomography or magnetic resonance
imaging. Because of the long inter
val between onset and detection, it
is not surprising that 15% of pa
tients have chest metastases at the
time of initial presentation.6 Com
puted tomography has also revolu
tionized the assessment of chest
metastases among sarcoma patients
(Fig. 3), and it now plays one of the
principal roles in the staging of
these tumours. When taken 5 mm
apart, a 3-mm nodule can be im
aged with the scanner, giving a
sensitivity that is an improvement
on the 6-mm pick-up with whole
lung tomography. However, the se
lectivity of the latter is much more
accurate. Lesions that are question
ably granulomatous necessitate ad
ditional tomography to assess the
presence of calcification thus fa

vouring granuloma rather than me
tastasis.
Magnetic resonance imaging rep
resents a marked improvement,
even on the information available
from computed tomography (Fig.
4). From both axial and coronal
cuts, the presence of the tumour
and its relationship to surrounding
anatomy is much better appreciat
ed. Magnetic resonance imaging is
also accurate in identifying fatty
tumours that may be malignant and
the presence of extra-abdominal de
smoid tumours, which have proven
difficult to identify with convention
al computed tomography because
the signals between muscle and
tumour are similar. Our current
philosophy for extremity, pelvic and
retroperitoneal soft-tissue tumours
is to favour magnetic resonance
imaging while recognizing that
computed tomography is more ac
curate in detecting chest metasta
ses.

Defining Histogenic Type and
Grade
After appropriate investigations
have delineated possible tumour ex
tension, the histogenic type and

FIG. 2 — This 28-year-old man presented with enlarging mass in left buttock.
Computed tomography shows large soft-tissue tumour which on open biopsy was
identified as high-grade malignant fibrous histiocytoma.
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FIG. 3 — Preoperative staging studies
of patient from Fig. 2 included comput
ed tomography of chest revealing soli
tary chest metastasis.
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grade of the tumour must be de
fined. An adequate biopsy must be
performed, if possible by the sur
geon who will ultimately do the
definitive resection. Undoubtedly,
there will be situations where excisional biopsies will be performed for
what was thought to be a benign
lesion, but histologically was
proved to be malignant. If there is
any suggestion of malignancy,
evoked by the size, rapid appear
ance or symptom complex of the
tumour, the patient should be re
ferred, before biopsy, to a centre
where the required expertise and
ancillary services are available. A
recent survey by the Musculoskele
tal Tumor Society3 compared the
efficacy of performing a biopsy on a
sarcoma in the referring centre and
in the treating centre. They found
that biopsy related problems oc
curred three to five times more
frequently when performed at a re
ferring institution. The Society
members strongly recommended
that all aspects of treatment of
sarcomas be conducted in a recog
nized facility capable of managing
such patients.45 If this is not feasi
ble, the following guidelines should
be observed to minimize the num
ber of confusing biopsy findings:

• In the extremities, flank and
pelvic area, place the biopsy skin
incision in line with the underlying
muscle fibres to avoid compromis
ing subsequent definitive surgical
procedures.
• Transverse incisions can make
skin coverage difficult after defini
tive surgical excision. The approach
to the underlying tumour should be
of muscle-splitting orientation to
minimize compartment contamina
tion and hemorrhage, which should
be accurately controlled before clo
sure. Representative tissue, which
can be determined from preopera
tive magnetic resonance imaging,
should be obtained and confirmed
by a pathologist before the biopsy
wound is closed.
• Aerobic and anaerobic swabs
should be taken at the same time as
the biopsy to exclude the possibility
of central necrosis with infection in
the tumour or the presence of an
unrecognized abscess.
• In the recovery room ice
packs should be placed around the
biopsy area and activity minimized
for 24 hours to discourage tracking
of hematoma along fascial planes.
The biopsy can be performed by
fine needle, needle, excisional or
incisional techniques, but the inci

sional method is preferred. Needlebiopsy material demands that the
pathologist makes a diagnosis on
cytologic examination alone; this is
a very difficult proposition, and de
finitive histogenic classification is
often impossible. It is also more
difficult to obtain truly representa
tive sections, to identify the needle
tract which must be incorporated in
the excision of the tumour, because
of contamination. Excisional biopsy
leaves residual tumour in the
wound with possible contamination
of surrounding tissue.
By electron microscopy and immunohistochemical testing a defini
tive histogenic type and grade of
the biopsy specimen can be deter
mined. This is of more than aca
demic interest because the natural
history of the various sarcomas is
quite different, necessitating altered
forms of adjuvant therapy.

Staging of Disease
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Possibly the most contentious
and currently debated aspect of
soft-tissue sarcomas is the means of
staging. The American Joint Com
mittee for Cancer Staging and End
Results Reporting has attempted to
extrapolate the TNM system, pri-
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Fig. 4a

Fig. 4b

Fig. 4c

FIG. 4 — (a) Computed tomogram of lesion from patient in Fig. 1 revealed solid tumour deep to adductor muscles extending to
underlying femur, (b) Magnetic resonance imaging, coronal cut. Proximity of tumour to superficial femoral vessels and sciatic
nerve are better demonstrated. Pseudocapsule and reactive zone around tumour appear more clearly, allowing more accurate
preoperative determination of contaminated tissues, (c) Magnetic resonance imaging, sagittal cut. Actual longitudinal extension
of tumour. Neurofibrosarcoma was ultimately removed with wide margins.
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marily used for carcinoma, to softtissue sarcomas. When the prog
nostic importance of grade became
evident it was included into the
staging system which became the
GTNM staging system. To physi
cians managing a large volume of
soft-tissue sarcomas it became obvi
ous that the extended TNM classifi
cation was not applicable to these
tumours. Members of the Musculo
skeletal Tumor Society pointed out
that there was no link between it
and treatment planning. Inconsis
tencies arose in prognosis, associat
ed with overlap of the various
stages, and the nodal metastases
introduced at stage III of the dis
ease implied a better prognosis than
usually seen with distant lymphnode metastases. Moreover, the ma
jority of physicians managing softtissue sarcomas also deal with osse
ous sarcomas, and the proposed
TNM classification for the former is
not applicable to the latter. There
fore, the Musculoskeletal Tumor
Society proposed an alternative
staging system for sarcomas,1'6 rec
ognizing that surgery was the de

finitive mode of treatment and thus
the staging system should have
direct influence on surgical man
agement. Furthermore, it was sub
sequently proven that there was no
intrinsic difference between histogenically similar lesions in soft
tissue and bone.
The present staging system used
by most orthopedic surgeons deal
ing with soft-tissue sarcomas is the
one subsequently formulated, which
maintains simplicity for universal
application and clinical correlation
with the natural history of these
tumours. Briefly, it is a three-stage
system based on the grade of the
tumour (low G1 or high G2) and
whether the tumour is intracompartmental (Tl) or extracompartmental (T2). The concept of compartmentalization is important be
cause it has a direct impact on the
subsequent surgical management
and because most anatomical areas
fall within specific compartments.
At times (5% of cases), confinement
within a given compartment proves
difficult and the classification is not
as effective. Stage III disease im

plies distant or nodal metastases,
recognizing that both carry a poor
prognosis. This three-stage system
has been applied to thousands of
soft-tissue and bone sarcomas with
reproducible prognoses. The ortho
pedic community and the interna
tional Musculoskeletal Tumor Soci
ety have universally accepted the
Enneking system because of its sim
plicity and accuracy of prognosis.
References
1. E nneking WF: A system of staging mus
culoskeletal neoplasms. Clin Orthop
1986; 204: 9-24
2. L awrence W j r , N eifeld JP, T erz JJ:
Manual of Soft-Tissue Tum or Surgery,

Springer-Verlag, New York, 1983
HJ, L ange TA, S panier SS: The
hazards of biopsy in patients with malig
nant primary bone and soft-tissue tumors.
J Bone Joint Surg [Am ] 1982; 64: 1121—
1127
4. E nneking WF: The issue of the biopsy
(E). Ibid: 1119-1120
5. S imon MA: Biopsy of musculoskeletal
tumors. Ibid: 1253-1257
6. E nneking WF. S panier S S , G oodman MA:
Current concepts review. The surgical
staging of musculoskeletal sarcoma. J
Bone Joint Surg [Am ] 1980; 62: 10271030

3. Mankin

r

PAAB
|ccpp
believe it.

This logo appearing on pharmaceutical advertisements in
professional journals means that the advertisements have
been reviewed— and cleared for publishing— by the Phar
maceutical Advertising Advisory Board/Conseil Consultatif
de Publicity Pharmaceutique.
This unique screening system for pharmaceutical advertis
ing Is the first of Its kind in North America. The Board of
Directors Is composed of Individuals representing the fol
lowing organizations: • Association of Medical Media •
Association des m6decins de langue frangaise du Canada
•Canadian Advertising Foundation •Canadian Drug Manu
facturers Association • Canadian Medical Association •
Canadian Pharmaceutical Association • Consumers’ Asso
ciation of Canada •Pharmaceutical Manufacturers Associ
ation of Canada.
The Health Protection Branch of Health and Welfare Canada
acts as advisor and resource body to the board.
The program ensures the accuracy of pharmaceutical ad
vertising to the health professions, so that it may continue
to serve the ultimate best interest of the patient.

V_______________
VOL. 31, NO. 6 NOVEMBER 1988/CJS

389

ROYAL COLLEGE SYMPOSIUM

2. The Role of Chemotherapy in
Multimodality Therapy
Vivien H.C. Bramwell, PhD, MB, BS, FRCPC

The role of chemotherapy in adult soft-tissue sarcomas is controversial. In this
review, the author examines the effectiveness of single-agent and combination
chemotherapy to manage advanced disease and the role of adjuvant combination
chemotherapy to control primary tumours and prevent the spread of the disease.
Doxorubicin (Adriamycin) is still considered the most effective single agent for
advanced soft-tissue sarcoma. Ifosfamide has given similar results and may have
greater potential in combination therapy than cyclophosphamide. A current study
using trimetrexate shows early positive results.
Doxorubicin, cyclophosphamide, vincristine and dacarbazine is currently the most
efficacious combination.
The efficacy of adjuvant chemotherapy remains to be established. The majority of
studies indicate some benefit with chemotherapy, particularly in the relapse-free
survival rate, but no consistent improvement in overall survival has been noted.

Le role de la chimiotherapie dans le sarcome des tissus mous de l’adulte est
discutable. Cette revue porte sur l’efficacite de la mono et de la polychimiotherapie
dans le traitement des cancers a un stade avance et du role de la polychimiotherapie
adjuvante dans la maltrise des tumeurs primitives et dans la prevention de la
dissemination de la maladie.
La doxorubicine (Adriamycine) est toujours consideree comme le medicament qui,
utilise seul, est le plus actif contre les sarcomes des tissus mous au stade avance.
L’ifosfamide a donne des resultats comparables a ceux de la doxorubicine, et semble
presenter de plus grandes possibility en polychimiotherapie que la cyclophosphami
de. Une etude presentement en cours avec le trimetrexate laisse prevoir des resultats
positifs.
Actuellement, la cyclophosphamide, la vincristine et la dacarbazine represented
l’association la plus active.
L’interet de la chimiotherapie adjuvante reste a etre demontre. La majorite des
etudes indique qu’elle peut etre d’un certain apport, particulierement en ce qui a
trait a la survie sans recidive, mais aucune amelioration notable dans la taux de
survie n’a ete note.

From the Department o f Medical Oncology, London Regional Cancer Centre, London, Ont.
Presented as part o f a symposium on current perspectives in the management o f soft-tissue
sarcomas, by the Royal College in cooperation with the Canadian Oncology Society, the
Canadian Orthopaedic Association and the Canadian Association o f Radiation Oncology, at the
56th annual meeting o f the Royal College o f Physicians and Surgeons o f Canada, Winnipeg,
Man., Sept. 12, 1987
Accepted fo r publication Apr. 25, 1988
Correspondence to: Dr. V.H.C. Bramwell, Chief, Department o f Medical Oncology, London
Regional Cancer Centre, 391 South St., London, Ont. N6A 4G5

390

lthough chemotherapy is of
proven benefit in embryonal
rhabdomyosarcomas of childhood,
its role in adult soft-tissue sarcomas
is more controversial. This review
examines the activity of single and
combination cytotoxic drugs in ad
vanced disease. The potential con
tribution of adjuvant chemotherapy
in providing local control of primary
tumours and preventing metastasis
is analysed.
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Advanced Disease
Single Agents
Of the anthracyclines, dox
orubicin (Adriamycin [ADR]), intro
duced into clinical practice in the
early 1970s, is generally acknowl
edged as the most active single
agent in the treatment of adult
soft-tissue sarcomas. A review of
relevant studies containing more
than 25 patients,1-8 showed an aver
age response rate of 24% (range
from 16% to 41%) in 930 patients.
An intensive search to identify an
thracyclines that retain the anti
tumour efficacy of ADR with less
toxicity, especially cardiotoxicity,
has been disappointing; Carm inom ycin,9 deoxydoxorubicin,10
Aclacinomycin1112 and demethoxydaunorubicin,13 each showed insig
nificant activity. When given at
identical doses (75 m g /m 2 every 3
weeks) in a study performed by the
European Organisation for Re-
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search and Treatment of Cancer
(EORTC), Epiadriamycin was less
toxic than ADR, but the response
rate was lower — 15 of 84 (18%)
versus 21 of 83 (25%) for ADR.14
This difference was not statistically
significant, but it is unlikely that
Epiadriamycin, even if used at a
dose equitoxic to ADR, will be more
active.
With respect to alkylating
agents, ifosfamide, an interesting
analogue of cyclophosphamide, was
synthesized in Germany in 1967.
Reported response rates are avail
able on 218 patients treated with a
variety of doses and schedules of
ifosfamide.15 The average rate of
28% (range from 18% to 38%) is
remarkably similar to that for
ADR.16 However ifosfamide has
been evaluated in considerably
fewer patients, and characteristical
ly the response rate of a new drug
is inversely proportional to the
number of patients in which it is
evaluated. Nevertheless, ifosfamide,
in contrast to ADR, has been used
more frequently as second-line che
motherapy. Response rates in an
EORTC study comparing ifosfamide
with cyclophosphamide were 18%
and 8% respectively17 and provided
the only single-agent data for cyclo

phosphamide. Ifosfamide produced
two responses in 28 previously
treated patients and three responses
in 31 patients crossed over after
failure of cyclophosphamide. The
response rates for patients who had
never received chemotherapy were
10 of 40 (25%) for ifosfamide and 5
of 38 (13%) for cyclophosphamide.
Although the rates were not signifi
cantly different by conventional sta
tistical analysis, ifosfamide caused
less myelosuppression than cyclo
phosphamide, suggesting greater
potential in combination.
Of other single agents, it is gen
erally accepted that dacarbazine
(DTIC) shows limited activity in
soft-tissue sarcomas,1819 the aver
age response rate in accumulated
series (97 patients) being 18%
(range from 15% to 25%). Cisplatinum is very active in osteosar
coma and has been extensively test
ed in soft-tissue sarcoma.2'3'5 An
average response rate of 9% in 150
patients does not warrant inclusion
in combination chemotherapy, par
ticularly as it is a very toxic and
expensive drug. The data on metho
trexate are intriguing. A study from
the United Kingdom20 reported a
response rate of 25% in 62 patients.
A variety of doses, routes and

Table 1 - Response to Combination Chemotherapy
Combination

No. of patients
750
592
70
80
199
100

CYVADIC*
ADR/DTIC
CYCL0/VCR/ADR
CYCL0/ADR/DTIC
CYCLO/VCR/ADR/DACT
CYCL0/ADR/MTX

Response, %
48
(15-68)
27.5 (20-42)
19
35
40
36

‘ Cyclophosphamide, vincristine, Adriamycin, dacarbazine.
ADR = Adriamycin, DTIC = dacarbazine, CYCL0 = cyclophosphamide, VCR = vincristine, DACT
= actinomycin D, MTX = methotrexate.
Table II - Combination Chemotherapy Including Ifosfamide
Series
Wiltshaw and associates, 198623
Schutte and associates, 198622
Elias and Antman, 198624

Combination

No. of
patients

Response,
%

ADR + IF0S
ADR + IF0S
ADR + IF0S + DTIC

47
178
65

36
36
52

ADR = Adriamycin, IF0S = ifosfamide, DTIC = dacarbazine.
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schedules were used in this trial. A
later EORTC study was unable to
demonstrate any activity for metho
trexate given intravenously every
week in previously treated pa
tients.21 Although high-dose metho
trexate has been used in several
small series,1 there is no evidence
that its activity is increased, and no
group has repeated the studies of
conventional-dose m ethotrexate.
The Canadian Sarcoma Group, in
conjunction with the National Can
cer Institute of Canada, is currently
performing a phase II study using
trimetrexate, a methotrexate ana
logue, and responses have been
seen.

Combination Chemotherapy

The drug combination most com
monly used to treat adult soft-tissue
sarcomas is CYVADIC (Table I). It
consists of cyclophosphamide (500
m g/m 2), vincristine (1.4 m g /m 2,
day 1), ADR (50 m g/m 2) and dacar
bazine (250 m g/m 2, days 1 to 5).1-8
The two most active single agents
(ADR and dacarbazine) have also
been used fairly extensively in com
bination,26 but the response rate
(Table I) seems lower than that of
CYVADIC. Other ADR combina
tions have activity in the same
range, but none are better than
CYVADIC.1-8
The addition of ifosfamide to
ADR2223 has been disappointing
(Table II). In the EORTC study22 of
178 patients treated with ADR and
ifosfamide, the overall response rate
of 36% was similar to that reported
for CYVADIC (39%). However,
nearly half the patients receiving
CYVADIC manifested disease pro
gression, whereas the correspond
ing figure for ADR and ifosfamide
was 19%. The addition of dacarba
zine seemed to improve the re
sponse rate.24 However, this partic
ular regimen was very myelosup391
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pressive; there was a 23% incidence
of granulocytopenic fever. A central
venous line had to be inserted in all
patients and treatment was given by
intravenous infusion for 5 days
every 3 weeks.
The EORTC is currently compar
ing ADR, CYVADIC and ADR plus
ifosfamide in a three-arm study;
393 patients have been entered in
22 months and the accrual should
be complete within 6 months. Com
parative response rates are not yet
available, but should be very inter
esting as ADR has never been di
rectly compared with CYVADIC.
This study should also clarify the
value of ifosfamide used in combi
nation.
The Canadian Sarcoma Group is
performing a pilot study of the

superiority for intra-arterial therapy
have generally compared their re
sults with historical controls from
their own centre or results reported
in the literature, both of which have
obvious flaws.
Another method of primary man
agement has been that of isolation
perfusion with or without hyper
thermia. Most studies using this
method were performed between
1960 and 1980 with drugs such as
melphalan, actinomycin D and ni
trogen mustard, whose activity in
soft-tissue sarcomas is minimal.
The results of several of these se
ries25"28 are compared in Table III
with the results reported by Lindberg and colleagues29 from a group
of patients treated by surgery and
radiotherapy in a major centre.
Limb salvage, local recurrence and
ultimate outcome in terms of over
all survival, show little advantage
for the complex, expensive and
cumbersome technique of isolation
perfusion.
The intra-arterial use of ADR
with or without radiotherapy preoperatively has been reported (Table
IV).30-32 EUber’s group3334 has the
most extensive experience and their
rates of limb salvage and local con
trol are impressive. However, com
plications, including pathologic
fracture of long bones, led them to
reduce the dose of radiotherapy in

combination of ADR, ifosfamide and
dacarbazine, using a shorter, more
convenient schedule than the Bos
ton group. The Boston group is
comparing their schedule of this
combination with ADR alone.

Primary Management
Intra-arterial Chemotherapy

To improve local control, chemo
therapy has been given intra-arteri
ally in conjunction with surgery and
radiotherapy. There have been no
randomized studies comparing this
route of therapy with other meth
ods for local control, such as radical
surgery or limited surgery plus ra
diotherapy. Investigators claiming

Table III - Isolation Perfusion With Melphalan, Actinomycin D and Nitrogen Mustard Plus
Hyperthermia Compared With Surgery Plus Radiotherapy
No. of
patients

Series
Chemotherapy
Stehlin and associates,
198425
Lehti and associates,
198626
McBride, 197627
Krementz and associates,
197728
No chemotherapy
Lindberg and associates,
198129

Limb
salvage,
%

Local
recurrence,
"/o

Metastases,
%

Overall
survival,
%

65

94

NS

NS

73

64
85

83
89

11
15

33
23

67
68

73

90

25

30

64

200

85

20

25

69

NS = not stated.
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Table IV - Intra-arterial Adriamycin With Radiotherapy Compared With Preoperative and Postoperative Radiotherapy Without Chemotherapy

Series
Chemotherapy
Mantravadi and associates, 198430
Denton and associates, 198431
Goodnight and associates, 198532
Eiiber and associates, 198433
198534
Protocol 2
Protocol 3
No chemotherapy
Karakousis and associates, 198635
Abbatucci and associates. 198636

No. of
patients

Follow-up,
mo.

Limb
salvage,
%

Local
recurrence,
%

Metastases,
%

Overall
survival,
"/o

32
15
17

15
24
32

91
80
88

3
6
0

25
NS
35

70
79
82

77
105

60
24

96
97

4
8

NS
NS

64
95

85
89

>24
60

96
93

13
14

NS
NS

68
66

NS = not stated.
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protocol 3 (from 3500 rad in 10
fractions to 1750 rad) and this
doubled the local recurrence rate.
Judging from the results of proto
col 2, the rate of metastasis was not
affected by improved local control
and the survival rate may not be
better. Protocol 3 still has a very
short follow-up. When the results
of preoperative and postoperative
irradiation as in the studies by
Karakousis and associates35 and Abbutucci and colleagues,36 are used
for comparison (Table IV), the local
recurrence rates with radiotherapy
only are slightly higher, but the
outcome is otherwise similar, again
casting doubt on the value of intra
arterial chemotherapy. Eilber’s
group is currently conducting a
randomized trial comparing intra

arterial versus intravenous preoper
ative chemotherapy, and it may be
that the theoretical advantages of
intra-arterial chemotherapy will not
be clinically evident.
Systemic Adjuvant Chemotherapy

Since the frequency of soft-tissue
sarcoma is approximately 2 in
100 000, the difficulties of perform
ing good randomized studies of
adjuvant chemotherapy in this het
erogeneous group of tumours are
obvious. Most studies published or
in progress are flawed.
To examine the role of adjuvant
ADR, the results of five randomized
studies37-41 are summarized (Table
V); each of them compares a che
motherapy group with a random

Table V - Randomized Studies of Adjuvant Adriamycin
Series

No. of
patients

Median
follow-up, mo

59

28

64
114
146
75

20
30
36
49

Gherlinzoni and associates, 198637

Antman and associates, 198738
Eilber and associates, 198639
Alvegard, 198640
Wilson and associates, 198641

Outcome
RFS p < 0.005
in favour of
ADR. No data on
overall survival
NS
NS
NS
NS

RFS = reiapse-free survival, NS = not significant.
Table VI - Randomized Studies of Adjuvant Combination Chemotherapy

Series
Edmonson and associates
(Mayo Clinic), 198444
Lindberg and associates
(M.D. Anderson
Hospital), 197645

Combination
VCR/DACT/CYCL0
alternating
VCR/ADR/DTIC
12 mo
VCR/ADR/CYCLO

VCR/DACT/CYCL0
Benjamin and associates
24 mo
(M.D. Anderson
Hospital), 198746
Rosenberg and associates ADR/CYCLO/HDMTX
(National Cancer
14 mo
Institute), 198547
Bramwell and associates,
CYVADIC
198748
8 mo

No. Of
patients

Median
follow-up,
mo

Outcome

61

64

NS

43

120

65

60

317

37

RFS, p = 0.04 in
favour of
chemotherapy OS
NS

RFS and OS, p = 0.04
in favour of
chemotherapy
RFS, p = 0.01 in
favour of
chemotherapy OS
NS

NS = not significant, OS = overall survival, HDMTX = high-dose methotrexate.
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ized control group treated only by
surgery with or without radiothera
py. The Scandinavian study of Alvegard40 is the largest but has been
reported only in abstract form and
the follow-up is relatively short.
Nevertheless, it has the greatest
power to detect differences between
the two arms, and the various prog
nostic factors are more likely to be
evenly distributed. The Boston/ECOG study of Wilson and
colleagues41 has much longer fol
low-up than the other studies, and
although there was a slight delay in
the appearance of metastases in the
ADR arm, there have been no sig
nificant differences in disease-free
survival or overall survival for all
patients or those with extremity
sarcomas only.
The only study giving positive
results, that of Gherlinzoni and col
leagues from Bologna,37 has been
severely criticized.42 The number of
patients was relatively small and
there were three different surgical
groups. These factors, combined
with a poor randomization tech
nique, led to considerable imbalance
in prognostic factors between the
arms. A recent update of this
study,43 involving 77 patients (33
receiving ADR and 44 controls),
demonstrated improvement in relapse-free and overall survival for
the ADR treated group, but the
median duration of follow-up was
not stated.
At present there is no firm evi
dence that adjuvant single-agent
ADR affords any substantial benefit
in soft-tissue sarcomas. However,
delay in the appearance of metasta
ses in some studies suggests that
more aggressive chemotherapy may
be worth pursuing.
Randomized studies of various
types of combination chemotherapy
versus control are depicted in Table
V J .« -4 8

The first study was performed by
Lindberg and colleagues at the
393
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M.D. Anderson Hospital and Tumor
Institute in the early 1970s and
reported after 18 months’ follow
up.45 At that time, the chemothera
py group was doing slightly, al
though not significantly, worse. Re
cently this study has been rea
nalysed after 10 years’ follow-up.46
The relapse-free survival now fa
vours the chemotherapy group, but
although overall survival is better
for that group, the difference is not
significant. Local recurrence was
lower in the chemotherapy arm (two
versus eight), but metastases oc
curred with similar frequency —
45% (9 of 20) in the chemotherapy
group versus 48% (11 of 23) in
controls.
Because the early results of the
M.D. Anderson Hospital study were
negative, the trial from the United
States National Cancer Institute
was the first randomized study47 to
suggest benefit for adjuvant chemo
therapy. It should be emphasized
that this study had serious flaws —
the number of patients was very
small, increasing the likelihood of
imbalance of known and, more im
portantly, unknown prognostic fac
tors between the arms; the control
group has done worse than expect
ed when compared with results re
ported by other centres, thus mag
nifying the difference between the
two arms. Because the ADR dose
was pushed to tolerance there was a
30% incidence of subclinical cardi
omyopathy detected by nuclear
medicine scans, and three patients
suffered congestive heart failure.
Benefit was observed only in ex
tremity sarcomas; the same chemo
therapy had no effect in head, neck
and trunk sarcomas. The most re
cent analysis,49 with median follow
up of 7 years, no longer demon
strates improved survival for the
chemotherapy group (p = 0.124).
Building on the results of their
previous study,47 and dismayed by
the high incidence of cardiomyopa
394

thy, Rosenberg and colleagues com
pared their “standard” chemothera
py with an abbreviated course of
treatment, giving much lower total
doses of ADR and cyclophospha
mide and omitting high-dose me
thotrexate.49 There were no signifi
cant differences between the two
treatments, in terms of 5-year dis
ease-free (72%) and overall (75%)
survival. In view of the lack of
efficacy of ADR as an adjuvant, and
the minimal activity of cyclophos
phamide in advanced disease, it
would be surprising if this combina
tion proves to be effective.
A Mayo Clinic study44 did not
demonstrate any benefit for adju
vant chemotherapy, but the inci
dence of local recurrence (30%) was
high in this trial, perhaps because
radiotherapy was not used. In addi
tion, the chemotherapy used was
inadequate — the vincristine, actinomycin D, cyclosphosphamide
combination is inactive in advanced
disease, and as vincristine, ADR,
dacarbazine was only alternated
every 6 weeks with the first combi
nation, patients received active
drugs only every 12 weeks, and at a
low dose intensity.
For all patients in the EORTC
study,48 there was a significant im
provement in relapse-free survival in
the CYVADIC arm (p = 0.01),
although this is of borderline signif
icance on subgroup analysis by site,
for both limb sarcomas (p = 0.06)
and those of the head, neck and
trunk (p = 0.09). However, there
was no benefit for any group in
terms of overall survival. In fact,
the improvement in relapse-free sur
vival was entirely accounted for by
reduced local recurrence in the CY
VADIC arm (p = 0.005) whereas
distant metastases occurred with
equal frequency in both arms (p =
0.28). It is intriguing that the re
duction in local recurrence seems to
be occurring in head, neck and
trunk tumours.

Conclusions
Although the majority of studies
suggest some limited benefit for
adjuvant chemotherapy, the optimal
regimen and timing of such therapy
remain to be established. The con
clusions of the National Institutes
of Health Consensus Development
Conference on Bone and Soft-Tis
sue Sarcomas, 1984, remain rele
vant — “the efficacy of adjuvant
systemic chemotherapy for high
grade sarcomas remains to be estab
lished within the context of pro
spective clinical trials.”50
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SESAP V Question
Items 253-255
A 54-year-old man has noted an increase in the size o f his left thigh over the last 18 months. Physical
examination reveals a fairly well-circumscribed, rubbery, nontender, 9.0- X 5.0-cm mass on the medial aspect of
the thigh, noticeably more prominent with the knee extended. The patient has no history of trauma or recent
infection.
253. The procedure LEAST likely to aid in management o f this patient is
(A) conventional roentgenography of the thigh
(B) angiography
(C) ultrasonography of the thigh
(D) computed tomography o f the thigh
(E) lymphangiography
254. A soft tissue mass is demonstrated in a subfascial plane o f the thigh. The most appropriate method for
determining the histopathology would be

-4

(A) multiple percutaneous aspiration needle biopsies
(B) incisional biopsy
(C) “ core"’ needle biopsy
(D) enucleation of the lesion for biopsy
(E) wide local excision
255. Pathologic examination shows liposarcoma. Definitive treatment might include each o f the following
EXCEPT

Y - t-

rr

(A) wide anatomic soft-part resection
(B) adjuvant postoperative radiotherapy
(C) adjuvant postoperative chemotherapy
r~

(D) preoperative radiation therapy
(E) preoperative systemic chemotherapy
For the incomplete statements above, select the one completion for each that is best of the five given.
For the critique of Items 2 5 3 -2 5 5 see page 426.
(Reproduced by permission from SESAP V Syllabus: Surgical Education and Self-Assessment Program No. 5.
For enrolment in the Surgical Education and Self-Assessment Program No. 5, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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3. Limb-Sparing Management in Extremity
Soft-Tissue Sarcomas in the Adult: the
Radiation Oncologist’s Viewpoint
Brian O’Sullivan, MB, FRCPC

Current management of extremity soft-tissue sarcomas achieves local control in a
high proportion of patients. This paper describes the local methods to conserve limb
function that have largely replaced traditional approaches of ablative surgery.
Frequently, these methods employ conservative surgery with preoperative or
postoperative radiotherapy. An understanding of the biology and behaviour of these
rare tumours is necessary to optimize the goals of limb conservation without
compromising local control. Appropriate surgical and radiotherapy techniques are
facilitated by planned pretreatment staging methods and communication between the
surgical and radiation oncology teams. Although a high rate of local control can be
expected, distant metastases continue to be a problem. Future strategies should be
directed towards scheduling of optimal local treatments with the investigation of
adjuvant systemic methods to reduce the rate of distant metastases.

Le traitement actuel des sarcomes des tissus mous des membres assure une cure
locale chez un grand nombre de malades. Cet article decrit les moyens utilises
localement pour conserver la fonction du membre, lesquels ont largement remplace
l’approche traditionnelle de chirurgie ablative. Souvent, ces methodes ont recours a
une chirurgie conservatrice accompagnee d’une radiotherapie pre- et postoperatoire.
II est necessaire de bien connaitre la biologie et le comportement de ces tumeurs
rares, si Ton veut optimiser l’objectif de conserver le membre sans compromettre la
cure locale. Les techniques chirurgicales et radiotherapeutiques appropriees sont
rendues plus faciles par une planification des methodes employees avant traitement
pour evaluer le stade evolutif de la maladie, et par une bonne communication entre
les equipes de chirurgie et de radiotherapie. Meme si on peut s’attendre a un bon
taux de cures locales, les metastases a distance demeurent un probleme. Dans
l’avenir, les strategies devront viser a etablir un programme des traitements locaux
optimums, tout en cherchant les therapies adjuvantes systemiques destinees a
reduire le taux des metastases a distance.

T

hirty years ago Cade1-2 noted
that radiotherapy combined
with surgery was of greater value
than surgery alone in treating softtissue sarcoma of the extremities.
Because of a long-standing miscon
ception that these tum ours were
resistant to radiotherapy,3 the main
stay of management continued to
be radical surgical excision, often
consisting of limb amputation, and
only recently have Cade’s observa
tions been widely accepted. An un
derstanding of certain biologic,
technical and behavioural features
of these lesions and their treatm ent
has resulted in a modified philoso
phy toward management. This dis
cussion focuses on some of these
issues, provides evidence for the
efficacy of adjuvant radiotherapy in
a conservative surgical approach
and describes the radiotherapy op
tions and methods of administra
tion.

Biologic Issues of Importance
for Radiotherapy
From the Department o f Radiation Oncology, The Princess Margaret Hospital, Toronto, Ont.
Presented as part o f a symposium on current perspectives in the management o f soft-tissue
sarcomas, by the Royal College in cooperation with the Canadian Oncology Society, the
Canadian Orthopaedic Association and the Canadian Association o f Radiation Oncology, at the
56th annual meeting o f the Royal College o f Physicians and Surgeons o f Canada, Winnipeg,
Man., Sept. 12, 1987
Accepted for publication Apr. 25, 1988
Reprint requests to: Dr. Brian O ’Sullivan, Department o f Radiation Oncology, The Princess
Margaret Hospital, 500 Sherbourne St., Toronto, Ont. M 4X 1K9
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The Compartmental Nature of
Soft-Tissue Sarcomas
Soft-tissue sarcomas typically re
spect fascial boundaries, interm us
cular septae, bones, tendons and
joint capsules. As a result, tum our
enlargement in most cases remains
confined to the compartment of
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origin and occurs centifugally along
fascial planes. Extracompartmental
spread by direct invasion is uncom
mon but may be seen in very large
or neglected lesions. Usually it re
sults from an extracompartmental
origin de novo or from diagnostic
(biopsy) or therapeutic (resection)
interventions, which have breached
a fascial boundary. Lesions arising
de novo in intercompartmental
spaces (extracompartmentally) pose
specific problems for both surgeon
and radiation oncologist in their
choice of appropriate resection or
radiation volumes. Such sites in
clude the femoral triangle, popliteal
fossa and antecubital fossa, axilla
and subcutaneous tissues where
distinct barriers to tumour spread
are not present. Management of
compartmental lesions, on the other
hand, can make use of the localized
nature of the tumour, thereby spar
ing unnecessary resection. Local
treatment must be planned with
knowledge of the precise localiza
tion of the tumour and the areas at
risk for subclinical disease. Where
available, magnetic resonance imag
ing and computed tomography help
to identify the anatomic extent of
the disease and also any important
structures that may be involved in
the dissection. Together with the
operative and pathology reports,

initial imaging information is also
useful when planning subsequent
postoperative radiotherapy fields.
Regional Node Involvement

Regional lymph nodes are in
volved in only 3% to 5% of adults
with an extremity lesion,4 an excep
tion being epithelioid sarcoma, for
which rates approaching 50% have
been quoted for synchronous and
metachronous nodal disease.5 How
ever, regional node dissections and
deliberate inclusion of nodes within
radiation treatment portals are not
routine. To do this would com
pound the technical problems in
volved in providing optimal preser
vation of limb function because of
complications relating to surgery
and radiotherapy.
The Capsule or Pseudocapsule

Unfortunately there is no defined
anatomic capsule to provide a local
barrier to tumour spread. On the
contrary, the apparent “capsule” is
nothing more than a layer of com
pressed normal tissue created by
the rapid centrifugal expansion of
tumour. This layer is invaded by
microaggregates of tumour as is
the surrounding reactive zone of
peripheral normal tissue (Figs. 1

and 2). Similar microaggregates can
be expected to exist some distance
from the margins of gross tumour
and may form tumour satellites or
micrometastases in higher grade le
sions. Furthermore, if the pseudo
capsule has been penetrated during
surgery, areas around the dissection
site or involved in residual hemato
ma will likely harbour tumour
cells.6 This explains local failure
after both conservative and radical
procedures involving marginal tu
mour removal. For the same rea
sons, if gross tumour is visible
within the wound it can be accepted
that tumour seeding has occurred,
even if the affected area is subse
quently totally resected through
the same incision. These concepts
also explain “field edge” local
failures after postoperative radio
therapy, when tumour cells may
have migrated some distance along
fascial planes during the dissection,
in postsurgical hematoma or pri
marily as micrometastases.6

4

~

A

Specific Pathologic Details

There is agreement that similar
management approaches are re
quired for the individual histologic
subtypes of soft-tissue sarcoma. Al
though different histologic subtypes may occur more commonly in

h

V>
♦v

FIG. 1 — Gross specimen of fibrosar
coma after compartmental resection.
Tumour is growing into surrounding
muscle (A) on most of surface where it
has formed pseudocapsule. Fascial
layer contains growth (B) in remaining
area.
398

Fig. 2a

Fig. 2b

FIG. 2 — (a) Part of pseudocapsule shows tumour cells infiltrating and
interdigitating between muscle fibres, (b) Fascial area shows tumour contained by
true barrier to tumour spread (hematoxylin and eosin, original magnification X

200 ).
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LIMB-SPARING IN LIMB SARCOMAS

certain age groups or anatomic
sites, their behaviour is more close
ly linked to tumour size and grade.
Indeed, alterations in management
have been suggested, depending on
the grade of the lesion; higher
doses and larger volumes are fa
voured for higher grade lesions.7
Microscopic findings of incomplete
removal are indications for further
treatment; further surgical removal
should be attempted when feasible
and is usually combined with adju
vant preoperative or postoperative
radiotherapy. In surgical resections
that included radical margins of
healthy tissue (minimum 2 cm), the
benefit of radiotherapy is unproven.

Adjuvant Radiotherapy

dures ranging from intralesional,
marginal and wide excisions to
more radical forms of surgery with
variable amounts of tumour residu
um. Both local and ablative surgical
excisions may be described by these
terms. An ablative operation includ
ing a radical margin of healthy
tissue is expected to provide at least
80% local control of the primary
lesion; if such margins cannot be
obtained this level of control cannot
be achieved and the tumour may be
better managed by using combined
approaches. Satisfactory outcomes
for conservative limb-sparing sur
gery alone or in combination with
adjuvant radiotherapy should pre
serve limb function at an acceptable
level of risk and also retain local
control and survival rates similar to
those of ablative surgery.

Goals o f Treatment
Principles in Adjuvant Radiotherapy

Table I4-8 describes the expected
outcome of surgery as the only
treatment. The terms used conform
to accepted terminology8 for proce
T a b le 1 -

Local Control After Surgery as the Sole Modality*
D efinition

P ro c e d u re t

C o n seq u en ces

Intralesional

Incision through
pseudocapsule

Excisional
(marginal)

Pseudocapsule removed

Wide

Removal with “ normal"
tissue
Removal with
uninvolved anatomic
barrier (> 2 cm)

Radical

Gross tumour can be controlled
by radiotherapy alone, but the re
sults are inferior to those achieved

Residual gross tumour.
All tissues
contaminated
“ Shell-out":
microscopic tumour
remains
Frequently leaves
microscopic tumour
No residual tumour

Local
fa ilu re , %

9 0 -1 0 0
8 0 -9 0
50
0-20

‘ Data from Simon and Enneking® and Leibel.4
tTerminology describes features of surgical margin not technique of removal.
T a b le II

- Patterns of Failure for Radical Surgery Alone and Conservative Surgery with
Postoperative Radiotherapy
No. of
c ases

Radical surgery and/or amputation
alone
Conservative surgery and postop
radiotherapy

Local fa ilu re
and d is ta n t
m e ta s ta s e s , %

D is ta n t
m e ta s ta s e s , %

464

18.1

31.5

416

18.3

22.6

‘ Data from Suit and colleagues.10
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by conventional approaches.9 Sur
gery alone necessitates radical mar
gins (2 cm minimum); if lesser mar
gins are planned, adjuvant radio
therapy should be considered. In
any treatment decision, it should be
realized that a satisfactory function
al result may be achieved by conser
vative resection with preoperative
radiotherapy instead of postopera
tive radiotherapy for an ablative
procedure with inadequate margins.
In the latter case, the patient has
received combined modality treat
ment without the benefits of limb
conservation.10
Strategies for the combined use
of radiotherapy and surgical resec
tion include preoperative,1011 post
operative,12-14 intraoperative10 and
brachytherapy techniques.15 Preop
erative radiotherapy has been com
bined with intra-arterial chemother
apy,1617 and frequently postopera
tive “boosts” are included. Altered
fractionation regimens have also
been described for both preopera
tive (with16 and without chemother
apy18) and postoperative sched
ules.19 The method of administra
tion of radiotherapy is governed by
a combination of factors, including
referral pattern, institutional poli
cies and the available resources.
Table II demonstrates pooled
data for the use of adjuvant radio
therapy compared with radical sur
gery. The important feature demon
strated is the excellent local control
achieved regardless of the adjuvant
treatment used. Survival outcome is
not prejudiced by conservative com
bined modality approaches com
pared with radical surgery.20
Table III illustrates the relative
merits of preoperative and postoper
ative radiotherapy. In general, a
smaller volume of normal tissue
requires treatment if the therapy is
administered preoperatively; postop
erative treatment must include a
margin of normal tissue beyond the
limit of surgical dissection. Thus,
399
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all skin incisions and tissue planes
that have been disrupted during the
procedure are at risk from contami
nation by tumour satellites and skip
lesions and require inclusion within
the zone of irradiation. This may
necessitate treatment to otherwise
uninvolved regions including joints,
an entire limb circumference or ex
tensive length of an extremity. Fur
thermore, a planned preoperative
course assists communication be
tween treating surgeons and radia
tion oncologists; surgical proce
dures are discussed beforehand with
knowledge of the proposed tissues
to be irradiated, and the topography
of surgical scars can be planned
with precision. Radiation treatment
portals can be reviewed in conjunc
tion with the diagnostic x-ray films
and histologic findings. In this man
ner difficult management issues can
be minimized.
Postoperative referral for radio
therapy may be associated with pro
cedures that counteract the goals of
limb-sparing treatment. If preopera
tive imaging has not documented
the tumour location and if the pa
tient has not been assessed before
hand by the radiation oncologist,
irradiation volumes tend to be ex
cessive. Unplanned surgical ap
proaches may result in transverse
incisions crossing from involved to
uninvolved compartments, and
drain sites positioned in unsatisfac
tory locations; these may signifi
cantly expand the potential regions
of contamination and the width of
limb requiring treatment. Conse
quent irradiation can result in pain
ful fibrosis, distal edema and loss of
function, which may ultimately lead
to limb amputation. Another con
sideration is the availability of a
final pathology report when using
postoperative radiotherapy. This is
a theoretical advantage because the
management approach should be
determined beforehand based on the
initial incisional biopsy. Rarely,
400
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wound healing may be delayed by
preoperative therapy and after ex
tensive or complicated surgery in
the absence of radiotherapy. In the
latter situation, one is faced with
the dilemma of an unhealed wound
that may contain active tumour,
and the need to delay therapy to
allow the wound to mature. Since
active tumour seedings will be pres
ent at the tumour margins, preoper
ative treatment allows combined
therapy to be completed in the
shortest time and problems of
wound healing can be considered
knowing the threat of tumour re
growth is less.
Finally, preoperative and postop
erative radiotherapy, although
providing essentially similar rates of
local control, are not truly compara
ble. Suit and associates10 showed
that their patients who received
preoperative therapy had a greater
number of lesions larger than 10
cm in dimension (43% versus 18%
for postoperative therapy). Al
though prospective comparison may
present a useful clinical exercise, its
feasibility would be affected by the
number of “inoperable” cases that
could not be managed in a postop
erative regimen, requiring preopera
tive treatment as the only realistic
approach and thereby rendering in
terpretation of the results difficult.

plans. Management of other forms
of malignant disease usually utilizes
standard treatment, involving radia
tion fields determined by variations
around conventional anatomic land
marks. In contradistinction, extrem
ity soft-tissue sarcomas are atypical,
and therapy is outlined according to
the principle of sparing a maximum
volume of normal tissue while en
compassing an acceptable target
volume.
Optimal dose delivery usually in
volves the use of several beams and
different qualities of radiation (i.e.,
photons, electrons or interstitial im
plants). Beam configurations should
be assessed initially on a simulator
(a diagnostic-like x-ray unit de
signed to mimic the precise geome
try of the chosen therapy machine).
Fluoroscopy and roentgenography
to demonstrate beam arrangements
are additional features of this proc
ess. Verification port films on the
treatment machine are then taken
before treatment begins. In general,
the goal of the therapy is the
administration of a moderate dose
(e.g., 50 Gy in 25 treatments) to a
volume judged to contain micro
scopic amounts of tumour. This
volume will differ, depending on
whether the situation is preopera
tive or postoperative. Most authors
recommend margins ranging from 5
to 10 cm beyond involved tissues
and advise the larger volumes for
high-grade lesions.721 Higher doses
are administered by reduced portals
to tissues at higher risk (the surgi
cal bed and scars) to provide mini-

Technical Factors and Radiotherapy

For the radiation oncologist, softtissue sarcomas present challenging
but time-consuming treatment
Table III -

Is s u e s in P re o p e ra tive and P o s to p e ra tiv e R a d io th e ra p y S c h e d u lin g

Issue
In te rs p e c ia lty c o m m u n ic a tio n
T u m o u r c o n tro l p ro b a b ility
“ In o p e ra b le ” d is e a s e
W o u n d h e a ling

Preoperative
E x ce lle n t
E x c e lle n t
S ta n d a rd
P o te n tia l d e la y

R a d io th e ra p y v o lu m e

M in im u m

P a th o lo g y d e ta ils
F u n ctio n a l o u tc o m e

B io p s y o n ly
S m a ll ra d ia tio n v o lu m e m a y
e n h an ce

Postoperative
F re q u e n tly a b s e n t
V e ry g o o d
P re o p re q u ire d
A ffe c te d s o le ly b y su rg ic a l
e x te n t
D e te rm in e d b y s u rg ic a l
e x te n t
F u ll sp e c im e n
A c c e p ta b le
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mum tumour doses of 60 Gy in 30
treatments for low-grade lesions
and 66 Gy in 33 treatments for the
higher grade lesions.7
The initial volume should include
all surgical scars and the tumour
area determined clinically and by
computed tomography and magnet
ic resonance imaging. Postoperative
treatment is facilitated by surgical
clips inserted at the tumour site
(Fig. 3). Radiotherapy planning is
assisted by computerized dosimetry
interphasing with computed tomo
graphic images of the patient in the
treatment position. This allows the
optimal choice of radiotherapy vol
ume (Fig. 4). As far as possible, a
generous longitudinal strip of the
limb circumference is protected dur
ing treatment to avoid circumferen
tial fibrosis and distal edema. Immo
bilization of the limb may enhance
repetition of the daily treatment

#-

plan. Beam modification by com
pensators and wedge filters may
contribute to a more uniform distri
bution of dose within the chosen
region by correcting for irregulari
ties in patient contour. Other beam
modifiers include shields, which ex
clude tissues from the treatment
volume, and a tissue-like bolus me
dium, which allows the dose to be
placed on the surface of scars and
grafted regions when using skin
sparing megavoltage (greater than
1 MeV) photon and electron beam
treatment.
Brachytherapy
Excellent local control has been
reported at Memorial Sloan Ketter
ing Center15 by combining conser
vative limb-sparing surgery with
postoperative tumour bed irradia
tion using iridium-192. The proce-

dure involves the postoperative in
sertion of iridium sources into the
tumour bed 72 hours after loading
catheters are positioned, 1 cm
apart, at the time of surgery. Doses
of approximately 40 Gy are admin
istered over 4 to 5 days and have
shown local control rates approach
ing 100%.15 The method offers an
alternative effective means of spar
ing the limb, but because it involves
a commitment to brachytherapy
techniques including technical ex
pertise and necessary cooperation
between a large group of different
specialties, it is not practised in
many centres.
Indications for Radiotherapy
Although “close” or positive
margins of surgical resection repre
sent indications for radiotherapy,
there is no uniform agreement that
radiotherapy should be carried out
in all such cases. Further surgical
resection may be indicated before
radiotherapy is administered if the
margins of resection are indeed in
adequate.
In their study, the Roswell Park
Group12 omitted radiotherapy in pa-

yl

Fig. 3a

V
—/

/

Fig. 3b

FIG. 3 — (a) Patient in prone position receiving postoperative radiotherapy for
tumour originating in left deltoid region. Megavoltage photons are directed to
spare medial side of left upper arm. (Field is defined by light field of treatment
unit.) Note longitudinal scar positioned in lateral deltoid area, (b) Simulator film.
Clips define surgical bed. Shield is to be introduced after dose of 40 Gy to protect
humoral head and shoulder joint.
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FIG. 4 — Preoperative radiotherapy
treatment plan for malignant fibrous
histiocytoma in lateral compartment of
lower leg. Surgeon believed lesion
could not be resected without entering
all three compartments of leg. Preop
erative treatment permits anterior
compartment to be spared. This would
have been impossible postoperatively.
(Field arrangement: two opposed cobalt-60 beams 10 X 15 cm.)
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tients whose tumours were resected
with a minimum margin of 2 cm.
The 5-year local control rates for
this group (83%) compared favoura
bly (93%) with a group who re
ceived postoperative radiotherapy
after tumour resection in which the
margins were less than 2 cm. De
tails of prognostic factors (grade
and size for both groups and micro
scopic residuum for the group with
margins less than 2 cm) were not
provided for the two groups sepa
rately. These data suggest that a
2-cm margin may be safe for resec
tion alone, although, in the absence
of information to the contrary, cau
tion should still be exercised for
large and high-grade lesions.
At the other extreme of patients
having tumour resection with
“close” margins, is the patient with
microscopic involvement of resec
tion margins. Leibel and associ
ates13 suggested that postoperative
radiotherapy can effectively sterilize
“ microscopic or small amounts of
visible tumour at the margin” . De
spite this report, postoperative ra
diotherapy, after incomplete sur
gery, has had an adverse effect on
local control in several reports, in
cluding a retrospective series (Bell
RS, O’Sullivan B: Unpublished data,
1988) from The Princess Margaret
Hospital in Toronto (Fig. 5). Four
groups were identified according to
whether the margins of resection
were microscopically involved, and
whether the margins were achieved
by a single or multiple surgical
procedures (excluding biopsy). For
the combined group with micro
scopic involvement of resection
margins, the 5-year actuarial local
control rate was 50% and the out
come for the two subsets was not
significantly altered by the number
of surgical procedures. For the
group with clear margins, regard
less of how close these were, the
Figure was 92% and remained unin
fluenced by a second procedure per
402

formed to obtain negative margins.
The detrimental effect of involved
surgical margins on local control
was independent of other known
adverse factors, including tumour
grade and size.
Two series10-20 reported unfavou
rable local control rates when dis
ease was present in the margins of
resection. Incomplete surgery and
postoperative radiotherapy for le
sions staged IIB, IIIB, and IVA
provided 5-year actuarial local con
trol of 58%, compared with 75% for
similar-stage recurrent disease and
83% for complete resection.10 Ro
senberg and colleagues20 reported
greater likelihood of local recur
rence if resection margins were pos
itive than if they were negative (p <
0.0001), despite the use of radio
therapy postoperatively.

Normal Tissue Effects After
Limb-Sparing Treatment
Criteria for assessing limb func
tion have varied between series and
the literature contains no confident
statements based on prospective
data. Nevertheless, acceptable func

tion can be expected in 80% to 90%
of patients after radiotherapy and
surgical resection, although this
rate will vary depending on the
nature of the underlying disease
process, the extent of surgical re
section and the volume of radiation
administered. Series in which preop
erative radiotherapy was used1016’17
had higher complication rates (more
than 10%) than those in which
postoperative radiotherapy was
used (6.5%).14 This may be because
of delayed wound healing after the
former but is more likely owing to
larger tumours requiring more ex
tensive surgery.

vx
*■

-X

JL.

Conclusions
Extremity sarcomas represent a
rare group of malignant lesions.
The combined efforts of many dif
ferent medical disciplines have suc
ceeded in improving management
over the past 20 years, mainly in
the area of local control where
similar rates of control and survival
have been achieved by limb-sparing
methods and by ablative surgery.
Unfortunately metastases still devel-
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FIG. 5 — Effect of resection margins on local control. Relapse-free rate for patients
with gross tumour resection who received adjuvant radiotherapy. Patients were
divided into four groups depending on involvement of surgical margins and
whether one or more procedures were used.
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op rapidly in high-risk patients.
Future efforts should be directed
toward more effective systemic ad
juvant therapy — innovations are
needed in scheduling radiotherapy
and chemotherapy to integrate
these two modalities with surgery.
In this manner, patient survival may
be enhanced without danger of
compromising local control and
functional outcome.
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4. Role of the Pathologist in the
Management of Soft-Tissue Sarcomas
A.J. Worth, MD, FRCPC

T

The contribution of the pathologist to the management of soft-tissue sarcomas is
threefold. First, and most important, is to establish the correct pathological
diagnosis which should include the histologic type, subtype and grade of the
tumour. This information, correlated with the size, site, clinical and radiologic
presentation, is the key factor in determining the biologic behaviour of the tumour.
As soft-tissue sarcomas frequently demonstrate histologic variability from one area
to another, biopsy with computed tomography or radiologic guidance and adequate
sampling is essential.
Second, careful marking of the surgical resection margins in consultation with
the surgeon is necessary to determine the completeness of excision.
Third, examination of the resected specimen may also provide useful information
on the sensitivity of the sarcoma to any previous radiation or chemotherapy which
the patient may have received.

he pathologist’s contribution
to the management of patients
with soft-tissue sarcomas is in mak
ing the correct diagnosis and ex
pressing the characteristics of the
tumour in such a way that the
management team has a clear un
derstanding of its biologic potential.
An appreciation of the local region
al growth patterns and the potential
of metastatic spread are essential in
planning the type and sequence of
the various treatments.

La contribution du pathologiste au traitement des sarcomes des tissus mous se fait
sentir a trois niveaux. En premier lieu, contribution la plus importante, il y a
l’etablissement d’un diagnostic precis, comprenant le type et le sous-type
histologiques, ainsi que le stade evolutif de la tumeur. Cette information, mise en
correlation avec la taille, la localisation et le tableau clinique et radiologique, est
primordiale pour determiner le comportement biologique de la tumeur. Comme les
sarcomes des tissus mous manifestent souvent une variabilite histologique d’une
region a l’autre, il est essentiel de pratiquer sous controle tomodensitometrique ou
radiologique, une biopsie avec prelevement adequat.
Second apport, la delimination soigneuse de la marge de resection chirurgicale,
etablie en collaboration avec le chirurgien, est necessaire pour permettre une
excision complete.
Troisiemement, l’examen du materiel reseque peut aussi fournir une information
utile sur la sensibilite du sarcome aux traitements radiologiques ou chimiotherapeutiques qu’aurait pu recevoir le malade, prealablement.

Behaviour
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To evaluate the behaviour of a
soft-tissue sarcoma, one needs to
know the cell type, grade, mitotic
rate, size, depth and site. These
factors, considered together, are the
most useful prognostic indicators.
In general, the smaller and the
more superficial the tumour is, the
less likelihood there is that metastases will develop. Similarly, tumours
located distally tend to metastasize
less frequently than more proximal
lesions that frequently are deeply
placed, large and of high grade.1-4
It is not surprising that tumours
situated deep within the soft tissues
tend to be larger at the time of
diagnosis as they are less likely to
be noticed by the patient and fre
quently are misinterpreted initially
as being reactive processes. Failure
to consider a soft-tissue sarcoma in
the initial differential diagnosis is
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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surprisingly common.5 This may re
sult in an inappropriately placed
biopsy incision or an incomplete
local incision, both of which may
compromise the subsequent defini
tive surgery and increase the
amount of potentially contaminated
normal tissue that must be removed
to ensure adequate margins.
Soft-tissue sarcomas are rare
ly truly encapsulated but may
be surrounded by pseudocapsule
of compressed normal tissues and
a reactive zone, giving a clinical
impression of encapsulation. They
usually display infiltrating mar
gins with tongues of tumour which
may, on occasion, extend several
centimetres beyond the palpable
disease. Malignant fibrous histi
ocytoma and dermatofibrosarcoma
protuberans are examples of such
tumours; both tend to grow along
fascial planes in a diffuse perme
ative fashion that the surgeon may
not notice.12 This accounts for the
multiple recurrences frequently
seen adjacent to or within scars of
previous incomplete excisions. A
superficially placed malignant fi
brous histiocytoma that has not
penetrated the fascia seldom metas
tasizes.1’2 Multiple recurrences may
lead eventually to dedifferentiation
or recurrence of the higher grade
components of the tumour which
precede metastatic spread.67 At
tempted enucleation or piecemeal
excision of soft-tissue sarcomas
usually fails, but when a carefully
planned excision is undertaken with
preoperative evaluation of the tu
mour by computed tomography or
magnetic resonance imaging and a
knowledge of the pathologic fea
tures and pattern of spread, local
control is achieved in the majority
of patients without amputation.

Typing
Many sarcomas may be subtyped
VOL. 31, NO. 6 NOVEMBER 1988/CJS

according to their histologic pat
tern. The subtypes frequently corre
late with the nuclear grade of the
tumour. For example, within the
liposarcoma category, a low-grade
well-differentiated lipoma-like subtype, a moderate-grade myxoid lipo
sarcoma or high-grade pleomorphic
or lipoblastic subtype may be recog
nized.12 The first two subtypes in
frequently metastasize, whereas the
pleomorphic or round-cell lipoblast
ic type of liposarcoma frequently
does.1’2 Sarcomas are often hetero
geneous, a single lesion presenting
with a variety of subtypes and vari
able histologic grade.12 It is impor
tant to realize this, as a single-nee
dle core or aspirate may not be
representative of the entire lesion.
Focal necrosis may also be present.
The usual metastatic pattern of
spread of a sarcoma is to lung and
bone, with infrequent involvement
of regional nodes.12 For example,
the histologic pattern reflects the
pattern of metastatic spread as well
as the metastatic potential. In con
trast to the usual metastatic spread,
synovial sarcomas may metastasize
to the regional lymph nodes in
approximately 20% of cases and
have a tendency to spread along
tenosynovial and aponeurotic planes
in a discontinuous fashion.12 The
surgeon must understand their be
haviour and carefully examine the
regional lymph nodes and the te
nosynovial plane resection margins
to ensure completeness of excision.
A preoperative computed tomogram
may be helpful, as may frozen sec
tions from the resection margins at
the time of definitive surgery. Em
bryonal and alveolar rhabdomyosar
comas also frequently metastasize
to regional nodes,12 whereas the
adult pleomorphic type infrequently
does.1’2 Some soft-tissue sarcomas
may have an unusual metastatic
pattern, such as epithelioid sarco
mas which may metastasize to the
soft tissue of the scalp.12 Although

locally aggressive, many soft-tissue
sarcomas are late to invade the deep
fascial planes and tend to displace
the neurovascular bundles;1-2 both
these features may be delineated on
the computed tomogram. Highgrade small cell tumours, such as
lymphomas and neuroepithelioid le
sions, are more permeative, sur
rounding and less frequently dis
placing neurovascular bundles, than
the large cell pleomorphic sarcomas
such as liposarcomas and fibrous
histiocytomas.12

Diagnosis
The differential diagnosis of softtissue sarcomas depends on the site
of the lesion and the age of the
patient;12 it is much more likely
that the soft-tissue sarcoma in a
child will be a small-celled highgrade one such as an embryonal
sarcoma, neuroblastoma, lymphoma
or Ewing’s sarcoma than in an
adult in whom such lesions, apart
from lymphomas, are infrequent.12
For a precise diagnosis and correct
evaluation of biologic potential, it is
important that the tumour be ade
quately sampled. This can best be
achieved by consultation between
the radiologist, surgeon and pathol
ogist, who together can evaluate
the radiologic appearance of the
tumour and plan the areas to be
sampled, choosing areas of different
texture, both close to the “ capsule”
and deep within the tumour, so that
the biopsy material obtained is rep
resentative of the entire lesion.

Tumour Sampling
Various techniques may be used
to obtain a sample of tumour. Fineneedle aspiration may be helpful
initially in determining whether the
lesion is a soft-tissue tumour rather
than an abscess or a reactive proc405
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ess. Great caution is required, how
ever, in interpreting such aspirates,
because highly mitotic, highly cellu
lar reactive proliferative lesions
such as necrotizing fasciitis, pseudosarcomatous fasciitis and myosi
tis ossificans may be easily misinter
preted as a high-grade malignant
lesion. Needle biopsies that yield
generous cores of tissue or open
biopsies are preferred for diagnosis
because they allow better histologic
evaluation of the tumour. In addi
tion to the routine processing of
tumours, electron microscopy, im
munologic staining, including mo
noclonal stains, flow cytometry and
chromosomal analysis may all be
helpful in arriving at a definitive
diagnosis. In order to utilize these
techniques, a variety of fixatives
may be desirable. The surgeon
should alert the pathologist of the
time of biopsy and the pathologist
should either obtain the specimen
directly from the operating room in
an unfixed state or have the speci
men sent immediately in transport
medium to the laboratory for pro
cessing. If this is not possible, the
pathologist should be consulted as
to the desired fixative or fixatives to
be used in each case.

Evaluation of Resection
Margins
Similarly, there should be close
cooperation between the surgeon
and pathologist in the evaluation of
the resection margins of the excised
specimen. In order to do this thor
oughly, it will help if the surgeon
orients the specimen for the pathol
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ogist, indicating the resection mar
gins of greatest concern. It should
be remembered that when fascial
planes are incised by the surgeon,
the fascial tissues tend to retract,
exposing adjacent muscular or fatty
tissues which did not constitute the
true excision margin. If the pathol
ogist cannot evaluate this and does
not have the surgeon’s assistance
to do so, he may inappropriately
mark margins that are thought to
represent excision margins. A vari
ety of solutions may be used to
mark the excision margins; these
include India ink, silver nitrate and
laundry bluing, the latter being
nontoxic and easy to handle.

ing long-term radiation reactions,
often is not perceptible until 3
months or more after the initiation
of radiotherapy.

Summary
The pathologist has an important
role to play in both the diagnosis
and management of patients with
soft-tissue sarcoma. Optimally,
there should be consultation be
tween the radiologist, pathologist,
surgeon and oncologist starting be
fore the initial biopsy investigation
so that the biopsy and subsequent
surgical management can be well
planned and chemotherapy and ra
diotherapy appropriately integrated
into the overall treatment regimen.

Radiotherapy and
Chemotherapy
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the pen icillin s against gram -positive aerobes including coverage of Streptococcus faecalis

plus
the aminoglycosides and 3rd generation cephalosporins
against gram-negative aerobes including coverage of Pseudomonas aeruginosa

plus
the antianaerobic agents including coverage of Bacteroidesfragilis

PRIMAXIN* is not active against Corynebacterium group JK, Fusobacterium varium, Mycobacterium spp.,
Chlamydia spp, Streptococcus faecium, Pseudomonas maltophilia, and some strains of: P. cepacia,
P. pseudomallei, methicillin-resistant staphylococci, and Flavobacterium spp.
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Single-agent antibiotic for
documented and empiric
therapy in many important
infections
□ infections usually treated with combination
therapy
□ infections complicated by underlying
disease
□ nosocomial infections

Imipenem and cilastatin sodium are present in a 1:1 ratio in PRIMAXIN* I.V.
Imipenem is the sole antibacterial component. The role of cilastatin sodium is to
prevent the inactivation of imipenem in the kidney and obtain antibacterial
concentrations of imipenem in the urine.

tCaused by organisms susceptible to PRIMAXIN* I.V.
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PRIMAXIN IV

(im ipenem and cilastatin sodium for injection) *

Clinical efficacy in many
important infections'
EFFICACY IN INTRA-ABDOMINAL INFECTIONS'

91% cure or
improvement
in 164 evaluable patients
1. Kager, L., Nord, C.E.: Im ipenem /
cilastatin in the treatm ent of intra
abdominal infections: A review of
worldwide experience, Rev Infect Dis
7 (Suppl 3): S518-S521, July-August
1985.

EFFICACY IN LOWER RESPIRATORY TRACT
INFECTIONS 2

85% cure or
improvement
in 204 evaluable
patients
2. Acar, J.F.: Therapy for lower
respiratory tract infections with
im ipenem /cilastatin: A review of
worldwide experience, Rev Infect Dis
7 (Suppl 3): S513-S517, July-August
1985.

+Caused by organisms susceptible to PRIMAXIN* I.V.

EFFICACY IN BACTERIAL SEPTICEMIA3

90% cure or
improvement
in 135 evaluable
patients
3. Eron, L.J.:
Imipenem/cilastatin
therapy of bacteremia,
Am J Med 78 (Suppl 6A):
95-99, June 7, 1985.

EFFICACY IN GYNECOLOGICAL
INFECTIONS4

97% cure or
improvement
in 72 evaluable
patients
4. Sweet, R.L.: Imipenem/
cilastatin in the treatment
of obstetric and gynecologic
infections: A review of
worldwide experience,
Rev Infect Dis 7 (Suppl 3):
S522-S527, July-August 1985.

PRIMAXIN IV

(imipenem and cilastatin sodium for injection)

PRIMAXIN* LV. offers management
advantages over combination therapy
that includes an aminoglycoside
Generally well tolerated safety profile
sim ilar to cefazolin'

’

EU 1723 patients, including the severely ill, have received therapy in clinical trials.
The incidence of the most common adverse experience (nausea) was no greater
than 2%.
0 Avoids the potential nephrotoxicity or ototoxicity experienced with

aminoglycosides.
□ Avoids the potential hypoprothrombinemia and clinical bleeding experienced
with cephalosporins with MTTf side chain.
□ Avoids the potential disulfiram-like effect experienced with metronidazole and
cephalosporins with MTT side chain.

Convenience of a single agent
The broadest spectrum single
agent antibiotic representing
a transform ation o f parenteral
antibiotic therapy
5. Calandra G.B., Ricci F.M., Wang C., Brown K.R.: Safety and
tolerance comparison of imipenem/cilastatin to cephalothin and
cefazolin, J Antimicrob Chemother 12(supplD): 125-131,1983.
f Certain antibiotics which possess, as part of their molecular structure, the l-methyl-5-thiotetrazole (MTT)
group have been associated with hypoprothrombinemia (and in some cases, clinical bleeding) and with
a disulfiram-like effect.
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Antibiotic
CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN’ especially when
recommended dosages based on renal function
and body weight were exceeded. These exper
iences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known factors
that predispose to seizures.

^ ACTION
Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic grampositive and gram-negative bacteria.
P R IM A XIN * c o n s is ts of tw o c o m pone nts:
** (1) im ipenem , a derivative of thienam ycin, a
carbapenem antibiotic; and (2) cilastatin sodium, a
*. -'specific inhibitor of dehydropeptidase-l a renal
enzym e w h ic h m etabolizes and in a ctiva te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
j antibacterial levels of imipenem to be attained in the
urine.
-i Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
*■ ' E s c h e ric h ia c o li and s e le c te d s tra in s of
Pseudomonas aeruginosa, imipenem has been
- shown to have highest affinity for PBP-2, PBP-1a
and PBP-1 b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
death without filament formation. When imipenem
M is removed prio r to complete killing of gram
negative species, the remaining viable cells show a
4 measurable lag, termed a “ post-antibiotic effect"
(PAE), prior to resumption of new growth.

-4 INDICATIONS AND CLINICAL USE
PRIMAXIN* (imipenem and cilastatin sodium for
* injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
of bacteria. Where considered necessary, therapy
’’ may be initiated on the basis of clinical judgment
before results of sensitivity testings are available,
v Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient’s clinical condition.
Imipenem is active in vitro against a wide range of
yy gram -positive and gram-negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactam ase producing. Patients have
responded while under treatment with PRIMAXIN*
for single or mixed infections of the following body
systems, when they were associated with a number
of pathogenic species and strains of the genera
listed

YW

1.
2.
3.
4.
5.

r 6’
!

L

7.
8.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
E ndocarditis caused by Staphylococcus
aureus
Bone and Joint Infections
Skin Structure Infections

- -i Gram-positive Aerobes

*

•
•
•

^

•

+

*

Listeria monocytogenes
Nocardia asteroides
S taphylococcus (excluding many strains
which are methicillin resistant)
Streptococcus (excluding S. faecium)

Gram-negative Aerobes

•
*
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus paraintiuenzae
Klebsiella
Morganella morganii

Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

•
•
•

Clostridium (excluding C. difficile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN* (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

WARNINGS
PRIMAXIN* (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN* OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EAC TIO N S MAY REQUIRE
E P IN E P H R IN E AND OTHER EMERGENCY
MEASURES.

and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
these or other species. In other studies, PRIMAXIN*
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
under TOXICOLOGY in the complete monograph).
Nursing Mothers

It is not known whether PRIMAXIN* is excreted in
milk. If the use of PRIMAXIN* is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN* is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

Concom itant administration of PRIMAXIN* and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN*.
PRIMAXIN* should not be mixed with or physically
added to other antibiotics. PRIMAXIN* has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN* with any other beta-lactam antibiotics
has any therapeutic advantage.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with
the use of PRIMAXIN*. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may
respond to drug discontinuance alone. In more
s e v e re c a s e s , m a n a g e m e n t m ay in c lu d e
s ig m o id o s c o p y , a p p ro p ria te b a c te rio lo g ic a l
studies, flu id , electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

PRECAUTIONS

ADVERSE REACTIONS
PRIMAXIN’ (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it difficult to
determ ine causal relationship of adverse ex
periences to therapy with PRIMAXIN*.
Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN* were:

General

Prolonged use of PRIMAXIN* (imipenem and
cila sta tin sodium for injection) may result in
overgrow th of resistant organism s. Repeated
evaluation of the patient’s condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusional*states, or seizures have been
reported with PRIMAXIN* especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
an d/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherence to recommended dosage
schedules is urged especially in patients with
known factors that predispose to seizures (see
D O S A G E A N D A D M IN IS T R A T IO N ). A n ti
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated ne urologically and placed on an ti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN*
should be decreased or discontinued.

Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
p o s s ib ly , p ro b a b ly , or d e fin ite ly re la ted to
PRIMAXIN* were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im p a irm e n t (see DOSAGE AN D A D M IN IS 
TR A TIO N - Dosage in P atien ts w ith Renal
Insufficiency).
Use in Pregnancy

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

The use of PRIMAXIN* in pregnant women has not
been studied, therefore, PRIMAXIN* should be used
during pregnancy only if clearly needed. Use of this
drug in women of childbearing potential requires
that the anticipated benefits be weighed against
possible hazards.

Special Senses

Reproduction studies with bolus I .V. doses suggest
an apparent intolerance to PRIMAXIN* (including
emesis, inappetence, body weight loss, diarrhea

transient hearing loss in
patients with impaired hearing
tinnitus

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

<0.1
<0.1

Respiratory
dyspnea
hyperventilation
thoracic spine pain

TABLE 1
0.1
<0.1
<0.1

Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Renal
oliguria/anuria
polyuria

<0.1
<0.1

Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Body as a whole
polyarthralgia
asthenia/weakness

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha
tase, bilirubin and LDH,
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.

Dosage in Infants and Children

ADULT DOSAGE OF PRIMAXIN*
I.V. A d m inistration
Severity
o f infection

Dose
(m g o f im ip en em )

Dosage
Interval

D aily
Dose

250 mg

6h

1.0 g

Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

CAUTION: CONTENTS OF VIALS NOT FOR .
DIRECT INFUSION.
*

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

Each reconstituted 250 mg or 500 mg dose should
be given by intravenous infusion over twenty to *
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who ,»
develop nausea during the infusion, the rate of
infusion may be slowed.

Mild

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

* Primarily some strains of Ps. aeruginosa.

Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

P a tie n ts w ith c r e a tin in e c le a r a n c e s o f
< 5 mL/min/1.73m2 (<0.08 mL/s/1.73m2) should
not receive PRIMAXIN* unless hemodialysis is
instituted within 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . The p a tie n t s h o u ld re ceive
PRIMAXIN* after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be carefully
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN* is recommended only when the benefit
outweighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN* in
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN*
IN RELATION TO RENAL FUNCTION

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN* (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN*
(imipenem and cilastatin sodium for injection)
represent the quantity of imipenem to be ad
ministered by I.V. infusion only. An equivalent
amount of cilastatin is also present in the solution.

RENAL
FU NC TIO N

M ild
im p airm e nt

M oderate
im pairm ent

Severe*
im p airm e nt

3 1 -7 0
(0 .5 2 -1 .1 7 )

2 1 -3 0
(0.35 - 0.50)

0 -2 0
(0 - 0 .3 3 )

DOSE

D O SA G E
INTERVAL

M AX IM UM
TOTA L
DAILY
DOSAGE

(g)

(h)

(9)

0.5

6 -8

1 .5 -2

0.5

8 -1 2

1 - 1 .5

0 .2 5 -0 .5

12

0.5 - 1 .0 * *

P a tie nts w ith c re a tin in e c le a ra n c e o f 6 to
20 mL/min/1.73 m2 (0.1 -0.3 mL/s/1.73 m2) should
be treated with 250 mg (or 3.5 mg/kg whichever is
lowed every 12 hours for most pathogens. When
the 500 mg dose is used in these patients, there may
be an increased risk of seizures.
x* The highest dose is only recom m ended fo r
infectio n s due to less susceptible organisms
primarily some strains of Ps. aeruginosa.

The dosage of PRIMAXIN* should be determined by
the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.

The median duration of treatment with PRIMAXIN*
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.

Males:

Dosage in Adults

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

*--•

Contents of the 13 mL vials must be suspended and -r*
transferred to 100 mL of an appropriate infusion
solution.
¥

Dosage in Patients with Renal Insufficiency

C R EA TIN IN E
CLEARANCE
m L /m in/1.73 m2
(m L /s/1.73 m2)

Administration

RECONSTITUTION

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.

Electrolytes: Decreased serum sodium, increased
potassium, increased chloride.
Renal: Increased BUN, creatinine.

The recommended total daily dosage of PRIMAXIN*
in children and infants 3 months of age and older is
60 to 100 mg/kg of body weight divided into 4 equal
doses given at six hour intervals. The higher
dosages should be used for infants and young
children. The total daily dosage should not exceed *
2 gram s. C lin ic a l data are in s u ffic ie n t to
recommend an optimum dose for infants and *
children with impaired renal function.

0.85 x above value.

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:

A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the*--*
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to *'•
ensure complete transfer of the contents of the vial
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.
u

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
t
5% or 10% Dextrose Injection
5% Dextrose Injection with 0.02% sodium
bicarbonate solution
5% Dextrose and 0.9% Sodium C hlo rid e
Injection
5% Dextrose Injection with 0.225% or 0.45% ►
saline solution
NORMOSOL-M in D5-W
*
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
V~*
Reconstituted solutions

v

Solutions of PRIMAXIN* range from colourless to
yellow. Variations of colour within this range do not
affect the potency of the product.
v~

PRIMAXIN*, as supplied in vials and reconstituted
as above maintains satisfactory potency for four *
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN* has been found to y „
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.
rV

DOSAGE FORMS
AVAILABILITY

*

PRIMAXIN* is supplied as a sterile powder mixture
in vials containing imipenem anhydrous and
cilastatin sodium as follows:

r

A

3514 Ca - 250 mg imipenem equivalent and 250 mg
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg
cilastatin equivalent in vials.
STORAGE

The dry powder should be stored at a temperature J
below 30° C.

FULL PRODUCT MONOGRAPH
AVAILABLE ON REQUEST
(318-a,7,87)

The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

(lean body weight, kg) x (140 - age, years) x 1.4736
(72) x (serum creatinine concentration, pmol/L)

*®Trademark

Dosage in Elderly Patients

and in females the estimated creatinine clearance
(mL/s) is:

I PAAB |

M EM BER

The recommended dosage of PRIMAXIN* in elderly
patients with normal renal function is the same as
given for adults above. Renal status of elderly
patients may not be accurately portrayed by
measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.

(lean body weight, kg) x (140 - age, years) x 1.2526
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN* is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.

♦
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ROYAL COLLEGE SYMPOSIUM

5. Definitive Surgical Management for
Soft-Tissue Sarcomas
H.R. Shibata, MD, FRCSC, FACS
The surgical management of soft-tissue sarcomas, a seemingly heterogeneous group
of malignant tumours, depends on the circumstances (e.g., untreated primary
tumour, inadequately resected primary tumour, local recurrence, metastasis) and
site.
The basic steps in managing a primary tumour include using the correct method
to establish a diagnosis, obtaining adequate tumour-free resection margins and
giving consideration to adjuvant radiotherapy or chemotherapy, or both. Local
recurrences and metastatic lesions require a multidisciplinary approach.
The relative rarity of this group of sarcomas and the low survival rate associated
with them make it mandatory that such patients be treated in centres able to provide
specialized care from the beginning.

Le traitement chirurgical des sarcomes des tissus mous, un groupe apparemment
heterogene de tumeurs malignes, depend des circonstances (qu’il s’agisse d’une
tumeur primaire non traitee ou non suffisamment resequee, d’une recidive locale ou
d’une metastase) et du foyer.
La marche a suivre dans le traitement d’une tumeur primaire commence par
1’utilisation de la methode diagnostique appropriee, et se poursuit par l’obtention
d’une marge de resection exempte de tumeur adequate en considerant la possibility
d’avoir a utiliser une radiotherapie ou un chimiotherapie d’appoint. Les recidives
locales et les metastases exigent une approche multidisciplinaire.
La rarete relative de ce groupe de tumeurs et le faible taux de survie qui y est
rattache obligent que les patients qui en sont frappes soient traites dans des centres
capables de fournir des soins specialises des le debut.

ith increasing knowledge of
the biology of soft-tissue sar
comas, their surgical management,
as with other human cancers, has
slowly evolved from conservative to
radical techniques and back to con-

W

servative combined with other mo
dalities.
The surgeon’s objective in man
aging patients with soft-tissue sar
comas is cure. Risk factors that are
important in determining the out

From the Department o f Surgery, Royal Victoria Hospital, M cGill University, Montreal, PQ
Presented as part o f a symposium on current perspectives in the management o f soft-tissue
sarcomas, by the Royal College in cooperation with the Canadian Oncology Society, the
Canadian Orthopaedic Association and the Canadian Association o f Radiation Oncology, at the
56 th annual meeting o f the Royal College o f Physicians and Surgeons o f Canada, Winnipeg,
Man., Sept. 12, 1987
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come in the patient with a soft-tis
sue sarcoma are: the size of the
tumour, site or tissue of origin, and
histopathologic grading of the tu 
mour. The smaller the tum our, the
better are the chances for margins
of resection that are free of tum our
and therefore give better overall
results. Sarcomas that originate in
the extremities, both upper and
lower, afford a much better survival
rate than those arising in the head
and neck, trunk, retroperitoneal
space and viscera. The importance
of obtaining a good history and
physical examination, appropriate
laboratory investigations, including
angiography, computed tom ogra
phy and magnetic resonance imag
ing, and a carefully planned biopsy
have already been emphasized.
These measures provide informa
tion essential in planning the defini
tive surgical procedure.

Surgical Treatment
The surgical procedure m ust be
adapted to the circumstances (an
untouched primary, inadequately re
sected primary, local recurrence,
metastasis) and site (extremities,
trunk, head and neck, retroperito
neal space, viscera) of the tum our.
Primary Tumour
Because local recurrence after
simple excision (“shelling o u t” )
ranges from 65% to 90%, the goal
of the surgeon must be surgical
407
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resection with tumour-free margins.
Although the local recurrence rate
may still be as high as 28% to 36%
for high-grade lesions, this may be
reduced by adjuvant therapy.1-2
Soft-tissue sarcomas of the ex
tremities can be managed by four
types of resection: local, wide local,
compartmental and amputation.
• Local resection is limited to a
very small margin of normal tissue.
At times, this may be called an
excisional biopsy, and, unfortunate
ly, no further local procedure is
performed for better local control.
• Wide local resection is the
treatment of choice for superficial
smaller lesions. Frozen-section ex
amination should be carried out
whenever possible at the time of
surgery to ensure tumour-free mar
gins.
• Compartmental resection
should be used for deeper tumours.
This procedure involves removal of
all the muscles in the particular
compartment containing the tu
mour, from their origin to insertion.
Adequate margins may be obtained
easily in a longitudinal axis, but the
distance from adjacent bone, nerves
and vessels may be quite small and
may be the limiting factor.3
• Amputation may be necessary
when the tumour is large and deepseated, compromising major ves
sels, nerves or bone. However, the
modern trend is toward limb sal
vage procedures with adjuvant ra
diotherapy or chemotherapy.4 In the
pattern of care survey of adult
soft-tissue sarcomas carried out by
the American College of Surgeons
in the United States for the periods
1977 to 1978 and 1983 to 1984,
little change was demonstrated in
operative procedures; 6.4% and
8.2% of patients underwent primary
amputation respectively (Table I).1
For tumours in other parts of the
body, the relation of the tumour to
vital structures will determine how
radical the excision must be. In
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traoperative biopsy with frozen-sec
tion examination may help to
achieve tumour-free margins of re
section but does not guarantee free
dom from local recurrence. Howev
er, the 5-year survival figures are
approximately 10% better if biopsy
proven tumour-free margins are
achieved.
Five-year survival rates are close
ly linked to site, being highest for
extremity tumours, intermediate for
head and neck and visceral tu
mours, and lowest for those in the
mediastinum or retroperitoneum.

therapy and chemotherapy
highly recommended.

are

Metastases

A.

If metastatic lesions are confined
to regional nodes, radical lymphadenectomy is recommended, but
the long-term prognosis is poor.5
Resection of pulmonary metastases
in selected patients whose tumour
has a slow doubling time may sal
vage 20% of such patients.6 Occa
sionally, resection of other meta
static sites, such as the liver, may
be appropriate.

***

¥

Inadequately Resected Tumours

If the sarcoma is superficial or of
low grade, or both, further wide
local excision may be adequate.
However, patients with poorly dif
ferentiated sarcomas are at risk for
greater local recurrence and dissem
ination because of previous tissue
contamination, and in such patients
adjuvant therapy should be consid
ered after further resection.

Combination Therapy
Figure 1 suggests an algorithm
that could be followed in the man
agement of soft-tissue sarcomas.
After a soft-tissue mass has been
diagnosed as a sarcoma by the
different methods outlined in the
second box, it can be classified into
subsets by age, site and stage of
disease. The primary resection can
then be performed; the possible
choices are a radical or a limited
local resection. The surgeon should
determine whether the margins of
resection are free of tumour or
involved, because this will influence
the postoperative treatment. The
grading and localization of the tu
mour can also be used to subdivide
management.
If the tumour is of low grade and
localized to the primary site and the
margins of resection are adequate,

Local and Regionally Recurrent
Tumours

Most tumour recurrences occur
within 2 years of primary manage
ment. Distant metastases from
poorly differentiated sarcomas also
develop during this time. If there is
no evidence of metastatic disease,
further resection following the
same principles as outlined for pri
mary tumours are appropriate, but
adjuvant treatments such as radio
Table 1-

*

y '

T y p e o f S u rg ica l P ro c e d u re s U se d in S a rc o m a P a tie n ts W ith o u t M e ta s ta s e s at T im e
o f D ia g n o s is

1977-1978
Procedure

No.

W id e lo c a l re s e c tio n
L im ite d lo c a l re s e c tio n
A n a to m ic c o m p a rtm e n ta l re s e c tio n
A m p u ta tio n
M o re th a n o n e typ e

879
455
168
108
69

T o ta ls

1679

%
5 2 .4
27.1
10 .0
6 .4
4.1

1983--1984
No.
%
1412
583
249
138
108

5 6 .7
2 3 .4
1 0 .0
5 .5
4 .3
4
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then the patient should be followed
up carefully with no further thera
py. If the margins are inadequate,
then repeat resection must be car
ried out; in this case, postoperative
options are radiotherapy or observa
tion. If the tumour is of high grade
(poorly differentiated and still local
ized), radiotherapy must be given
postoperatively; following this, ad
juvant chemotherapy is optional.
If distant metastases are identi
fied and localized, then surgical
resection should be attempted fol
lowed by systemic therapy of some
type. If the metastases are multiple
and multiorgan in nature, then che
motherapy is indicated.

Discussion
It is interesting that there was
very little improvement in the surgi

tomography.
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cal management of soft-tissue sar
comas in North America during two
separate 2-year periods (1977 to
1978 and 1983 to 1984) surveyed
by the American College of Sur
geons. Although their survey did
not indicate the reasons for this
lack of improvement, it appeared
that many North American sur
geons did not adhere to the basic
principles of good surgical manage
ment from the time of surgical
diagnosis to local and regional con
trol (Table I).
Because of the rarity of soft-tis
sue sarcomas, they should ideally
be managed at tertiary care centres
which can carry out multidiscipli
nary treatment. The correct tech
niques for making a surgical diag
nosis should be taught in all surgi
cal training programs and the im
pression made that surgical resec
tion should be performed in the

majority of patients by a surgeon
with expertise and experience in the
field, who also acts as a vital mem
ber of the oncology team. Improve
ment in local control as well as
overall survival can only be
achieved in this manner.
There is an urgent need to inform
practising surgeons of all disci
plines involved in the management
of this type of cancer that multidis
ciplinary management and par
ticipation in clinical trials are neces
sary.
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Guidelines for the Surgical Management
of Soft-Tissue Sarcoma. Report of the
Canadian Sarcoma Group
W.J. Temple, MD, FACS, FRCSC;* V. Bramwell, PhD, MB, BS, FRCPC;t E. Eisenhauer, MD, FRCPC;|
R D.T. Jenkin, MB, FRCR, FRCPC;§ F. Langer, MD, FRCSC;1 A.J. Worth, MD, FRCPCH
The Canadian Sarcoma Group was formed in 1985 by interested surgeons,
oncologists and pathologists. In the evaluation of new protocols, standard surgical
guidelines have been developed which incorporate the concepts of multimodality
therapy, particularly radiotherapy and chemotherapy. Also defined are the
procedures performed: biopsy, marginal resection, wide local excision, radical
resection and the principles to be considered when doing a diagnostic biopsy and a
curative resection, particularly with limb salvage in mind. To optimize local control
of the disease, centres treating sarcomas should have access to computed
tomography, radionuclide scanning, to radiation and medical oncologists, and
members of other surgical specialties. This team approach increases survival by 10%
and also provides the best circumstances in which to study adjuvant therapy.
Surgical guidelines are also essential in order to compare the results of different
clinical trials.
En 1985, des chirurgiens, oncologues et pathologistes interesses formerent le
Groupe canadien pour les sarcomes. A 1’evaluation des protocoles, des directives
chirurgicales standard furent elaborees, lesquelles enveloppent des concepts de
therapie multimodale comprenant radiotherapie et chimiotherapie. Les interventions
pratiquees ont aussi ete definies: biopsie, resection de marge, excision locale
etendue, resection radicale et les principes devant etre consideres quand on effectue
une biopsie de diagnostic ou une resection a visee curative, particulierement quand
on envisage la conservation d’un membre. Afin d’optimiser le controle local de la
tumeur, les etablissements oil Ton traite les sarcomes doivent disposer de la
tomodensitometrie, de la scintigraphie isotopique, de radiotherapeutes et d’oncologues, en plus des membres des diverses specialites chirurgicales. Cette approche
d’equipe augmente la survie de 10% et offre des conditions ideates pour etudier les
therapies adjuvantes. Des directives chirurgicales sont aussi essentielles pour
pouvoir comparer les resultats de differentes etudes cliniques.
From The Canadian Sarcoma Group (CSG) affiliated with the National Cancer Institute o f
Canada and the Canadian Musculoskeletal Society
*Tom Baker Cancer Centre, Foothills Hospital, University o f Calgary, Calgary, Alta.
fLondon Regional Cancer Centre, University o f Western Ontario, London, Ont.
tO n tario Cancer Foundation, Kingston General Hospital, NCIC Clinical Trials Group, Queen’s
University, Kingston, Ont.
§Ontario Cancer Foundation, Toronto Bayview Regional Cancer Centre, University o f Toronto,
Toronto, Ont.
HToronto General H o sp ita l/M o u n t Sinai Hospital, University o f Toronto, Toronto, Ont.
UCancer Control Agency o f British Columbia, University o f British Columbia, Vancouver, BC
Reprint requests to: Dr. W.J. Temple, Tom Baker Cancer Centre, 1331
Calgary, Alta. T2N 4N2
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29th Street NW,

1985 the Canadian Sarcoma
I nGroup
(CSG) was formed by in

terested general surgeons, orthope
dic surgeons, medical oncologists,
radiation oncologists and patholo
gists, supported by the National
Cancer Institute of Canada (NCIC)
Clinical Trials Group. Its purpose is
to develop national protocols and to
initiate or participate in internation
al protocols for sarcoma treatment.
One essential component of the
program is a set of surgical guide
lines to assure adequate local treat
ment. In workshops with the Cana
dian Orthopaedic Association and
the NCIC Clinical Trials Group spe
cific guidelines have been accepted
as a basis for any ongoing or future
adjuvant trials in which the CSG
participates. These guidelines em
brace modern concepts of limb sal
vage surgery for soft-tissue sarco
ma and define minimum criteria for
the eligibility of patients in primary
management multicentre trials. It
is our premise that optimum local
control not only reduces morbidity
but contributes to the overall cure
rate in as many as 10% of patients.1
A standard set of definitions has
been adopted to describe a surgical
procedure.
• Biopsy is removal of a portion
of the tumour for diagnosis.
• Intralesional resection is exci
sion through the pseudocapsule
leaving gross tumour.
• Marginal resection is incom
plete excision, when gross and his
tologically negative tumour margins
are present, but the periphery of the
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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tumour is very close to the resec
tion edge (as close as 1 mm) in one
or more planes.
• Wide resection is excision of
the tumour and at least one layer of
uninvolved fascia or 2 cm gross
distance between tumour and resec
tion edge, proven histologically.
• Radical resection is a compartmental excision involving removal
of muscle groups from origin to
insertion and one fascial plane be
yond the tumour.2

Biopsy Technique
All deep or large soft-tissue mass
es must be considered sarcomas
until proven otherwise. They should
be approached in two stages — a
diagnostic, incisional biopsy fol
lowed by therapeutic excision once
the diagnosis is determined histo
logically.3 The error of doing two
operations for a benign soft-tissue
lesion is less serious than removing,
in one stage, an unsuspected sarco
ma without appropriate planning.
Poor biopsy planning may result in
unnecessary loss of limb.4
Physical examination and com
puted tomography or nuclear mag
netic resonance imaging help to
localize the tumour and permit the
most direct approach to biopsy. A
longitudinal incision is preferred to
a transverse incision so that the
residual scar can be included in the
en-bloc excision of the sarcoma. To
avoid tumour extension the ap
proach to the lesion should be
intra- not intercompartmental. The
adequacy of the specimen may be
verified by frozen-section examina
tion. If a drain is used, it should be
brought through the wound at a
site that will be excised en bloc with
the tumour. Once a precise diagno
sis has been made and the search
for metastatic disease completed,
the patient can be treated appropri
ately.
VOL. 31, NO. 6 NOVEMBER 1988/CJS

Definitive Surgery
The prerequisite for successful
sarcoma surgery is to obtain a
microscopically clear margin around
the tumour, through normal tissue,
not through or near the reactive
pseudocapsule. The fact that mega
voltage irradiation can eradicate mi
croscopic residual disease means
that margins smaller than those
required for radical resection or
amputation may be adequate. How
ever, because of the nature of local
spread of sarcomas along tissue
planes and into unexpected areas, it
is useful arbitrarily to define a wide
surgical margin: a fascial plane sep
arating the tumour from normal
tissue is considered to be the mini
mum acceptable margin. For the
above reasons only basic guidelines
for resection of sarcomas can be
proposed, and these will change
somewhat according to the size of
the tumour and its location. When
these guidelines are followed, opti
mal local control rates should be as
high as 90%.
Guidelines for definitive surgical
resection of sarcoma are as follows:
• When possible a 2-cm margin
of normal tissue should be obtained
around the sarcoma. When an unin
volved fascial plane intervenes, a
margin less than 2 cm is acceptable
but the fascial plane must be includ
ed in the specimen.
• Using frozen sections, the sur
geon must document all margins of
resection as being tumour free at
the time of surgery. The sections
are best taken from the residual
tissue defect in the patient rather
than from the specimen itself. The
closest margin should be checked
by at least two samples and the
other four margins checked with
one sample each. The margins
should include deep, lateral, medial,
caudad and cephalad sites. If the
skin is also infiltrated, frozen sec
tions of its margins should also be

obtained. The best sites for biopsy
include fascial planes involved by
the tumour which are often areas of
microscopic extension. Clinical ex
perience has shown that a minimum
tissue margin of 2 cm around the
gross specimen is associated with
the highest chance of a histological
ly disease-free margin and a low
risk of inadvertently exposing the
tumour. If the tumour is not re
moved intact, the chance of local
control of disease is thought to be
reduced. When larger margins can
be achieved without substantially
sacrificing limb function, so much
the better.
• Intraoperatively, the patholo
gist and surgeon together should
cut the specimen and locate areas
where tumour is close to the mar
gins. The corresponding areas in
the resection defect should then be
checked by frozen-section examina
tion before the operation is com
pleted.
• When the skin is not involved,
any previous biopsy or excision scar
should be removed with approxi
mately 2 cm of tissue en bloc with
the tumour. If the skin is involved,
then margins should be larger and
frozen-section examination is neces
sary to confirm the tumour-free
margins.
• When an amputation is re
quired, the distance from the tu
mour to the transection level should
be recorded if the sarcoma is in the
same limb segment; this also ap
plies to disarticulation. When the
amputation is performed more than
one joint above the tumour, then
the distance to the tumour need not
be recorded.
• Metal clips should be placed in
the margins of excision, because
many of these patients will require
adjuvant radiotherapy postoperatively.
• These guidelines for sarcomas
apply to local excisions, marginal
excisions, compartmental excisions
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and high- and low-grade tumours
when adjuvant radiotherapy is used.
In low-grade lesions not requiring
pre- or postoperative radiation, a
wide margin of healthy tissue is
essential to reduce the risk of local
recurrence.
• Radiotherapy may be used
preoperatively to assist limb salvage
procedures, facilitating dissection of
the tumour from adjacent major
structures, especially for high-grade
or large sarcomas.
• After resection of high-grade
or large sarcomas by wide local
excision or amputation in the same
limb segment, postoperative radia
tion is advisable.
• These guidelines are applica
ble not only to limb sarcomas but
also to head and neck, trunk and
chest wall sarcomas and retroperito
neal sarcomas.

Summary
Optimal primary sarcoma surgery
usually takes place in a tertiary care
facility where access to computed
tomography, angiography and a
staff of neurosurgeons, vascular
and plastic surgeons, medical on
cologists, radiation oncologists, pa
thologists and physiotherapists are
available to support the primary
orthopedic or general surgeon. Op
timal local control rates should be
80% to 90% when these specific
guidelines are followed. We expect
the implementation of these guide
lines in limb salvage surgery will
reduce the morbidity and mortality
associated with local recurrence of
the sarcoma. The true value of
adjuvant local or systemic treat
ments such as radiotherapy or che
motherapy may then be accurately

determined. We hope that the ma
jority of sarcoma patients will be
treated in the context of prospective
trials by experienced teams acquir
ing information and thereby im
proving the rate of cure.
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BOOK REVIEWS
continued from page 384

leading. For example, there is a valu
able chapter on renal masses, which
contains an excellent discussion of renal
cysts. However, in dealing with solid
renal masses, the value of ultrasonogra
phy is underemphasized. In my clinical
experience, ultrasonography is the most
valuable aid for screening and diagnos
ing solid renal masses, yet the author
tends to downplay its role as compared
with intravenous pyelography and com
puted tomography. There are some
minor criticisms of the book’s organiza
tion and content. The long chapter on
the malfunctioning kidney tends to be
repetitive and dull, since there are very
few diagnostic features to differentiate
the many intrinsic renal diseases. The
chapter on prostate ultrasonography is
slightly outdated owing to the rapid
advances made in the last 2 years. The
machines available now produce much
better images than those presented in
this book and also allow for very accu412

rate transrectal (as opposed to transperineal) biopsy techniques which are
not discussed in this text.
Two of the more interesting chapters
are those on interventional ultrasonog
raphy and ultrasonography of the fetal
genitourinary system. As well as being
thorough and accurate, these chapters
make fascinating reading.
This is an excellent atlas (not a
textbook) of genitourinary ultrasound
imaging. As well as being a reference
aid for the ultrasonographer, it is also
an excellent learning tool for the non
radiologist who is involved in the diag
nosis and treatment of genitourinary
disease.
David R. Mador, MD, FRCSC
Assistant Clinical Professor,
Royal Alexandra Hospital,
University o f Alberta,
Edmonton, Alta.
T5H 3V9

GROWTH FACTORS AND OTHER
ASPECTS OF WOUND HEALING.
BIOLOGICAL AND CLINICAL IMPLI
CATIONS. Edited by Adrian Barbul,
Eli Pines, Michael Caldwell and Thom
as K. Hunt. 342 pp. Illust. Alan R.
Liss, Inc., New York, 1988. $68.00.
ISBN 0-8451-5116-9.

This book presents concise and infor
mative chapters on the proceedings of
the second international symposium of
tissue repair, held at the Innisbrook
Resort, Tarpon Springs, Florida in May
1987; the symposium brought together
world-class researchers in this field. The
editors are leaders in the field of wound
repair and wound healing and they
report the results of the researchers
consistently and extensively. The
book’s format of grouping together the

continued on page 440
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Unusual Gastric Foreign Body: a Case
Report
William M. Kuzon, Jr., MD, MSc; Craig A. McFadyen, MD; Frederick L. Moffat, MD, FRCSC
Ingestion of foreign bodies, either intentionally or accidentally, is quite common.
The authors report an unusual case in which a 32-year-old man deliberately
assembled a large metallic aggregate in his stomach by swallowing magnets and
coins in order to relieve epigastric discomfort. The collection was retrieved by
laparotomy and gastrotomy; a gastric ulcer was also found and it was oversewn.
Management of this patient is discussed and the principles of treatment for ingested
foreign bodies are reviewed.

L’ingestion intentionnelle ou accidentelle de corps etrangers est assez frequente.
Les auteurs signalent un cas etrange, celui d’un homme de 32 ans qui, deliberement,
assembla dans son estomac un important aggregat metallique par l’absorption
d’aimants et de pieces de monnaie. Cet assemblage fut retire par laparotomie et
gastrotomie; un ulcere gastrique fut egalement decouvert et suture. Le traitement de
ce patient est commente et les principes de traitement lors de l’ingestion de corps
etrangers sont passes en revue.

or accidental inges
D eliberate
tion of foreign bodies is rela
tively common, and there have been
numerous reports1-5 of strange and
bizarre objects that have found
their way into the gastrointestinal
tract. We describe the case of a man
who deliberately accumulated a
large metallic mass in his stomach
by swallowing magnets and coins;
ultimately he required surgery to
remove the mass.
Case Report

A 32-year-old man was seen in
the emergency department com

plaining of epigastric discomfort.
He said he had been ingesting for
eign material for over 2 years to
remedy the vague pain. He had a
known history of psychiatric illness,
which included two suicide attempts
(drug overdoses), and was consid
ered to have a schizoid-type person
ality. Initially, his self-administered
treatment relieved his pain, but with
time the “therapy” became less
effective, and he was again troubled
by nondescript upper abdominal dis
comfort. He had noted the passage
of coins in his stool.
About 5 months before he pre
sented at our hospital, he began to

From the Department o f Surgery, University o f Toronto, Toronto, Ont.
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swallow small magnets in addition
to coins, believing that if he could
retain the coins in his stomach
longer, they would “do more
good” . His abdominal pain persist
ed and he sought medical attention
because the magnets and coins had
not passed in his stool.
There was no history of gastroin
testinal bleeding or of obstructive
symptoms. His abdominal pain was
epigastric in location, moderate in
intensity and was relieved some
what by meals. He could feel a
heavy mass in his abdomen which
shifted with changes in position.
He was an asthenic young man.
He wore an excessive amount of
jewellery; both forearms were en
tirely covered by metal bracelets of
various types and he wore over 50
necklaces. The areolae of both
breasts had been pierced and held
metal ringlets.
On abdominal examination there
was a large, firm, mobile mass in
the left upper quadrant; it was best
palpated in the epigastrium with the
patient on his hands and knees.
There was no abdominal distension
or tenderness and no other abnor
mal physical signs.
Routine laboratory investigations
gave normal results; hemoglobin
concentration 158 g /L and serum
amylase 162 U /L (normal range
from 0 to 400 U/L).
X-ray films with the patient su
pine showed a large, irregular, radi
opaque mass in the right upper
quadrant; with the patient in the
413

KUZON, ET AL.

left lateral decubitus position the
mass was shown in the left lower
quadrant (Fig. 1).
Flexible esophagogastroduodenoscopy performed the day after ad
mission to hospital revealed a con
glomerate of small magnets and
coins in the stomach. Superficial
gastric erosions were also noted,
but the entire stomach was not
visualized due to the size of the
collection. Attempts to fragment
the mass with the endoscope were
unsuccessful. The esophagus and
duodenum appeared normal.
At laparotomy, the stomach, py
lorus and duodenum appeared nor
mal. Through a mid-body gastrotomy the mass of coins and magnets
was removed from the stomach
(Fig. 2).
A careful inspection of the gastr
ic mucosa, pylorus and duodenum
revealed a small gastric ulcer, ap
proximately 1.0 cm in diameter, on
the lesser curve 4.0 cm proximal to
the cardiac incisure of the stomach.
The ulcer had a fibrinous base
suggesting chronicity. The overly
ing serosa was normal. The ulcer
was excised down to the deep layers
of the muscularis mucosae and the
resulting partial thickness defect
closed with 2-0 silk sutures. Micro
scopic examination of the ulcer re
vealed no evidence of malignant
disease.
The patient recovered without
complications and was discharged
from hospital on postoperative day
7, taking ranitidine for his gastric
ulcer. He is currently undergoing
psychiatric treatment.
The mass removed from the pa
tient’s stomach weighed 585 g and
contained 66 Canadian nickels, 23
button magnets (2 cm in diameter
and 0.5 cm in length), 2 cylindrical
magnets (1 cm diameter and 2 cm
in length), 2 iron spheres (1 cm
diameter), 1 small square magnet (1
X 0.5 cm) and 12 irregular iron
fragments of various sizes and
414

shapes (Fig. 3). Some of the irregu
lar fragments were pieces of larger
magnets that had been broken up.

Discussion
The management of ingested for
eign bodies relates to the type of
patient, the nature and size of the
objects, their location in the gas
trointestinal tract and the presence
or absence of complications. Several
authors6"8 have presented algo
rithms useful in the management of
these patients.
The problem is usually found in
children, psychiatric patients, men
tally impaired persons, prisoners,
drug and alcohol abusers, denture
wearers, or those engaged in cer
tain occupations.2'49-11 In children
and workers in particular occupa
tions, the object is usually swal
lowed accidentally when placed in
the mouth during play or work. In
substance abusers and those wear
ing dentures, diminished palatal
sensation or gag reflex may contrib
ute to the accidental ingestion. In
prisoners, mentally retarded individ-

uals or psychiatric patients, foreign
bodies may be swallowed deliberate
ly and repeatedly.2'11
The nature of the ingested object
is important in determining the ap
propriate management. Sharp ob
jects may perforate the gut; large
objects or conglomerations can
cause intestinal obstruction.71213
The object itself may be corrosive
or contain toxic substances, making
immediate removal mandatory.8'1114
Usually, small blunt objects, such
as the coins ingested by our patient,
can be managed conservatively, es
pecially if they have reached the
stomach.711
There is general agreement that
any object lodged in the pharynx or
esophagus must be removed urgently6'715"17 because complications
associated with foreign-body impac
tion above the diaphragm are seri
ous. The complications include air
way obstruction or pulmonary aspi
ration, esophageal perforation, mediastinitis, esophageal obstruction,

FIG. 2 — Conglomerate of small mag
nets and Canadian nickels removed
from stomach by gastrotomy.
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FIG. 1 — Supine plain film showing
large, multisurfaced, radiopaque mass
in right upper quadrant.
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FIG. 3 — Individual components of
mass.
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and, rarely, aortoesophageal fistula.610'1618-20 Objects usually be
come lodged in the esophagus at
the three anatomic points of nar
rowing: the cricopharyngeal mus
cle, the aortic impression or the
gastroesophageal junction.616 Car
cinoma or strictures of the esopha
gus predispose to impaction of for
eign bodies, especially in cases of
the food bolus “ cafe coro
nary” .6’10-16 Although the use of
papain to digest a meat bolus is no
longer recommended, in some cases
relaxation of the smooth muscle of
the esophagus using intravenous
glucagon and sedation can cause
the object to pass into the stom
ach.6 Blunt objects at this level can
be removed endoscopically3’6’10’16 or
with a Foley catheter.21 Metallic
objects may sometimes be removed
using a magnet mounted in the end
of a nasogastric tube.8 Sharp ob
jects generally require endoscopic
removal; surgery is rarely neces
sary.3’61016 Using an endoscope, the
object may be pushed into the
stomach in order to turn it around
before extraction or in the hope it
will eventually pass in the feces.6
If the foreign body has reached
the stomach, as in our patient,
small- or medium-sized objects,
even sharp ones, usually will be
evacuated without complication in
80% to 90% of cases.6 711 However,
obstruction, ulceration, pressure
necrosis, perforation, steatorrhea,
protein-losing enteropathy, gas
trointestinal bleeding, diarrhea and
obstructive jaundice have all been
described.1’3’6’9’12-13’22 In specific cir
cumstances, including symptoms of
pain, fever, obstruction, jaundice,
persistent diarrhea and bleed
ing,7’91215'22 removal of a foreign
body from the stomach or gut is
warranted. Long, slender objects
should be removed from the sto
machs of children under 2 years of
age due to the high incidence of
duodenal impaction and perfora
VOL. 31, NO. 6 NOVEMBER 1988/CJS

tion.15 Pre-existing disease, such as
pyloric stenosis, is also a relative
contraindication to a conservative
approach.23 If the object is in the
stomach or proximal duodenum, an
attempt at endoscopic removal is
recommended,3’6’1016 but if the ob
ject is located more distally and is
producing symptoms, laparotomy is
required.
The management of asymptomat
ic retained foreign bodies in other
wise healthy adults is more contro
versial. Aboral progress may be ar
rested at the pylorus, duodenal
sweep, ligament of Treitz, ileocecal
valve, appendix, sigmoid or rec
tosigmoid colon.1322 Some reports1’7
recommend intervention if the ob
ject is within reach of the endo
scope or if x-ray films indicate that
impaction has occurred or is likely
to occur because of the object’s
size. Others211 prefer a conservative
approach. Since it is difficult to
assess the likelihood of complica
tions associated with foreign-body
ingestion, management decisions in
asymptomatic patients will likely re
main controversial.
Our patient had a personality
disorder and displayed a tendency
toward self-mutilation, both of
which are characteristic of individu
als who repeatedly swallow foreign
objects.2 However, his motivation
was quite lucid and most unusual in
that he consciously produced his
bezoar for the purpose of treating
abdominal symptoms. The result
was a large, blunt, gastric conglom
eration of magnets and nickels
(which are magnetic). Although
there was no evidence of bleeding
or obstruction, laparotomy was in
dicated because of the size of the
mass and his abdominal pain. In
retrospect, it cannot be determined
with certainty whether the gastric
ulcer was the cause of his original
symptoms or secondary to the
mass. Therefore, removal of the
mass with partial thickness excision

since this was a gastric foreign
body, a more aggressive attem pt to
dislodge and remove the compo
nents of the mass endoscopically
should have been attempted first.
As mentioned, the first gastroscopic
examination indicated that this
would not likely succeed, so a lapa
rotomy was judged to be safer.
Vagotomy and pyloroplasty were
considered when the ulcer was
found, but because of known surgi
cal complications of this procedure,
and since the ulcer would likely
respond to medical management we
elected not to perform a gastric
resection or an acid-reducing proce
dure once intraoperative frozen-sec
tion examination had ruled out neo
plasia.
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Uterine Leiomyosarcoma With Cardiac
Metastases

1
A

Fredrick Hoy, MD, FRCSC; Robert Boucher, MD; Anthony Brody, MD, FACS
Leiomyosarcoma metastatic to the heart is rare and is usually fatal. The authors
present the case of a 58-year-old woman who had a history of uterine
leiomyosarcoma. Echocardiography and cardiac catheterization revealed a large
right ventricular mass. Computed tomography confirmed the presence of the mass
which extended into the pulmonary artery. The inferior vena cava was free of
disease. At operation, a large tumour originating in the right ventricle and
protruding through the pulmonary valve was found. Histologically, it was a
leiomyosarcoma. Because there were numerous septal and intramural foci of tumour,
complete resection was impossible, but palliative resection was performed
successfully and the patient was alive and active 1 year after operation.

Les leiomyosarcomes avec metastases cardiaques sont rares et habituellement fatals.
Les auteurs decrivent le cas d’une femme de 58 ans ayant des antecedents de
leiomyosarcome uterin. Une echocardiographie et un catheterisme cardiaque
revelerent une importante masse au ventricule droit. La tomodensitometrie confirma
la presence de cette masse qui s ’etendait jusqu’a l’artere pulmonaire. La veine cave
inferieure n’etait pas touchee. A Toperation, on decouvrit une grosse tumeur
partant du ventricule droit et faisant saillie a travers la valvule pulmonaire. A
l’histologie, on identifia un leiomyosarcome. Comme il y avait plusieurs foyers
tumoraux sur et a l’interieur de la paroi, il fut impossible d’effectuer une resection
complete. Une resection palliative fut pratiquee et la patiente etait toujours vivante
et active un an apres Toperation.

eiomyosarcoma is a common
primary malignant lesion of the
heart, but metastatic to the heart it
is a rare, highly invasive and usual
ly fatal lesion. A review of the
literature revealed only four detailed
reports of uterine leiomyosarcoma
metastatic to the heart. We present
a fifth, but only the third to report
an antemortem diagnosis and surgi
cal palliation.

L

Case Report
A 58-year-old woman was admit
ted to hospital complaining of exer
tional dyspnea that had developed 3
days earlier. Six months before, she
had undergone total abdominal hys
terectomy and bilateral salpingooophorectomy for a stage III poorly
differentiated uterine leiomyosar
coma with metastases to the right
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ovary. Whole lung tomography at
that time revealed two nodules,
each less than 1 cm in diameter, in
the left lung, believed to represent
metastatic disease. Postoperatively,
the patient had received chemother
apy with doxorubicin.
On examination, the woman was
mildly tachypneic. There was a
grade III/VI systolic murmur heard
diffusely along the right sternal
border. Her chest film showed no
evidence of congestive heart failure.
2D echocardiography demonstrated
a large mass attached to the right
ventricular free wall. Cardiac cathe
terization revealed a mean right
atrial pressure of 16 mm Hg and a
right ventricular pressure of 70/20
mm Hg. A large filling defect occu
pied most of the right ventricle
(Fig. 1), extending through the pul
monary valve. In addition, there was
a filling defect in the right atrium.
Computed tomography (Figs. 2 and
3) confirmed these findings. Lei
omyosarcoma metastatic to the
heart was diagnosed and a palliative
tumour resection was undertaken.
The right ventricle was markedly
enlarged and a firm mass occupied
the chamber of the entire right
ventricle, the right ventricular out
flow tract and extended into the
pulmonary artery. Under cardioplegic arrest, the right atrium was
incised and an organized thrombus
removed from the appendage. No
tumour was present. The pulmo
nary artery was then opened longi
tudinally revealing a large friable
mucoid tumour protruding through
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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the pulmonary valve. When the
right ventricle was opened a tumour
was found occupying most o f the
right ventricular chamber and was

densely adherent to the septal, ante
rior and inferior aspects. Multiple
septal and intramural areas of tu
mour foci made complete resection

*

J

impossible, but the major portion o f
the tumour mass was excised. A
large organized thrombus was also
removed from the right ventricle.
The patient recovered without com 
plications. The central venous pres
sure decreased to 8 cm H20 from
16 cm H20 and her symptoms were
alleviated. She was discharged 8
days postoperatively.
She was started on a second
course o f chemotherapy but tolerat
ed this poorly. Five months postop
eratively, she had some recurrence
o f dyspnea and peripheral edema. A
2D echocardiogram showed recur
rence o f the tumour or thrombus in
the right ventricle. She is alive and
moderately active 1 year after the
palliative resection.

Pathological Features

FIG. 1 — Ventriculogram demonstrates filling defect in right ventricle.
► -
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Specimens removed at operation
were friable, gelatinous, myxoid
masses with multifocal areas o f he
morrhage. Fragments o f myocardi
um adherent to the tumour revealed
extensive necrosis and infiltration
by a malignant neoplasm showing
large pleomorphic nuclei and nu
merous mitotic figures consistent
with metastatic leiomyosarcoma.

► f

Discussion

FIG. 2 — Contrast computed tomogram of thorax shows filling defect in right
atrium and right ventricle.

VOL. 31. NO. 6 NOVEMBER 1988/CJS

Cardiac metastases occur in 5%
to 20% o f patients who die o f
malignant disease.1 Secondary car
diac tumours are 16 to 50 times
more common than primary ones;2
75% to 90% of them arise from
tumours of the breast, bronchus,
lymphoid tissue or skin. These sec
ondary tumours are rarely the sole
metastases3 and are symptomatic in
15% to 30% of patients.1
Sarcomas metastasize to the
heart more frequently than car
cinomas.2 Cardiac metastases from
leiomyosarcomas o f the uterus are
extremely rare — 6 out o f 2600
419

patients in one series.4 Most neo
plastic lesions of the heart are si
lent; symptoms result from im
pingement on adjacent structures
and include arrhythmias, conduc
tion disturbances, effusion, embo
lism, valve dysfunction, angina, ob
struction of blood flow and conges
tive heart failure. Cardiac dysfunc
tion in a patient with a known
neoplasm should arouse suspicion
of a cardiac metastasis. Survival
from the onset of symptoms is
usually short.2 Of patients whose
cardiac involvement is symptomatic,
80% die of cardiac complications.3
Uterine leiomyosarcomas are
rare, constituting less than 3% of
all tumours, and are associated with
an incidence of 0.6 per 100 000
females.5 Metastases are usually to
liver and lung. Cardiac metastases
from leiomyosarcomas of the uterus
are extremely rare, only 6 out of
2600 cases being reported in one
series.4 A review of the literature
revealed only four other cases in

which clinical data were available.
Symptoms developed 1 to 12 years
after resection of the uterine lei
omyosarcoma. Two patients died
before a diagnosis was made.46
Both had large tumour masses orig
inating in the right ventricle. In one
who underwent surgery for pericar
dial effusion, a tumour mass at
tached to the myocardium by a
pedicle 2 cm in diameter was found
arising from the surface of the right
ventricular outflow tract. This was
resected with a large disk of right
ventricular wall and the patient was
well 15 months postoperatively.7
Diagnosis of an intracardiac tumour
was made preoperatively in the
fourth patient. She underwent pal
liative resection of the right ventric
ular tumour, but died of low cardiac
output 48 hours postoperatively.8
The diagnosis and operative man
agement of our patient were aided
by the use of 2D echocardiography
and computed tomography. The pa
tient’s symptoms were caused by

low right-sided cardiac output due
to obstruction of blood flow by the
tumour mass and by thrombus sec
ondary to stasis. The tumour interdigitated with the tricuspid valve
and trabeculae of the right ventricle
so that only palliative resection
could be performed. Postoperative
ly, the mean central venous pres
sure decreased markedly and the
patient was symptomatically much
improved. The highly malignant na
ture of her tumour is attested to by
the disappointing early return of
symptoms and recurrence of tu
mour. Cardiac symptoms in patients
with known metastasis should sug
gest the possibility of an intracar
diac metastasis. Since the survival
from the onset of symptoms is
usually short, palliative resection is
justified. The diagnosis can be
greatly aided by noninvasive tech
niques and prolonged symptom-free
survival may be obtained in patients
with tumours of lower-grade malig
nancy or those that are more re
sponsive to chemotherapy or radio
therapy.
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Normoglycemia After Implantation of
Purified Islet Cells in Dogs
G.L. Warnock, MD, MSc, FRCSC;* M.S. Cattral, MD;* R.V. Rajotte, BSc, MSc, PEng, PhDt
A major problem that limits the effectiveness of clinical trials of islet transplantation
is the inability to isolate sufficient pure viable islets from a single pancreas. The
authors have evaluated this problem, using dogs rendered diabetic by total
pancreatectomy. An average of 123 ± 11 X 103 highly purified islets (mean graft
weight 0.75 ± 0.1 g) were implanted as splenic allografts (seven dogs), splenic
autografts (six dogs) or liver autografts (six). In the autograft recipients, fasting
normoglycemia was maintained during follow-up to 10 months; onset of
hyperglycemia was delayed in three liver recipients and one splenic autograft
recipient at 1.5, 2, 8 and 10 months respectively. The K values (decline in glucose
levels in %/min) during intravenous glucose tolerance testing were more than 1.0.
Six recipients of allografts and cyclosporine (CsA) were normoglycemic when CsA
trough serum levels were greater than 300 pg/L, although the fasting plasma
glucose level was higher than that in autograft recipients. These data show that
purified islets isolated from a large mammal will maintain fasting normoglycemia for
prolonged periods after auto- or alloimplantation.
Un probleme majeur limite l’efficacite des essais cliniques de greffes d’llots de
Langerhans, soit l’incapacite d’isoler suffisamment d’ilots purs et viables d’un seul
pancreas. Les auteurs ont etudie ce probleme chez des chiens rendus diabetiques par
pancreatectomie totale. Une moyenne de 123 ± 11 X 103 ilots hautement purifies
(poids moyen de la greffe: 0.75 ± 0.1 g) ont ete greffes sous forme d’allogreffes
spleniques (sept chiens), d’autogreffes spleniques (six chiens) ou d’autogreffes
hepatiques (six chiens). Chez les receveurs d’autogreffes, une normoglycemie a jeun
s’est maintenue durant une periode de controle de 10 mois; une hyperglycemie
d’apparition retardee est survenue chez trois receveurs de greffes hepatiques et chez
un receveur d’autogreffe splenique apres, respectivement, 1.5, 2, 8 et 10 mois. Les
valeurs de K (la baisse de la glycemie en %/min) durant les epreuves d’hyperglycemie provoquee par voie intraveineuse ont toutes ete superieures a 1.0. Six
porteurs d’allogreffes, qui recevaient de la cyclosporine (CsA), sont demeures
normoglycemiques alors que les concentrations plasmatiques minimums de CsA
etaient inferieures a 300 ng/L, bien que leur glycemie a jeun ait ete superieure a
celle des receveurs d’autogreffes. Ces donnees demontrent que des ilots purifies,
preleves chez un grand mammifere peuvent maintenir une normoglycemie a jeun
pendant une periode prolongee apres une auto- ou une allogreffe.
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ifteen years have elapsed since
the initial report1 of a cure for
experimentally induced diabetes in
rodents by implanting free grafts of
insulin-producing tissue. Further
studies2 showed that islet cell trans
plantation prevents or reverses the
complications of diabetes mellitus.
These procedures have been less
successful in large mammals and
humans, casting doubts on their
feasibility. As with other organ
grafts, islet allografts are subject to
rejection, but a major problem has
been the inability to isolate suffi
cient pure, viable islet cells from a
single pancreas. Although the yield
can be increased by collecting isletcontaining pancreatic microfrag
ments,3 their implantation results in
severe portal hypertension.4
Recent advances in islet cell isola
tion suggest that a technique may
soon be available for clinical trials.
Alejandro and colleagues5 isolated
sufficient purified islets to reverse
diabetes in pancreatectomized dogs;
however, delayed graft failures oc
curred, suggesting that a marginal
ly adequate islet mass had failed.
We have combined the methods of
collagenase perfusion by way of the
ducts,6 gentle trituration of tissue7
and density gradient centrifugation8
to separate purified islets from the
canine pancreas. Our studies
showed that more than 5 000 isle ts /k g body weight (average endo
crine particle size 122 nm) consis
tently induced normoglycemia.9 In
this study, we subjected these high
ly purified grafts to prolonged fol
low-up and evaluated the effects of
allograft implantation and cyclospo
rine (CsA) immunosuppression.
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Materials and Methods
Pancreatectomy

Under general anesthesia with so
dium pentobarbital (30 m g/kg
body weight), the pancreas in 29
adult mongrel dogs (weight range
from 13 to 25 kg) was mobilized.
The major vascular connections
were preserved until just before
excision. Cannulas (20 gauge) were
inserted into both main branches of
the pancreatic duct and into the left
duct by a cutdown 5 cm from the
tip of the gland. After excision of
the pancreas the abdomen was
closed in three dogs (controls), the
seven dogs that provided islets for
allografts were subjected to eutha
nasia while under anesthesia and
the remaining 19 dogs were main
tained under general anesthesia
while the islets were being prepared
for implantation (about 3 hours).
Islet Isolation
The cannulas were perfused (300
mm Hg) with Hanks’ solution (Gibco, Chagrin Falls, Ohio) at 4°C for
10 minutes. The perfusate was then
changed to a solution of collagenase (type XI or V; Sigma Chemical
Co., St. Louis, Miss.) at a concen
tration of 1600 U/ml in Hanks’
solution at 37°C. For six isolations,
the collagenase solution (1100
U/ml) was perfused immediately
after excision of the pancreas, with
out preliminary flushing with
Hanks’ solution. Perfusion was con
tinued at 37 °C until the gland
became mucoid (25 minutes for
type V, 12 minutes for type XI
collagenase). The digested tissue
was dissociated by teasing and tritu
ration,7 weighed and resuspended at
4°C to a total volume of 120 ml in
Medium-199 with 25 mmol/L
Hepes (Gibco, Chagrin Falls, Ohio),
10% fetal calf serum (vol/vol, Gib
co, Grand Island, NY), penicillin
422

100 U /m l.and streptomycin 100
Mg/ml. Aliquots of 4 ml were re
moved to 50-ml tubes, suspended in
a mixture of 4.3 ml of 5X Medi
um-199 and 16.7 ml of Ficoll (den
sity 1.125, Sigma) and overlaid with
5 ml each of Ficoll with densities of
1.085, 1.075 and 1.045.5 The tubes
were centrifuged at 550 X g for 25
minutes at 22°C. Tissue was col
lected from the interface of the
1.045/1.075 and 1.075/1.085 lay
ers, washed, recombined, weighed
and resuspended to a final volume
of 30 ml in culture medium.
Islet Counts and Size
Ten samples, each containing 20
pL of freshly-isolated islets, were
placed on a microscope slide and
protected with a coverslip. Slides
were viewed through a stereomicro
scope at 25X magnification with
side illumination from a fiberoptic
light source; islets were identified
by their rounded shape, opalescent
blue colour and finely granular tex
ture. Islets and islet fragments more
than 60 /tm in greatest dimension
were counted, and the total was
estimated from the sample mean.
An additional aliquot was examined
without a coverslip; the greater and
lesser diameter of 10 randomly se
lected islets of minimum size 60 nm
was measured with a graticule and
the average islet diameter deter
mined. Purity was estimated by
comparing the ratio by volume of
islet to exocrine tissue.
Implantation
In each case of autografting, the
suspended purified islets from the
pancreas were either refluxed into
the splenic veins (six dogs, group 1)
or embolized by way of the portal
vein to the liver (six dogs, group 2).
Portal venous pressure was mea
sured by connecting the infusion
catheter to a manometer before and

immediately after infusion of the
islets. Postoperatively exocrine en
zyme supplements (12 capsules) of
Cotazym (Organon Canada Ltd.,
Montreal, PQ) were provided daily
for all 19 dogs. Recipients of sple
nic allografts (seven dogs, group 3)
received CsA (Sandoz Pharmaceuti
cal Co., Basle, Switzerland) intra
muscularly daily; the initial daily
dose of 20 m g/kg was tapered to 5
m g/kg.
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Blood Indices
c

Blood samples were taken preoperatively, postoperatively during
glucose tolerance testing, then daily
postoperatively for 1 week and sub
sequently once a week for the dura
tion of follow-up. Fasting plasma
glucose (mg/dl) was measured with
a Beckman 2 analyser (glucose oxi
dase; Beckman Instruments, Fuller
ton, Calif.). The level of immunoreactive insulin (IRI, mU/L)
was determined by double-antibody
radioimmunoassay,10 using Phar
macia RIA kits and human insulin
standards (Pharmacia, Uppsala,
Sweden). For glucose tolerance
testing, saphenous veins were cannulated, glucose (0.5 g /k g body
weight) was injected intravenously
and blood was collected at 0, 1, 5,
10, 15, 30, 60 and 90 minutes for
assay of glucose. The K value (de
cline in glucose level [%/min]) was
determined from glucose levels at 5,
10, 15 and 30 minutes.11 Glucose
tolerance testing was repeated at 1
and 3 months in normoglycemic
recipients. Trough levels of CsA
were measured daily by radioim
munoassay.
Data Analysis
Numbers of islets per kilogram
implanted, plasma glucose levels
and K values for dogs that received
liver and splenic autografts were
compared using Student’s t-test for
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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tered into the liver (4763 ±
53 7 /k g [±SD]) was similar to that
for the spleen (5446 ± 689, p >
0.05). After infusion of islets into
the portal vein the mean increase in
portal pressure was 3.7 ± 0.9 cm
H20; the pressure returned to base
line values within 10 minutes. All
recipients maintained their preoper
ative weight. These dogs became
normoglycemic immediately after
implantation (Fig. 1) and normoglycemia was maintained at 1
month; plasma glucose values were
then 89 ± 6 m g/dl in group 1 and
85 ± 3 m g/dl in group 2 (p >
0.05). Delayed failures in graft
function occurred in three group 2
dogs at 1.5, 2 and 8 months respec
tively and a single graft failed in
group 1 at 10 months after implan
tation. The remaining dogs conti
nue to be normoglycemic. To prove
conclusively that endocrine function
was provided by the graft in the
splenic site, two group 1 dogs were
subjected to splenectomy; the insu
lin level in the splenic vein was 20
± 4 mU/L versus 4 ± 1 mU/L in

paired data. The values of plasma
glucose in splenic autografts versus
allografts were compared using Stu
dent’s f-test for unpaired data. Val
ues were considered significant at p
< 0.05.

Results
Grafts

The mean tissue weight after
purification with Ficoll was 0.75 ±
0.1 g (±SD). An average of 123 ±
11 X 103 (range from 78 to 188 X
103) islets and islet fragments were
recovered per pancreas. Most of the
islets were completely free of at
tached exocrine cells and the aver
age diameter was 122 ± 5 /in>
(range from 60 to 240 /urn). By
estimating the relative amount of
islet to nonislet tissue, the islets
appeared to be 80% to 90% pure.
Autografts

The number of islets adminis

the artery. Hyperglycemia ensued
rapidly after splenectomy. Postoperatively, the K value declined from
3.6 to 1.8 at 1 month in group 1
(Fig. 2a) and from 3.9 to 1.6 in
group 2 (Fig. 2b), but had not
declined significantly more at 1.7
and 1.4 respectively after 3 months.
The insulin levels were reduced in
all dogs postoperatively and the
peak response was delayed after
islet implantation into the spleen.
Allografts

Doses of 8645 ± 1149 islets/kg
were refluxed into the spleens of
seven dogs. In one recipient with
initial CsA levels less than 300
iug/L the graft failed at 9 days.
Figure 3 shows the results for six
dogs that had initial CsA levels of
more than 300 /xg/L. Compared
with apancreatic dogs, the allograft
recipients showed immediate fasting
normoglycemia, which was main
tained for more than 30 days. The
fasting plasma glucose value was
always higher with allografts than
autografts (p < 0.05).

Discussion

0 1

2

3

4

pancreatectomy & islet transplant

5

6

7

8

9

10

Months

FIG. 1 — Fasting plasma glucose levels (m g/dl) after autoimplantation of purified
islets in liver (triangles) or spleen (circles). Normoglycemia was maintained for
more than 1 month in all dogs and hyperglycemic response to splenectomy (S)
proves graft function. Delayed failures (F) of graft function were observed in three
liver recipients after 6 weeks, 2 months and 8 months. One splenic graft failed at
10 months. Squares = Apancreatic control dogs. Numbers in brackets indicate no.
of islets/k g.
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Large mammals are the most
suitable models for studying the
clinical application of islet cell
transplantation. The compact pan
creas in these species requires three
key steps in islet separation: ade
quate intralobular disruption of the
connective tissue stroma, avoidance
of mechanical trauma to the islets
and density gradient purification.6-8
We have used these principles to
isolate an average of 123 000 high
ly purified islets. Function was as
sessed by prolonged follow-up after
autoimplantation or alloimplantation.
The purity of the preparations
and the small graft mass (0.75 g)
allowed us to embolize the tissue to
423
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the liver. Although a transient rise
in portal pressure occurred, portal
hypertension was not a problem, in
contrast with previous studies4 in
which impure preparations were
used. At the outset, fasting plasma
glucose levels were normal in all
autograft recipients and there was
no significant difference between
the two groups. On prolonged fol
low-up, delayed autograft failures
occurred, as previously observed for
intraportal canine islet grafts.5 Al
though similar quantities of islets
were implanted into the liver and
spleen, in our study three of the
four failures were in recipients of
liver implants. This may have been
due to fatigue of an initial marginal
ly adequate mass of islets, but this
does not account for the observa

tion that two of the intraportal
failures occurred after greater than
average numbers of islets were im
planted. Alternative mechanisms for
delayed failure may be reduced engraftment in the intraportal location
or chronic stimulation of the islets
by hyperglycemia within the portal
venous blood. Because of the small
number of grafts in each of the two
groups, statistical analysis cannot
be used to validate the observation
that they failed more frequently
when implanted into the liver.
Serial glucose tolerance tests
showed that the K value had de
clined significantly (p < 0.05) from
pretransplant levels in both auto
graft groups, but levels in each
were similar and the dogs remained
nondiabetic (K > 1.0%/min). The

reduced level postoperatively was
likely due to a smaller mass of
functioning B cells, as reflected by
the lower plasma insulin response
after glucose challenge. A qualita
tive difference in insulin release was
seen between the group 2 dogs,
showing a peak response within 1
minute, and group 1 dogs whose
peak response was delayed to 5 to
10 minutes. This may result from
reduced hepatic extraction of insu
lin, which is released directly from
intrahepatic islets into the postsinusoidal hepatic veins.
Allografts of purified islets in
duced fasting normoglycemia, evi
dent throughout the 30-day follow
up, when initial CsA trough blood
levels were more than 300 ng/L .
When one dog had initial levels

FIG. 2 — Response to intravenous glucose (0.5 g /k g ) after (a) splenic or (b) liver autoimplantation showing plasma glucose
(m g/dl) and corresponding plasma insulin (mU/L) levels. Rate of glucose decline is slower postoperatively and is accompanied
by reduced insulin response. Peak insulin response occurred at 5 to 10 minutes in spleen recipients (a) and at 1 minute in liver
recipients (b). n = number of dogs, K = decline of glucose level (%/min).
424
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below 300 n g /L , rejection occurred
at 9 days, a finding similar to that
of the nonimmunosuppressed con
trols. Greater numbers of islets
were available for allografts than
autografts and provided a mass of
endocrine tissue well in excess of
the critical amount that we found
necessary to induce normoglycemia.
We believe this enabled us to distin
guish graft failure due to rejection
rather than fatigue of a marginally
adequate islet mass, inadequate engraftment or the toxic effects of
CsA. Furthermore, islets were not
allografted into the liver because of
the frequency of delayed autograft
failures at this site. The results
showed that function of allografts
of pure islets was assured when an
adequate mass of tissue from one
donor was implanted into a CsAimmunosuppressed recipient. This
compares favourably with the re
sults of Alejandro and associates12
who frequently required purified is
lets from multiple donor dogs to
provide adequate graft function in
one recipient and Kneteman and
colleagues13 who used impure pan-

FIG. 3 — Results of alloimplantation
of pure islets into spleen with CsA
immunosuppression (squares). Com
pared with three apancreatic controls
(diamonds) normoglycemia occurred
immediately and was maintained
throughout study in six recipients of
CsA at trough serum levels greater
than 300 jtg/L . Fasting plasma glu
cose (m g/dl) after splenic allograft
implantation was higher than that
after splenic autograft implantation
(triangles).
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creatic microfragments. The high
levels of CsA required to prevent
allograft rejection may, at least in
part, have accounted for the higher
plasma glucose levels seen in the
allograft recipients, but did not
cause graft failure within 30 days.
A critical question is, Do the
results of our experiments in a
large mammal suggest that islet
transplantation can be made to
work in man? Three key observa
tions may assist us in achieving this
difficult goal. First, earlier attempts
at human islet transplantation did
not account for an accurately quan
tified mass of viable islets. Our data
indicate that more than 5000 islets
with an average size of 120 ^m
must be provided per kilogram of
body weight to induce long-term
normoglycemia consistently in
dogs.9 Since human islets are larger
(150 /itm), a 70-kg adult recipient
would require 2895 islets/kg or
approximately 202 640 islets. We
recently used the described isolation
procedure to isolate pure viable
human islets and found that yields
of this order can be achieved.14
Second, delayed failures of auto
graft function can occur and the
factors responsible for this require
further study. Our data suggest
that the intraportal site, if chosen
for implantation, may play a role.
Third, when allografts are implan
ted, the adverse effects of im
munosuppressive agents on islet
function are of concern. Among
these are the effects of steroids and
azathioprine13 and potential adverse
effects of CsA.15 Our data suggest
that function of pure islets can be
assured when CsA alone is used;
however, the high serum trough
levels of CsA would cause serious
toxicity in humans. Therefore, some
form of islet allograft immunomodulation may be needed to re
duce the requirements for immuno
suppression.
In summary, our data show that

purified islets of Langerhans can
maintain prolonged fasting normo
glycemia in a large mammal. Some
delayed failures of autograft func
tion occur, which may be due to the
intraportal site of implantation. Sin
gle-donor purified islets induced
normoglycemia after alloimplanta
tion into pancreatectomized recipi
ents on CsA immunosuppression
who had adequate serum CsA lev
els. This information will promote
studies on immunomodulation of
islet allografts in large mammals
and encourage a realistic approach
to clinical islet transplantation for
juvenile onset diabetes.
We are grateful for expert technical
assistance from D. Ellis, T. DeGroot, D.
Untch, C. Erickson, K. Toth and V.
Manikavel, and we thank C. Gardner for
preparing the manuscript.
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SESAP V Critique
Items 253-255
Diagnostic techniques used in patients with soft tissue sarcomas define the location, nature, and extent of the
disease. Conventional roentgenograms may demonstrate deformity of fascial planes and tumor calcification.
Angiography can diagnose tumor vascularity, extent of disease, and relationship to major vessels, and may be
used for infusion chemotherapy and tumor embolization. Ultrasonography differentiates cystic, solid, and
complex masses. Computed tomography, the most useful radiographic procedure for axial soft tissue sarcomas,
allows recognition of alterations in compartment anatomy. Because fewer than 5% of patients with soft tissue
sarcoma have regional node involvement, lymphangiography is infrequently of value.
Although small superficial soft tissue tumors are suitable for excisional biopsy, incisional biopsy is preferred
for adequate sampling of large lesions. The biopsy site must be included in the definitive surgical resection.
Needle aspiration and “ core” biopsies may be acceptable for metastatic disease, but for most tumors, the tissue
obtained may be insufficient for a full pathologic evaluation. Wide local excision should not be performed until a
tissue diagnosis has been established.
Wide anatomic, soft-part resection is indicated for liposarcoma of an extremity. The resection should include
previous biopsy sites and a wide margin of uninvolved tissue. The role of additional treatment in the
management of patients with soft tissue sarcomas is not currently well-defined. Radiation therapy may be used
preoperatively to reduce the size and deep fixation of a tumor, and postoperatively to eradicate possible residual
disease. Preliminary results with adjuvant postoperative chemotherapy suggest an improvement in disease-free
and over-all survival. Although preoperative regional infusion chemotherapy has been used, no evidence
currently favors preoperative systemic chemotherapy.
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Oophorovesicular-Colonic Fistula: a Rare
Complication of Crohn’s Disease
S.D. Goldberg, MD, FRCSC;* R.R. Gray, MD, FRCPC;t K.I. Cadesky, MD, FRCSC;$
R.L. Mackenzie, MD, FRCSC*

Salpingitis and vesicular fistulas are rare complications of Crohn’s disease. In this
report the authors describe a case of oophorovesicular-colonic fistula secondary to
Crohn’s disease. The patient presented with bleeding from the bladder during
menstruation, fecaluria and pneumaturia. A single-stage left salpingooophorectomy, sigmoid resection and repair of the fistula were carried out, with
complete resolution of symptoms and preservation of fertility potential.

Les salpingites et les fistules vesiculaires sont deux complications rares de la
maladie de Crohn. On decrit dans cet article un cas de fistule ovario-vesciulo-colique
secondaire a une maladie de Crohn. La patiente montrait des signes de saignement
par voie vesicale durant les menstruations, de fecalurie et de pneumaturie. Une
intervention en un temps, comprenant une salpingo-ovariectomie gauche, une
resection sigmoi'dienne et une reparation de la fistule, amena une resolution
complete des symptomes, avec conservation possible de la fertilite.

rohn’s disease is often compli
cated by fistula formation but
salpingitis and vesicular fistulas are
both rare. We report a case in
which the patient had an oo
phorovesicular-colonic fistula sec
ondary to Crohn’s disease.

C

Case Report

A 31-year-old woman presented
with complaints of crampy lower
abdominal pain, generalized mal
aise, weight loss and bloody diar

rhea, diagnosed by barium enema
examination and colonoscopy as
Crohn’s disease. Her symptoms re
solved with steroid treatment. She
returned 16 months later with dif
fuse lower abdominal pain and a left
lower quadrant mass which was
found at laparoscopy to involve the
left adnexa, sigmoid colon and uter
us. The patient was treated with
broad-spectrum antibiotics. There
was some shrinkage of the mass,
but 3 weeks later she complained of
hematuria, which subsequently be
came cyclic and was accompanied

by urinary frequency, urgency,
pneumaturia and fecaluria.
Culture of a urine sample grew
Proteus mirabilis, Escherichia coli
and Staphylococcus sp, all with
more than 100 000 colonies/ml of
urine.
An intravenous pyelogram re
vealed a dilated left ureter with mild
hydronephrosis. A Hypaque enema
examination demonstrated a fistu
lous connection between bowel and
bladder, and contrast computed to-

FIG. 1 — Computed tomogram demon
strating gas-containing left adnexal
mass.
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FIG. 2 — Computed tomogram of
pelvis revealing air in bladder with
intravenous contrast.
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mography of the abdomen (Fig. 1)
and pelvis (Fig. 2) confirmed dilata
tion of the left ureter and showed
evidence of a poorly defined soft-tis
sue mass involving uterus, bladder
and colon. Contrast medium was
evident in the uterus and left fallo
pian tube.
Cystoscopy revealed bullous
edema of the bladder wall and a
small fistulous opening 1.5 cm pos
terior to the ureteral orifices. Dif
fuse mucosal inflammation with
pseudopolyps at 25 to 30 cm was
seen on flexible sigmoidoscopy and
granulation tissue was seen pro
truding from the cervical os on
vaginal examination.
We performed a single-stage left
oophorectomy, salpingectomy, ante
rior sigmoid resection (with end-toend anastomosis) and closed the
vesicular fistula tract. The right
fallopian tube and uterus appeared

FIG. 3 — Left adnexal mass connect
ing left tube, ovary, bladder and colon.

unaffected and, to preserve fertility,
were not removed. The operative
specimen (Fig. 3) revealed active
inflammatory changes in the sig
moid colon consistent with Crohn’s
disease. At follow-up 3 months later
the patient was asymptomatic and
having normal menstrual periods.

al symptom complex of cyclic hema
turia.
The combined urologic and radi
ologic investigations permitted ac
curate preoperative diagnosis of the
condition and successful multiteam
surgery with preservation of fertility
potential.

Discussion
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Fine-Needle Aspiration Biopsy of an Islet
Cell Tumour Simulating Pancreatic
Carcinoma
Arthur H. Zalev, MD, FRCPC;* Harriette J. Kahn. MD, FRCPC;f Wedad Hanna, MD, FRCPCt
The importance of distinguishing between malignant islet cell tumour and
pancreatic carcinoma is emphasized in this report of a 57-year-old woman who
presented with an epigastric mass. Clinically and radiologically it was diagnosed as a
pancreatic adenocarcinoma. A fine-needle aspiration biopsy specimen obtained under
ultrasonic guidance showed tumour cells suggestive of an islet cell tumour.
Immunostaining and electron microscopy were performed on the aspirate. The
tumour cells stained positive with antibodies to keratin, glucagon and gastrin;
ultrastructural examination revealed neurosecretory granules, confirming the
diagnosis of an islet cell tumour. Angiography was performed to assess the
possibility of debulking the mass. This case demonstrates the value of
immunohistochemistry and electron microscopy on fine-needle aspiration biopsy
specimens of the pancreas to differentiate islet cell tumours, which are potentially
curable, from pancreatic adenocarcinomas, which carry a 5-year survival rate of less
than 2%.

On souligne dans cet article l’importance de savoir distinguer une tumeur maligne
des cellules insulaires d’un carcinome pancreatique. Le cas d’une femme de 57 ans
presentant une masse epigastrique serf a illustrer le fait. Le tableau clinique et
radiologique etait compatible avec un diagnostic d’adenocarcinome pancreatique.
Une ponction-biopsie a l’aiguille fine obtenue sous echographie revela des cellules
tumorales evocatrices d’un insulinome. L’echantillon de biopsie fut soumis a une
immuno-coloration et a la microscopie electronique. Les cellules tumorales
presentment une coloration positive avec des anticorps contre la keratine, le
glucagon et la gastrine; l’examen ultrastructural revela des granules
neurosecretoires confirmant le diagnostic d’un insulinome. Une angiographie fut
pratiquee afin d’evaluer la possibility de reduire la masse tumorale. L’etude
immunohistochimique et l’examen au microscope electronique des echantillons de
ponction-biopsie sont utiles pour differencier les insulinomes qui sont curables, des
adenocarcinomes pancreatiques, lesquels presentent une survie a 5 ans de moins de
2%.
ancreatic carcinoma has a poor
prognosis, the 5-year survival
rate being less than 2%> In spite of
modern imaging techniques only

P

15% to 20% of tumours diagnosed
are potentially resectable. Occasion
ally, pancreatic masses with more
favourable prognoses, such as islet
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cell tumours, may mimic adenocar
cinomas, and in such cases mul
tidisciplinary investigations — radi
ology, fine-needle aspiration cytolo
gy with immunopathology and elec
tron microscopy — can give a defin
itive diagnosis without resort to
more invasive techniques. We pres
ent a case of non-functioning islet
cell tumour in which the patient
had clinical manifestations of a pan
creatic adenocarcinoma. Our experi
ence demonstrates the feasibility of
using special techniques on material
obtained by fine-needle aspiration to
reach a conclusive diagnosis.

Case Report
A 57-year-old woman had a
1-month history of increasing epi
gastric pain radiating to the right
side and back. During this time she
lost 6.4 kg and became constipated.
A hard, fixed epigastric mass, 10
cm in diameter, was palpable. Ul
trasonography and computed to
mography (Figs. 1 and 2) suggested
a pancreatic neoplasm. The comput
ed tomogram showed superior mes
enteric arterial and venous encase
ment, indicating that the mass was
unresectable (Fig. 2). At endoscopic
retrograde cholangiopancreatogra
phy (ERCP) only the common bile
duct could be cannulated, and the
ampullary segment was narrowed.
Fine-needle aspiration was carried
out under ultrasonic guidance. The
resulting diagnosis of islet cell tu429
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mour led to angiography, which
showed a mass involving the pan
creatic head, neck and uncinate
process, encasing the superior mes
enteric vein (Fig. 3). Laparotomy
was performed with the intention of
debulking the tumour, but this was
impossible because of its vasculari
ty. The patient was subsequently
discharged from hospital and che
motherapy was started. Periodic so
nograms showed gradual enlarge
ment of the tumour and dilatation
of the common bile duct. Hepatic
metastases developed and the pa
tient died 1 year after her initial
presentation.

Diagnosis
Methods

A portion of the specimen ob
tained by fine-needle aspiration was
alcohol-fixed and stained by the
Papanicolaou method. Small frag
ments were also fixed in Bouin’s
fixative for a cell block preparation.
The biopsy tissue obtained from
surgery was fixed in 10% buffered
formalin. For light microscopy, sec
tions were stained with hematoxylin
and eosin.
The Bouin-fixed material and the
formalin-fixed paraffin-embedded
tissue sections were stained by the
peroxidase antiperoxidase technique
using antibodies to insulin, gluca
gon, serotonin, gastrin and lowmolecular-weight keratin, which
recognizes keratins of 39, 43 and
50 kilodaltons. The antibodies were
obtained from Dako Corp., Santa
Barbara, Calif., Immuno-Nuclear
Corp., Stillwater, Minn, and Beckton Dickinson, Mountain View, Ca
lif. Appropriate negative and posi
tive controls were used.
A portion of the needle aspirate
from the pancreas was placed in
universal fixative. The specimen
was centrifuged and the pellet pro
430

cessed for routine electron micros
copy. The sections were stained
with uranyl acetate and lead citrate
and examined by a Phillips 300
electron microscope.

from 130 to 230 nm, compatible in
size and morphology with glycogen
and gastrin granules. No insulin
granules could be seen.

Results

Discussion

The fine-needle aspirate from the
pancreas showed clusters of uni
form cells with little pleomorphism
(Fig. 4) and an occasional mitotic
figure — features suggestive of an
islet cell tumour. Light microscopy
of the subsequent surgical specimen
confirmed the diagnosis of an islet
cell tumour.
Immunohistochemical staining of
the cell block of the needle aspirate
and the biopsy specimen showed
positive staining of the tumour cells
for glucagon (Fig. 5a), serotonin
and gastrin but not for insulin (Fig.
5b). They also stained positively for
low-molecular-weight keratin.
Ultrastructural examination of
the aspirate revealed nests of tu
mour cells joined by desmosomes
and containing numerous neuro
secretory granules (Fig. 6), thus
confirming the diagnosis of islet cell
tumour. The granules varied in size

it is important for therapy and
prognosis to distinguish islet cell
tumours from pancreatic adenocar
cinomas. Prolonged survival has
been reported after excision of the
former, even those larger than 10
cm,2 and isolated involvement of the
portal vein does not preclude resec
tion.2 Adjuvant chemotherapy may
provide effective palliation in onethird of patients with malignant
islet cell tumours.23 Fine-needle as
piration biopsy is an effective meth
od of obtaining material for diag
nosing pancreatic carcinoma.4-6 The
risks are minimal, the accuracy is
about 86% and the technique obvi
ates laparotomy.4 Islet cell tumours
may be diagnosed from the cytology
material but are sometimes difficult
to differentiate from pancreatic car
cinoma.
Radiology plays an important
role in the diagnosis and manage-

FIG. 1 — Transverse ultasonogram at level of pancreatic head. Tumour is
hypoechoic and encases superior mesenteric vein (arrow).
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ment of pancreatic lesions.7-9 Func
tioning islet cell tumours usually
present while still small. They are
diagnosed biochemically, and radi
ologic techniques are used for pre
operative localization. 310 Nonfunc
tioning islet cell tumours resemble
adenocarcinomas in that they are
usually large at the time of presen
tation and may be assessed as “ma
lignant” and unresectable. Clinical
ly, both types of tumour can pres
ent such symptoms as abdominal
pain, nausea, vomiting, malaise,
weight loss and jaundice. Although
radiology is helpful in their evalua
tion,3 they can both have the same

radiologic appearance. They are
seen as irregular, solid masses
encasing the adjacent vessels on
ultrasonography and computed
tomography . 1011 They produce
abrupt, irregular strictures or occlu
sions of the pancreatic and common
bile ducts on ERCP; they also are
seen displacing and invading the
stomach and duodenum on barium
contrast studies. 11 Computed to
mography may suggest an islet cell
tumour if contrast enhancement
shows a homogeneous vascular or
hypervascular lesion. 1012 In our pa
tient the diagnosis was not suspect
ed on computed tomography be

Fig. 2a

cause the tumour had multiple
areas of hemorrhage and necrosis
resulting in a heterogeneous ap
pearance. Adenocarcinoma and
“malignant” islet cell tumours can
be differentiated by selective arteri
ography; both encase and displace
the adjacent blood vessels. Howev
er, the former are uniformly hypovascular and the latter show vascu
lar or hypervascular areas (capillary
blush). Hepatic metastases resemble
their respective primary tumours.
Arteriography is usually reserved
for patients with potentially resect
able lesions. 1113 In our patient, ul
trasonography and computed to-

Fig. 2b

FIG. 2 — Computed tomograms at level of pancreatic head. Tumour shows heterogeneous enhancement with intravenous
contrast, (a) Superior mesenteric vein (long arrow) and artery (arrowhead) are encased, (b) Dilated right colic veins are seen
(arrows).

FIG. 3 — Epinephrine-enhanced common hepatic arteriogram.
Larger arteries are constricted. Vascular mass is seen in
pancreatic head supplied by dorsal pancreatic artery (arrow
head) and branches of gastroduodenal artery.
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FIG. 4 — Fine-needle aspirate of pancreatic mass shows
clusters of uniform cells with little plemorphism (Papanico
laou’s stain, original magnification X 240).
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mography revealed encasement of
the superior mesenteric vessels and
therefore unresectability. Arteriog
raphy was performed because of the

Fig. 5a

unexpected cytologic diagnosis and
the possibility of surgical debulking.
In addition to routine Papanico

laou staining, the cytology material
is also suitable for the application
of immunohistochemical and ultrastructural techniques.14^16 The pres-

Fig. 5b

FIG. 5 — Immunoperoxidase staining of cell block shows (a) positive staining of tumour cells with antibody to glucagon and (b)
no staining with antibody to insulin (original magnification X 384).

FIG. 6 — Electron photomicrograph of pancreatic aspirate shows cluster of tumour cells joined by desmosomes. Surface is
covered by microvilli (MV). Apical portion of cytoplasm contains neurosecretory granules (arrowheads) (original magnification
X 9200) which are shown at higher magnification in inset (original magnification X 35 000). N = nucleus.
432
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ence of low-molecular-weight kera
tins in the tumour cells confirms
the epithelial nature of the neo
plasm, since keratins are the inter
mediate filaments that have been
detected in both adenocarcinomas
and islet cell tumours.1718 However,
they may not differentiate between
these two types of neoplasms. Immunohistochemically, the presence
of pancreatic hormones confirms
the diagnosis of islet cell tumours.19
A single hormone or multiple hor
mones have been detected immunohistochemically in tissue sec
tions of pancreatic endocrine tu
mours.19
No clinical syndrome was evident
in our case, indicating that the
tumour cells were producing the
hormones but not secreting them
into the circulation. A block in the
secretion of hormones has been
described in a number of islet cell
tumours.19 The type of hormone
produced may also be of prognostic
significance; tumours secreting in
sulin tend to have a benign course
whereas most gastrin-producing tu
mours are malignant.20 In this case,
the cells were positive for glucagon
and gastrin, confirming that the
mass was an islet cell tumour. With
cells containing gastrin, one would
expect the tumour to behave more
aggressively than if the cells were
producing other hormones. The
fact that the tumour was located in
the head of the pancreas, was al
ready 10 cm in size at the time of
presentation and had not caused
biliary obstruction, suggests that it
was slow growing and had been
present for some time. Thus, the
prognosis was considered better
than a pancreatic adenocarcinoma
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but worse than an islet cell tumour
producing insulin.
Material obtained from fine-nee
dle aspirates is adequate for ultrastructural evaluation, providing it is
representative of the tumour. Even
if the tumour is necrotic and the
material poorly fixed, neurosecreto
ry granules can still be identified,
thus helping to differentiate islet
cell tumour from adenocarcinoma.
Fine-needle aspiration is an effec
tive method for diagnosing pancre
atic tumours.56 A conclusive diag
nosis can be obtained by electron
microscopy and immunohistochemistry on the aspirate obtained under
ultrasonic guidance. A prognosis
may also be made, depending on the
hormone produced by the tumour
cells, even if it is not secreted into
the bloodstream.

9.

10.

11.

12.

13.
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Residual Hypothermia in Patients
Recovering in the Intensive Care Unit
From Cardiac Surgery
Daniel Marelli, MD; Ray C-J. Chiu, MD, PhD, FACS, FRCSC; David M. Fleiszer, MD, FRCSC;
Rea A. Brown, MD, FRCSC
Because of inadequate rewarming or equilibration of body temperature, patients who
undergo cardiac surgery with hypothermia often are still hypothermic after arrival
in the intensive care unit. The incidence of residual hypothermia and its
hemodynamic effects were assessed in this study.
Of 82 adults who underwent cardiac surgery, 41 were normothermic with core
temperatures of 35.5°C or higher (mean 36.0 ± 0.1°C) and 41 were hypothermic
with temperatures below 35.5°C (mean 34.9 ± 0.1 °C) on arrival at the intensive
care unit (p < 0.005). Patients with hypothermia had significantly (1.9 ± 0.1 versus
2.2 ± 0.1, p < 0.05) lower cardiac indices. Although not statistically significant,
there was a trend toward higher systemic vascular resistance in the patients with
hypothermia.
The authors conclude that mild residual hypothermia is still common after cardiac
surgery and may contribute to the depressed hemodynamic status of these patients.

Que ce soit du a un rechauffement insuffisant ou a un probleme d’homeothermie, les
patients qui subissent une chirurgie cardiaque sous hypothermie sont souvent
encore hypothermiques a leur arrivee aux soins intensifs. La presente etude mesure
l’incidence de l’hypothermie residuelle ainsi que ses effets hemodynamiques.
D’un groupe de 82 adultes soumis a une operation cardiaque, 41 etaient
normothermiques avec une temperature de 35.5°C ou plus (moyenne 36.0 ± 0.1 °C)
a leur arrivee aux soins intensifs, alors que 41 etaient hypothermiques avec une
temperature inferieure a 35.5°C (moyenne 34.9 ± 0.1 °C, p < 0.005). Les patients
souffrant d’hypothermie presentaient un index significativement plus faible (1.9 ±
0.1 par rapport a 2.2 ± 0.1, p < 0.05); chez ces memes patients on constatait une
tendance vers une resistance vasculaire generate plus elevee, quoi que la difference
ne soit pas statistiquement significative.
Les auteurs concluent qu’il est frequent de recontrer une faible hypothermie
residuelle apres une chirurgie cardiaque. Ceci pourrait contribuer a abaisser le
statut hemodynamique de ces patients.

S

ystemic hypothermia is widely
used during cardiac surgery,
and patients are routinely rewarmed
before they are taken off cardiopul
monary bypass. Because of inade
quate rewarming or equilibration of

uneven body temperature, they fre
quently manifest a drop in body
temperature in the early postopera
tive period.12 Such' hypothermia
may reduce myocardial contractility
and increase myocardial irritability

From the Surgical Intensive Care Unit, The Montreal General Hospital and M cGill University,
Montreal, PQ
Accepted for publication Mar. 21, 1988
Reprint requests to: Dr. Ray C-J. Chiu, Rm. 947, The Montreal General Hospital, 1650 Cedar
Ave., Montreal, PQ H3G 1A4
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and peripheral resistance, thus add
ing to afterload in unanesthetized
patients. We assessed the incidence
of hypothermia after cardiac sur
gery and determined its possible
effects on cardiovascular function.

Patients and Methods
We reviewed the charts of pa
tients who returned to the intensive
care unit after cardiac surgery, for
the 3 months from Oct. 1 to Dec.
31, 1986. During this period 82
patients underwent open-heart sur
gery and were eligible for the study.
They were divided into two
groups of 41, according to body
core temperature on arrival at the
intensive care unit: group 1 was
normothermic (core temperature
more than 35.5°C as measured with
the Swan-Ganz catheter with
thermistor tip) and group 2 hypo
thermic (core temperature less than
35.5°C). Central venous, pulmo
nary artery and capillary wedge
pressures were also measured with
the Swan-Ganz catheter. Heart
rates and blood pressures were
monitored by radial artery cannulation. Cardiac output was deter
mined by the thermodilution meth
od. We used the Gould Cardiac
Computer (Critical Care Division,
Spectramed Inc., Oxnard, Calif.) to
calculate cardiac index, systemic
vascular resistance and stroke work
index. Student’s t-test was used to
evaluate differences in hemodyna
mic status between the groups. The
X2 frequency distribution was used
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to analyse the use of vasodilators
and inotropic agents.

Approximately 25% of the pa
tients in each group initially re
quired inotropic agents after sur
gery. Similarly, 20% required vaso
dilator therapy. There was no statis
tical difference between the two
groups in this respect (Table III).

Findings
In group 1 (normothermic) pa
tients the core temperature ranged
from 35.5° to 37.7°C and in group
2 (hypothermic) temperature ranged
from 34.0° to 35.4°C. Aortocoro
nary bypass was the most common
operation and in both groups males
predominated.
The mean cardiopulmonary by
pass time and average aortic cross
clamp time were comparable for
both groups (Table I).
Comparison of hemodynamic sta
tus between the two groups re
vealed significantly (p < 0.05) lower
cardiac indices in group 2 (Table II).
Although not statistically signifi
cant, there was also a trend toward
higher systemic vascular resistance
in these patients. Stroke work
index was not significantly different
in the hypothermic patients.

Table 1-

Discussion
Hypothermia and its physiologic
effects have been studied extensive
ly. As the core temperature falls,
cell metabolic rate is reduced. This
depresses various cell functions and
accounts for most of the physiolog
ic changes noted in hypothermia.3
During cardiac surgery, periods of
inadequate systemic circulation may
occur, and experiments by Bigelow
and colleagues4 have led to the
widespread use of hypothermia in
these circumstances. This enables
vital tissues to survive periods of
anoxia or ischemia.5
Early animal studies6 showed that
cardiac output decreases with in

C lin ic a l D ata

Group 1
S ex (m a le : fe m a le )
M ean age (ra n g e ), y r
M ean b y p a s s tim e (ra n g e ), m in
M ean a o rtic c ro s s -c la m p tim e (ra n g e ), m in
T ype o f s u rg e ry , n o . o f p a tie n ts
ACBP
M VR
AVR
M V R /A V R
A V R /A C B P

(n = 41 )

Group 2
(n = 41)

3 1 :1 0
6 2 (3 4 - 7 7 )
101 ( 4 1 - 1 5 6 )
60 ( 1 5 - 105)

2 9 :1 2
6 2 (3 2 - 84)
9 6 (4 3 - 143)
5 7 ( 1 4 - 108)

33
5
1
1
1

35
2
2
1
1

ACBP = a o rto c o ro n a ry b y p a s s , M V R = m itra l va lve re p la c e m e n t, A V R = a o rtic v a lv e re p la c e m e n t.

Table II -

Group
1
2

H e m o d y n a m ic S ta tu s (M e a n ± S E M ) o n A rriv a l a t th e In te n s iv e C are U n it

Core
temperature,
°C

Stroke
work index,
g-m/m2■beat'1

Cardiac
index,
L/min ■n r 2

3 6 .0 ± 0.1
(n = 4 1 )
3 4 .9 ± 0.1
(n - 4 1 )

2 5 .5 ± 1 .5
(n = 2 9 )
2 5 .8 ± 2.1
(n - 1 5 )

2 .2 ± 0 . 1
(n = 3 6 )
1 .9 ± 0.1

p

<

0 .0 0 5

NS
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(n
p

= 27)
< 0 .0 5

Systemic
vascular
resistance,
dyne/s ■cm5
1484
(n =
1 6 0 8 .8
(n =

± 9 4 .6
34)
± 9 8 .8
27)

NS

duced hypothermia. This was also
shown7 to occur in man in the
operating-room setting. More re
cently, Roberts and associates8
found that 90% of patients who
underwent coronary artery bypass
grafting displayed a decrease in
ejection fraction, left ventricular
stroke work index and cardiac in
dex, 2 hours postoperatively. Fur
ther studies9 have shown that after
myocardial revascularization there
is transient temperature-dependent
hemodynamic dysfunction during
the rewarming period.
For the purpose of this study we
defined hypothermia as a core tem
perature of less than 35.5°C. Fifty
percent of patients were found to be
hypothermic on arrival at the inten
sive care unit after cardiac surgery.
Why this happened is uncertain,
because all patients are rewarmed
after cardiopulmonary bypass, but
insufficient rewarming combined
with a redistribution of heat to
reduce the temperature gradient
within body tissues is the likely
explanation. Another possible ex
planation may be the effect of anes
thetic drugs on thermoregulation;
these agents may impair responses
to cooling such as vasoconstriction,
shivering and increased metabolism.
They also can alter feedback to and
from the central nervous system.10
Hypothermia decreases myocardi
al contractility and increases myo
cardial irritability.5 Among the pa
rameters of cardiovascular function
studied, cardiac index was found to
be significantly (p < 0.05) lower in
patients with hypothermia. This
may reflect reduced myocardial con
tractility. Other findings suggest an
increase in peripheral resistance and
stroke work index, but the differTable III

- U s e o f P h a rm a c o lo g ic A g e n ts

Group

Inotropic
agents, %

Vasodilators, %

1
2

2 6 .8
2 6 .8

22
17
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(^liefoxin
(sterile cefoxitin sodium, MSD Std.)

ANTIBIOTIC
ACTION

ences noted were relatively small
and were not statistically signifi
cant.
Our study revealed that mild re
sidual hypothermia is still common
after cardiac surgery. Although
generally mild, it may partially ac
count for the hemodynamic dys
function observed in patients upon
their arrival at the intensive care
unit. Continued vigilance is needed
to prevent residual hypothermia
and, thus, cardiac depression dur
ing this critical period.
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INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - In tra -a b d o m in a l in fe c tio n s such as
peritonitis and intra-abdominal abscess
2 - G y n e c o lo g ic a l in fe c tio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the sus
ceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
O rganism s p a rtic u la rly a p p ro p ria te fo r
therapy with MEFOXIN' are:
Gram positive
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E. coh
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN* is not active against Pseudomonas,
most strains of enterococci, many strains of
Enterobacter cloacae,
and meth ici 11inre s is ta n t s ta p h y lo c o c c i and L is te ria
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
who are a lso re c e iv in g c a rb e n ic illin ,
gentamicin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable for
patients with bacteremia, bacterial septicemia,
or other severe or life-threatening infections,
or for patients who may be poor risks because
of lowered resistance resulting from such
d e b ilita tin g co n d itio n s as m a ln u tritio n ,
trauma, surgery, diabetes, heart failure, or
malignancy, particularly if shock is present or
impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
postoperatively) to patients undergoing
vaginal or abdominal hysterectomy and ab
dominal surgery when there is a significant
risk of postoperative infection or where the
occurrence of postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)

and postoperative use of MEFOXIN* may
reduce the incidence of surgery related post
operative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
adm in istra tio n of any a n tib io tic beyond
24 hours follow ing surgery increases the
possibility of adverse reactions but, in the
m ajority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN*, cephalo
sporins, penicillins or other drugs. MEFOXIN*
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of p a rtia l c ro s s -a lle rg e n ic ity between
cephamycins and the other beta-lactam anti
b io tics, p e n ic illin s and cephalosporins.
Severe reactions (including anaphylaxis) have
been re p o rte d w ith m ost b e ta-la cta m
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is important to considers diagnosis of pseudo
membranous colitis in patients who develop
diarrhea in association with antibiotic use.
While studies indicate that a toxin produced
by Clostridium difficile is one primary cause of
antibiotic-associated colitis, other causes
should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN" occurs,
administration of the drug should be discon
tinued. Serious hypersensitivity reactions may
require treatment with epinephrine and other
emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN’ is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and prolonged serum antibiotic con
centrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling’s solutions
but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN*
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
Increased nephrotoxicity has been reported
fo llo w in g concom itant adm inistration of
cephalosporins and aminoglycoside antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
e s ta b lis h e d . If th e a d m in is tra tio n of

MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition
is essential and if superinfection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100 m g/kg/day and
above) have been asso cia te d w ith an
increased incidence of eosinophilia and
elevated SGOT.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
re a c tio n s ra re ly req u ire d ce ssa tion of
treatment and usually have been mild and
transient.
Local Reactions
Thrombophlebitis has occurred with intra
venous administration. Some degree of pain
and tenderness is usually experienced after
in tra m u s c u la r in je c tio n s using w a te r.
Induration has occasionally been reported.
Allergic
M acu lo p a p u la r rash, urtica ria , pruritus,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia,
hem olytic anemia, and thrombocytopenia
have been reported. Some individuals, particu
la rly those with azotemia, may develop
positive direct Coombs tests during therapy
with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
Kidney
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been rep o rte d rarely. The role of
MEFOXIN* in changes in renal function tests
is d iffic u lt to assess, since factors pre
disposing to prerenal azotemia or to impaired
renal function have often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered intravenously
or intra m u scu la rly when required. (See
complete monograph on ADMINISTRATION
and RECONSTITUTION.)
TREATMENT DOSAGE
Adults
The usual adult dosage is 1 g or 2 g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.

Usual Adult Dosage
Type of
infection

Daily
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

•Including patients in whom bacteremia is
absent or unlikely
Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infectionsshould be maintained
for at least 10days to guard against the risk of
rheum atic fever or glomerulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
After a loading dose, the following recommen
dations for maintenance dosage may be used
as a guide:

pected, an appropriate antibiotic should be
used.
A t present there is in s u ffic ie n t data to
recommend a specific dosage for children
with impaired renal function. However, if the
administration of MEFOXIN* is deemed to be
essential the dosage should be m odified
consistent with the recom m endations fo r
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN* is recommended as follows:
Vaginal or abdom inal h yste re cto m y and
abdominal surgery
2 g administered intram uscularly or in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
MEFOXIN* is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.

PRODUCT MONOGRAPH AVA ILA B LE
ON REQUEST

*®Trademark
RENAL
FUNCTION
Mild
impairment
Moderate
impairment
Severe
impairment
Essentially
no function

CREATININE
CLEARANCE
mL/min

DOSE

FREQUENCY

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

(425-a,6,87x)

In the patient undergoing hemodialysis, the
loading dose of 1 - 2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Neonates (Inclu d in g Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants
with Body Weights
Above 1500 g

MSP
MERCK
SHARft
DOHME
I paab I

I P“ AC I

P.O. Box 1005, Pointe Claire
Dorval, Quebec H9R 4P8

20-40 mg/kg every 12 h l*.V.

Neonates
01 week of age20-40 mg/kg every 12 h I.V.
20-40 mg/kg every 8 h I.V.
1- 4 weeks of age
Infants
1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN* is not recommended fo r the
therapy of meningitis. If meningitis is sus
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Complications immediates de la resection
transuretrale de la prostate: etude de 1000
cas consecutifs

1

Jean-Marie Paquin, MD, FRCSC; Jean-Paul Perreault, MD, FRCSC; Raymond Faucher, MD, FRCSC;
Franqois Mauffette, MD, FRCSC; Luc Valiquette, MD, FRCSC; Steven Lapointe, MD, FRCSC
Les auteurs ont revise les dossiers de 1000 patients qui ont subi une resection
transuretrale de la prostate. L'etude a porte sur les 30 jours postoperatoires. Des
complications ont ete rencontrees chez 139 patients et il y eut 6 deces. Les
problemes d’infection (urinaire dans 63 cas et septicemie dans 23 cas) sont les plus
frequents, suivis de l’hemorragie et de la retention. Les deces etaient relies a des
causes cardiaques.

pies chez 21 patients (tableau I).
Six patients sont decedes en postoperatoire.
Nous allons etudier de facon
detaillee notre morbidite qui fut de
14%.

The authors reviewed the charts of 1000 patients who underwent transurethral
resection of the prostate. When the 30-day postoperative period was studied, it was
found that 139 patients suffered complications and 6 died. Infectious complications
(urinary tract in 63 cases and septicemia in 23 cases) were the commonest followed
by hemorrhage and urinary retention. The deaths were related to cardiac problems.

Infection urinaire

a resection transuretrale de la
prostate est une intervention
pratiquee de fagon quotidienne. Elle
est consideree comme comportant
peu de mortalite ou de morbidite.1
Afin de preciser ces donnees nous
avons etudie 1000 cas consecutifs
de patients operes dans le service
d’urologie de l’hopital Saint-Luc a
Montreal.

L

malades variait de 45 a 97 ans
(moyenne de 68.5 ans). Le sejour
hospitalier moyen fut de 8.4 jours
(de 3 a 61 jours). Au point de vue
histologique, 864 patients etaient
porteurs d’une pathologie benigne
et 136 patients d’un cancer de la
prostate.

De 1980 a 1986, 1000 patients
furent admis pour traitement d’une
pathologie prostatique. L’age des

Nous avons releve les complica
tions postoperatoires immediates
sur les 1000 dossiers etudies. Centdix-huit ont eu une complication
unique alors qu’elles furent multi-

Du departement de chirurgie, Universite de Montreal, service d ’urologie, hopital Saint-Luc,
Montreal, PQ
Accepte pour publication le 12 janvier, 1988
Les demandes de tires a part doivent etre adressees au: Dr Jean-Marie Paquin, Departement de
chirurgie, Hopital Saint-Luc, 1058. rue Saint-Denis, Montreal, PQ H2X 3J4
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Hemorragie postoperatoire

Resultats
Patients

4

L’infection urinaire, prouvee a la
culture des urines, a ete retrouvee
chez 63 patients. Ces cultures fu
rent faites au moment ou la sonde
uretrale fut retiree et lors de la
visite de relance. Les germes les
plus frequemment rencontres furent
FEscherichia coli, l’enterocoque, le
Klebsiella et le Staphylococcus epidermidis. Tous furent traites par
antibiotherapie orale et les cultures
de controle furent negativees.

Trente-cinq patients ont presen
te une hemorragie post-prostatectomie.2 Celle-ci a ete immediate
dans 20 cas et retardee dans 15.
T a b l e a u 1 - C o m p lic a t io n s
C o m p lic a t io n

No.

I n fe c t io n u rin a ir e

63

H e m o r r a g ie

35

R e te n tio n u rin a ir e

27

S e p tic e m ie

23

C a r d io - v a s c u la ir e

9

I n c o n t in e n c e

9

F a u x t r a je t s

4

E p id id y m ite

2

H y p o n a t r e m ie d e d ilu t io n

2

P n e u m o n ie

1
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COMPLICATIONS DE LA PROSTATECTOMIE TRANSURETRALE

Le cas le plus tardif a ete rencon
tre au 21e jour postoperatoire. Le
traitement approprie pour cette con
dition fut varie; tous les malades
ont bien repondu a la therapie
(tableau II).
Retention urinaire

Vingt-sept patients ont presente
une retention urinaire apres
l’exerese de la sonde uretrale.
Chez 21 patients le traitement a
consiste a l’emploi d’un parasympathicometique3 et de la mise en place
d’une sonde uretrale pour des periodes variant de 24 a 48 heures.
Si le residu fait apres le retrait de
la sonde etait inferieur a 100 ml
le patient etait considere comme
ayant repondu au traitement. Quatre patients ont quitte l’hopital
avec une sonde a demeure; ils
etaient connus comme souffrant
d’une atonie en preoperatoire.
Deux patients ont du subir une
nouvelle resection transuretrale
pour adenome residuel.

autres etaient porteurs d’une infec
tion urinaire. Cette faible incidence
de septicemie s’explique par la
preparation preoperatoire des mala
des porteurs ou presumes infectes
en preoperatoire.4 En effet, ces derniers ont requ de l’ampicilline et de
la tobramycine intra-veineuse avant
l’intervention et durant les jours
postoperatoires.
Complications d ’ordre
cardio-vasculaire

Neuf patients ont presente des
complications cardiaques et vasculaires. L’oedeme aigu rencontre
chez quatre malades etait du a une
surcharge vasculaire post resection
transuretrale. Trois patients ont fait
un infarctus du myocarde dans les
24 premieres heures; ils n’avaient
aucune histoire anterieure de maladie cardiaque. Un patient a fait une
thrombophlebite necessitant une
anticoagulotherapie, tandis qu’un
autre a fait une embolie pulmonaire
non mortelle.

Septicemie

Incontinence urinaire

Chez les 1000 patients operes,
23 ont presente une septicemie avec
une hemoculture positive en periode
postoperatoire.
Onze de ces patients avaient une
urine sterile a l’admission et les 12

Neuf patients ont presente de
l’incontinence urinaire en posto
peratoire. Quatre manifestaient de
l’incontinence d’effort qui a disparu
avec le temps et chez cinq autres
patients nous avons retrouve une
vessie spastique pour expliquer
leurs symptomes qui se sont amendes avec un parasympathicolytique.
Aucun patient n’a eu d’incontinence
urinaire totale.

Tableau II - Traitement
Periode immediate
Electrocoagulation
Ligature chirurgicale des arteres
prostatiques
Transfusion
Periode eloignee
Electrocoagulation
Mise en place d'une sonde et
irrigation avec ou sans
transfusion

Faux trajets

Tableau III - Mortalite
Cause
Choc septique
Oedeme aigu du poumon
Infarctus aigu du myocarde

No.
1
2
3
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Quatre patients ont eu durant les
manipulations preoperatoires et peroperatoires des faux trajets uretraux. Deux de ces patients etaient
deja porteurs d’une cystostomie ins
ta lls en urgence. Un de ces pa
tients a subi une perforation rectale
au moment de l’introduction du

resectoscope. Une derivation par
cystostomie fut faite et 2 mois plus
tard il subissait une resection tran
suretrale sans aucune sequelle.
Hyponatremie

Deux patients ont presente une
hyponatremie de dilution symptomatique. Dans les deux cas les
symptomes se sont manifestos dans
les 12 heures qui suivirent l’inter
vention.
Epididymite

Seulement deux patients ont
presente une epididymite dans la
periode postoperatoire. Un patient
porteur d’une sonde etait infecte
avant l’intervention.
Mortalite

La mortalite postoperatoire fut
minime (0.6%). La moyenne d’age
des patients decedes etaient de 76
ans. Le choc septique, l’oedeme
aigu du poumon et l’infarctus furent les principales causes de deces
(tableau III).

Discussion
La mortalite et la morbidity rattaches a la resection transuretrale de
la prostate sont faibles. En effet,
seulement 14% des patients ont
presente des complications. Pres de
la moitie, c’est-a-dire 63 patients
sur 139, etait secondaire a une
infection urinaire.
L’hemorragie postoperatoire im
mediate, bien que rare, peut etre
corrigee en insistant davantage sur
une meilleure hemostase5 tandis
que l’hemorragie a long terme, bien
que non previsible, pourrait etre
evitee en donnant les conseils d’usage, a savoir eviter les activites
sexuelles et les activites physiques.
La septicemie peut etre reduite
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avec une plus grande rigueur d’asepsie et une identification des malades susceptibies d’etre infectes ou
porteurs d’infection avant (’inter
vention de fagon a pouvoir leur
donner une antibiotherapie preven
tive au prealable.
La mortalite de 0.6% est basse et
elle est comparable aux autres
series connues. Afin de la diminuer
il est tres important que tous les
patients a risque aient une evalua
tion preopera toire.
L’incontinence postoperatoire secondaire a la technique s’est amelioree beaucoup a travers les annees.
Nous pouvons constater que nous
n ’avons pas d’incontinence a long

terme mais seulement une inconti
nence d’effort temporaire.
Les stenoses uretrales et les
stenoses du col vesical sont des
complications beaucoup plus tardives qui surviennent encore malheureusement et pour lesquelles nous
n’avons pas trouve de solution.

Conclusions
La resection transuretrale de la
prostate est une intervention chirurgicale a faible incidence de mortalite
et de morbidite. II est toutefois tres
important que le malade soit bien
prepare et bien evalue.
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BOOK REVIEWS
continued from page 412

reports of each scientist in paper form
allows for close scrutiny of the data.
The book is geared more to the
research and research-oriented clinical
laboratory in the field of growth factors
and wound healing. The chapter dealing
with platelet-derived wound healing fac
tors in human clinical trials is especially
relevant to surgical practice as is the
chapter on clinical experience with
crude preparation of growth factors and
healing of chronic wounds in humans.
The authors present state of the art
information on alternatives to healing
difficult ulcers or wounds for which
conventional therapy is slow or ineffec
tive.
The book is easy to read but would
have benefited by more editorial com
ment on how the various scientific
presentations relate to clinical pratice.
However, this does not deter from the
overall aim of the book. It serves as an
excellent reference for the research sci
entist in the area of growth factors and
other aspects of wound healing and is a
very interesting and clinically relevant
440

reference source for the practising clini
cal surgeon.
Nicolas V. Christou, MD, PhD, FRCSC,
FACS
Associate Professor o f Surgery,
McGill University,
Department o f Surgery,
Royal Victoria Hospital,
687 Pine Ave. W,
Montreal, PQ
H3A 1A1

PRINCIPLES AND PRACTICE OF
RESEARCH. Strategies for Surgical
Investigators. Edited by Hans Troidl,
Walter 0 . Spitzer, Bucknam McPeek,
David S. Mulder and Martin F.
McKneally. 385 pp. Illust. SpringerVerlag, New York. $58.00 (US). ISBN
0-387-16340-9.
This book on surgical research is divid
ed into six sections. The first section on
the rationale of surgical research deals
with the historical and philosophical

aspects and the role and training of the
investigator. The second section con
cerns itself with practical tools required
by the investigator, including such top
ics as literature review and appraisal,
statistics, computers and preparation of
grant proposals. The chapter on statis
tics, entitled “Statistics demystified”, is
excellent as a review or for the student
who has had no exposure to research.
The various aspects of surgical re
search are covered in the next section.
They include animal experimentation,
clinical research, multicentre trials and
health service research. Three well-writ
ten chapters in this section deal with
particularly important subjects, not
only for the surgical investigator but
for every academic surgeon; they dis
cuss the conduct and pitfalls of clinical
trials, including multicentre clinical tri
als, and the evaluation of the diagnostic
process in medicine. Practical examples
of how to calculate patient size in a
clinical trial and how to evaluate diagcontinued on page 447
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Acute Pancoast’s Syndrome Caused by
Fungal Infection
F.M. Shamji, MB, ChB, FRCSC;* J.R. Leduc, MD, FRCSC;* J. Bormanis, MD, FRCPC;t
H.J. Sachs, MD, FACS, FACCP, FRCSC*
Nonmalignant causes of Pancoast’s syndrome are extremely rare. The authors
report the case of a 32-year-old man, receiving treatment for acute lymphoblastic
leukemia, who had a clinical picture resembling that of Pancoast’s syndrome.
Invasive mucormycosis was diagnosed as the cause of the syndrome at emergency
thoracotomy undertaken to control massive hemoptysis. In spite of adequate
treatment, the patient died 5 weeks postoperatively of overwhelming sepsis. A
review of the literature disclosed only two other similar cases. The authors conclude
that the development of Pancoast’s syndrome in the immunosuppressed patient
should raise suspicion of an invasive fungal infection. A precise early diagnosis may
allow successful, specific antifungal therapy to be instituted.

Les causes non malignes du syndrome de Pancoast-Tobias sont rares. Les auteurs
decrivent le cas d’un homme de 32 ans traite pour leucemie aigue lymphoblastique,
qui presenta un tableau clinique evocateur d’un syndrome de Pancoast-Tobias. Lors
d’une thoracotomie pratiquee en urgence pour venir a bout d’une hemoptysie
massive, une mucormycose fut diagnostiquee comme cause de ce syndrome. En depit
d’un traitement approprie, le patient deceda 5 semaines plus tard d’une septicemie
irrepressible. Une revue de la litterature n’a revele que deux autres cas similaires.
En conclusion, les auteurs indiquent qu’il faut soupfonner une infection fongique
invasive quand un syndrome de Pancoast-Tobias apparait chez un patient dont les
fonctions immunitaires sont deprimees. Un diagnostic precis et precoce pourrait
permettre le succes d’un traitement antifongique specifique.

ancoast’s syndrome, the associ
ation of pain in the shoulder
and arm, sensorimotor symptoms in
the involved upper limb and an
ipsilateral Horner’s syndrome, is
usually caused by a malignant api
cal lung tumour invading the struc
tures of the thoracic inlet.1 We
present a case of rapidly evolving
Pancoast’s syndrome that resulted
from a fungal infection.

P

Case R eport

A 32-year-old man presented with
a 3-month history of fatigue, night
sweats and anorexia. He had be
come jaundiced 3 weeks earlier and
his urine was dark. He had suffered
from rheumatic fever as a child.
Physical examination revealed a
jaundiced young man with petechiae scattered over most of his body.

From the *Division o f Thoracic Surgery and fD ivision o f Hematology, Ottawa Civic Hospital,
University o f Ottawa, Ottawa, Ont.
Accepted for publication Apr. 14, 1988
Reprint requests to: Dr. F.M. Shamji, Division o f Thoracic Surgery, Ottawa Civic Hospital, 1053
Carling Ave., Ottawa, Ont. K 1Y 4E9
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He had enlarged cervical, axillary
and femoral lymph nodes and hepatosplenomegaly. A chest film ap
peared normal (Fig. 1). Blood smear
and bone-marrow examination were
diagnostic for acute lymphoblastic
leukemia. Induction chemotherapy
was with vincristine, prednisone and
daunorubicin; the hepatosplenomegaly and lym phadenopathy
quickly resolved. Remission as
assessed by bone-marrow examina
tion was achieved by 3 weeks.
During the neutropenic period,
approximately 5 days after the initi
ation of chemotherapy, severe cons
tant pain developed in his left
shoulder and over the left scapula.
He remained afebrile with no cough
or hemoptysis. Over the next 4
days, the left shoulder pain in
creased in severity and radiated
down the medial aspect of the left
arm; paresthesia developed in the
fourth and fifth fingers.
The patient became febrile, so
tobramycin, 100 mg intravenously
every 8 hours, and cefazolin, 1.5 g
every 6 hours, were started. All
cultures were sterile but the patient
remained febrile and a cough with
mild hemoptysis developed. A chest
film now revealed left upper lobe
consolidation (Fig. 2). Ticarcillin, 3
g intravenously every 4 hours, was
substituted for cefazolin. Two days
later, approximately 11 days after
the initiation of chemotherapy, a
left Horner’s syndrome developed
and a supraclavicular mass that was
fluctuant, tender and not erythema
tous appeared on the left side.
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There was cavitation within the
consolidation of the left upper lobe
and subcutaneous emphysema in
the left side of the neck (Fig. 3). A
provisional diagnosis of lung ab
scess or leukemic infiltration of the
left upper lobe was considered.
Fiberoptic flexible bronchoscopy
revealed erythema of the left upper
lobe bronchus but no evidence of
pus or active bleeding. Biopsy speci
mens and cytologic brushings were
obtained, and tissue was cultured.
Apart from a light inflammatory
exudate and nonspecific bronchitis,
there was no evidence of malignant
cells, bacteria or fungi. Approxi
mately 8 hours after bronchoscopy,
sudden massive hemoptysis devel
oped and the patient suffered a
cardiorespiratory arrest. He was re
suscitated, but large quantities of
arterial blood continued to drain
through the endotracheal tube.
On fiberoptic flexible bronchos
copy, the diseased left upper lobe
was found to, be the source of
bleeding. An emergency left thora
cotomy, under one-lung ventilation
using a Carlen’s tube, was then
undertaken to remove the diseased
lobe, which appeared to be consoli
dated, necrotic and intimately in
volved within the apex of the tho
rax. Mobilization of the diseased
necrotic lung from the thoracic
inlet was difficult and when the
lung was entered the necrotic proc
ess was seen to involve the cervical
sympathetic chain, the left subclavi
an artery and the lower part of the
brachial plexus. The dissection re
sulted in extensive bleeding at the
apex of the chest wall, apparently
from the left subclavian artery; the
bleeding was controlled with diffi
culty using fine vascular sutures. A
left upper lobectomy was then com
pleted.
Amphotericin-B therapy was be
gun; the initial dosage was 5 m g/d
intravenously and he received a cu
mulative dose of 1.57 g. Gram
442

negative septicemia developed sec
ondary to left lower lobe pneumonia
and in spite of vigorous antibiotic
and supportive therapy, aortic valve
endocarditis and meningitis due to
Serratia marcescens developed. He
died of severe systemic sepsis 5
weeks postoperatively.

Discussion
The pathological examination re
vealed mucormycosis. The lung tis
sue was necrotic and very friable
with local thrombus formation in
the blood vessels secondary to fun
gal infection. Numerous fungi were
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FIG. 1 — Normal chest film on admission.
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FIG. 2 — Nine days after induction chemotherapy, film shows consolidation of
upper lobe of left lung.

VOL. 31, NO. 6 NOVEMBER 1988/CJS

ACUTE PANCOAST SYNDROME

seen in the lumen of the blood
vessels. Examination of the bron
chus showed evidence of chronic
nonspecific bronchitis only. There
was no leukemic infiltrate in the
lung tissue or the hilar lymph
nodes.
It was our impression that the
necrotic disease process in the tho
racic inlet of this patient resulted in
a bronchovascular fistula between
the subclavian artery and the ab
scess cavity in the left upper lobe;
in addition to massive hemoptysis,
this fistula was also the source of

considerable bleeding that we en
countered when we dissected the
lung from the chest wall. Involve
ment of the left brachial plexus and
sympathetic chain was responsible
for the left arm pain, paresthesia,
and Horner’s syndrome.
A review of the medical literature
revealed two reports23 of a rapidly
evolving Pancoast’s syndrome oc
curring in immunosuppressed pa
tients and caused by invasive fungal
infection. Our case resembled these
in that all three patients were
young adults, suffering from hema

tologic malignant disease in whom
an invasive fungal infection oc
curred during or just after chemo
therapy when neutropenia was pro
found. The picture of well-estab
lished Pancoast’s syndrome was ob
vious in these cases within 4 weeks
of receiving the induction chemo
therapy. The cause of the infection
in our case was mucormycosis; As
pergillus sp and Allescheria boydii
were seen in the other cases. Only
one patient survived with antifungal
therapy;2 the other3 died of over
whelming sepsis, as did our patient.

Conclusions
The development of a rapidly
evolving Pancoast’s syndrome in an
immunosuppressed patient is sug
gestive of an invasive fungal infec
tion. A precise early diagnosis will
allow specific antifungal therapy to
be instituted, and treatment of the
infection may be successful.
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Peritoneovenous Shunts — Devices of
Last Resort
Karen E. Shepherd, MD;* Brian J. Miller, MD, FRCSCt
This study examines the usefulness of peritoneovenous shunts through a
retrospective review of the charts of 16 patients who received this shunt at the
University Hospital in Saskatoon up to May 1987. Fourteen shunts were placed for
malignant ascites, 1 for alcoholic cirrhosis and 1 for nephrogenic ascites. All
patients had symptoms related to abdominal pressure or dyspnea. Diuretics were
most frequently used as initial management, and paracentesis was performed to
relieve symptoms in all but one patient. However, a trial of sodium restriction was
used in only eight patients, and only five of these trials lasted longer than 1 week.
Thus, the adequacy of medical management was questionable. The death of one
patient was directly attributable to the shunt, and the deaths of four others were
suspected to be sequelae of surgery or shunting. Only five shunts were functioning
at the time the patient died. In this study, the majority of the patients received little
benefit from the peritoneovenous shunt.

and variations in method may ac
count for the variability in the re
ported results. Even with identical
data, different conclusions may be
drawn because interpretation of
data and perception of “benefit”
vary between observers.
Thus, we wished to determine the
value of peritoneovenous shunts in
the context of our patient popula
tion, selection criteria and perioper
ative management regimens.

Cette etude sur l’utilite des derivations peritoneo-veineuses fut faite par un examen
retrospectif des dossiers de 16 patients qui regurent ce type de derivation jusqu’en
mai 1987, a l’Hopital universitaire de Saskatoon. Quatorze derivations furent
placees pour ascite maligne, 1 pour cirrhose alcoolique et 1 pour ascite nephrogenique. Tous les patients presentaient de symptomes relies a la pression abdominale ou
a la dyspnee. Les diuretiques avaient le plus souvent ete utilises comme traitement
initial, et une paracentese avait ete pratiquee pour soulager les symptomes chez
tous les patients, sauf un. Toutefois, un apport hyposodique ne fut tente que chez
huit patients seulement, et l’essai dura plus d’une semaine chez seulement cinq
d’entre-eux. II est done possible que le traitement medical n’ait pas ete optimum. Le
deces d’un des patients est directement attribuable a la derivation, et on soupconne
que la mort de quatre autres soit une sequelle de la chirurgie ou de la derivation.
Seulement cinq derivations etaient permeables au moment du deces des malades.
Dans cette etude, la majorite des patients a peu profite d’une derivation peritoneoveineuse.

Methods

ince peritoneovenous shunts
S were
introduced in 1974 for the

management of ascites, opinions of
their benefits and drawbacks have

been conflicting. Patient selection is
an important factor in determining
outcome. Postoperative manage
ment may play an important role,
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The charts of all 16 patients who
received peritoneovenous shunts at
University Hospital, Saskatoon, up
to May 1987 were reviewed. Infor
mation gleaned from the records
included the patient’s age, disease,
symptoms, management of the asci
tes before surgery and the surgical
procedure used (including type of
shunt). The effectiveness of the
shunt was determined by comparing
preoperative and postoperative pa
tient weights, abdominal girths and
symptoms (on postoperative day 7,
on discharge and as last reported in
the chart or from the family physi
cian’s, home or hospital record).
Supplemental treatments, patency
studies (e.g., Doppler flow) and au
topsy findings were noted. Compli
cations postoperatively and patient
survival were also considered.

Findings
Patient age ranged from 21 to 79
VOL. 31. NO. 6 NOVEMBER 1988/CJS
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years (mean 55 years) at the time
the shunt was placed. In most pa
tients, the disease giving rise to the
ascites was malignant (Table I).
The symptoms present before
shunt placement included abdomi
nal pressure in 15 and dyspnea in
13 patients. Pleural effusions, pres
ent in 6 of the 13, likely contribut
ed to the feeling of dyspnea; 1 of
the 13 had congestive heart failure.
Heartburn in two patients and back
pain in one were less notable symp
toms.
Initial medical management of
the ascites varied widely. Diuretics
were most frequently used (14 pa
tients, Table II). Agents used were

hydrochlorothiazide, furosemide
and spironolactone. Paracentesis
was also a popular therapeutic mea
sure preoperatively. Of the 16 pa
tients, 15 had at least one therapeu
tic paracentesis (Table III). Only
eight patients underwent a trial of
sodium restriction to treat their
ascites, and this lasted for less than
1 week in three patients, less than 1
month in two and less than 4
months in two others. Fluid restric
tion was tried in 3 of the 16
patients; 2 were restricted for 5
days and 1 for 29 days.
Until 1982, all shunts used were
the LeVeen type (seven patients).
Denver shunts were then intro

Table 1 - Diseases In Patients Who
Received a Peritoneovenous Shunt

Table IV - Complications After Shunt
Placement

Disease
Malignant
Adenocarcinoma of
breast
colon
endometrium
gallbladder/common
bile duct
ovary
pancreas (suspected)
stomach
Leiomyosarcoma
(anaplastic)
Lymphocytic lymphoma
Nonmalignant
Alcoholic cirrhosis
Renal failure/nephrotic
ascites

No. of patients

1
3
1
2
2
2
1
1
1
1
1

Table II - Courses of Diuretics Given
Preoperatively
Length of course, wk
0- 1
1- 2
2- 4
4- 8
8 -1 6
> 16

Complication

No. of patients (%)

Congestive heart
failure
Coagulopathy (new)*
Asymptomatic
Symptomatic
Venous thrombosis
Infection
Wound
Sepsis
Ascitic leak
Pulmonary embolism
Cerebrovascular
accident
Renal failuref
Shunt displacement

2(12)
3(20)
1(7)
2(12)
1(6)
1(6)
1(6)
1(6)
1(6)
1(6)
1(6)

*2 patients had coagulopathy preoperative
ly that was unchanged postoperatively.
Coagulation studies were not done on 1
patient.
tPrerenal in nature, especially on days 3 to
7, then resolved.

duced, and the other nine patients
received this shunt.
Eleven patients (69%) had prob
lems after shunting; in all, there
were 15 complications (Table IV).
In one of the four patients who
received prophylactic antibiotics perioperatively, an enterococcal
wound infection developed; the
same patient also suffered sepsis
due to Peptostreptococcus.
Autopsy was performed on five
patients; three had postoperative
complications — congestive heart
failure, massive pulmonary embo
lism and cerebrovascular accident.
The congestive heart failure oc
curred 5 days postoperatively, the
pulmonary embolism occurred 2
hours postoperatively in a patient
who had been heparinized at opera
tion and the cerebrovascular acci
dent occurred 5 days after opera
tion (the autopsy reported “ tumour
embolism” as a cause of the
stroke). In each of these cases, the
complication undoubtedly con
tributed to the patient’s death.
When autopsy was not done, it was
impossible to prove that the compli
cations were responsible for the
patient’s death. We noted the time
that elapsed between diagnosing
the complication and death (Table
V).
The length of patient survival
with a functioning shunt was deter
mined in patients surviving longer
than 1 week (Table VI, Fig. 1). The

No. of patients
2
0
4
2
2
4

Table III - Peritoneal Taps Preoperatively
No. of taps

No. of patients

1
2
3
4
> 4

1
6
4
3
1
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Table V - Survival Related to Complications
Complication
Congestive heart failure
Congestive heart failure
Symptomatic coagulopathy
Wound infection + sepsis
Thrombosis of superior vena cava
Thrombosis of superior vena cava?
Ascitic leak
Renal failure
Cerebrovascular accident
Pulmonary embolism
Shunt displacement

Postop time of
death, d
7
10 mo
30
30
3 mo
31
22
22
5 wk
2 h
-*

Time from diagnosis
to death, d
2
10 mo
6
19
83
13
12
19
30
-

"Alive 3 yr postoperatively.
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patient with alcoholic cirrhosis was
still alive at the time of writing. The
patient with nephrotic ascites, who
died 10 months after shunt place
ment, required repeated paracen
teses, starting 5 months after oper
ation. For at least 50% of his re
maining life, he received no pallia
tion from the shunt. Figure 2
shows the results obtained with the
shunt in patients who had malig
nant ascites and survived longer
than 1 week.
During the first week after shunt
placement, most patients received a
course of diuretics and, in some
cases, sodium restriction. Nine of
the 13 who survived longer than 1
week required supplemental treat
ment (Table VII).

tes)1 and in as few as 2% (mixed
malignant and nonmalignant asci
tes).2 The disproportion of malig
nant cases (14) in our series may
account for the relatively low coa
gulopathy rate, because postopera
tive coagulopathies have been
found to develop less frequently in
patients with malignant ascites than
in those with cirrhosis.3 The infec
tion rate in reported studies has
ranged from 25%' to 2%,2 and ve
nous thrombosis from 11%4 to 0%^
Similarly, reports of shunt failure
have been inconsistent, but compar
isons are difficult because of vary
ing forms in which the data are
presented (e.g., cumulative patency,
patencies of selected subgroups at a
given time, median patency dura
tion). Grischkan and colleagues,5

Discussion
The results of reported studies to
date have been comparable to ours.
The complications we experienced
have also been reported by other
groups, although in varying propor
tions. For example, coagulopathy
has been reported in up to 39% of
patients (all with nonmalignant asci
T a b le V I - R e su lts A fte r S h u n t P la c e m e n t
Days
a fte r shunt
p la c e m e n t

N o. of
p a tie n ts
a liv e

N o. w ith
fu n ctio n al
shunts

1
7
14
30
60
90
120
180
360

15
13
13
9
6
5
3
3
2

15
11
10
6
6
4
2
1
1

FIG. 1 — Patient survival and shunt
function after placement of peritoneovenous shunt. Solid line = patients
alive, dotted line = patients alive and
shunt functioning.

for example, reported that 8 of 11
patients studied required either a
revision or replacement of the shunt
due to malfunction, and Fry and
associates6 found that 55% (33 of
60 patients) had patent shunts at 3
months. In the study of Lund and
Moritz,2 only 10% (5 of 49) shunts
failed “in long-term follow-up”
(time unspecified).
High death rates have been re
ported after shunt placement, par
ticularly in patients with underlying
malignant disease. One-year surviv
al rates have ranged from 52%1 to
19%.2 For malignant ascites, 1-year
survival has been reported to vary
from 0%3 to 11%2 compared with
50%3 and 54%2 for patients with
cirrhosis. In our study, only three
patients (18%) were still alive at 1
year, and this included one of the
two patients with nonmalignant as
cites.
Patient selection in our institu
tion is based mainly on the referrals
of our oncologists and gastroen
terologists. The disproportion in
the number of patients who had
malignant ascites in our study com
pared with those who had cirrhotic
ascites reflects the biases of these
specialists. We could not determine
from chart review if, or how many,
patients referred for shunt insertion
were rejected by the surgeons.

120

T a b le V II - S u p p le m e n ta l T re a tm e n ts
R e q u ire d in P a tie n ts S u rv iv in g M o re T h a n 1
W eek A fte r S h u n t P la c e m e n t
T re a tm e n t
D iu re tic s
S o d iu m re s tric tio n
F lu id re s tric tio n
R e p e a te d para ce n te se s
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N o. of p a tie n ts
8
4
1
2

FIG. 2 — Lifespan and shunt function in 10 patients with malignant ascites who
survived longer than 1 week after peritoneovenous shunting. Black bars = total
days of life, lined bars = days of shunt function.
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However, it was apparent that sev
eral patients receiving shunts had
not had optimal medical therapy
first, and in many patients the in
tractability of the ascites was ques
tionable. Sodium restriction, the
mainstay of ascites management,
was not even tried in two patients
and several had only brief courses.
Diuretics were used, but again
courses in many patients were brief.
(Because fluid restriction can pre
cipitate hepatorenal syndrome, it
may have been considered undesir
able.)
Morbidity and mortality were
striking in this small series; 69%
(11) of patients had complications.
Surgery or the shunt itself likely
contributed to the death of at least
38% (six) of patients. Cause and
effect could not be proved, even
with autopsy, because of the myriad
of variables. In all but two patients

with complications, death occurred
within 30 days of diagnosis.
Overall, patients did not live long
after receiving their shunts. Only
nine patients were alive 1 month
postoperatively, three at 4 months
and two at 1 year. Patients who
survived longer than 1 week did not
necessarily obtain palliation from
their shunts for the rest of their
lives (Fig. 2). In some cases, pallia
tion was very brief. The majority of
patients (69%) required some form
of supplemental treatment, includ
ing repeated paracentesis, in an
attempt to control the ascites.
LeVeen and Denver shunts are
not inexpensive. On the other hand,
it is an ethical question whether
palliation for a day or a month is
worth the expense. We found that
patients receiving a shunt had a
high complication rate, adding to
morbidity, and that, generally, they

did not live long enough to benefit
substantially from the shunt.
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nostic tests are provided. These chap
ters are among the best in the book.
The fourth section deals with the
reporting of research; abstracts, oral
presentations and written presentations
are considered. There is an excellent
chapter on chairing panels, seminars
and consensus conferences, areas that
are not usually dealt with. All investiga
tors no matter how senior can learn
from this chapter.
The fifth section entitled “Interna
tional perspectives on surgical re
search” deals with contributions made
from different countries. Particularly
interesting in this section is a discus
sion of the problems of developing
clinical trials in Japan, given by Drs.
Aoki and Hioki and Muto.
The final section of the book is
concerned with opportunities and the
future of surgical research with a chap
ter written by Dr. F.D. Moore.
The book has a number of shortcom

VOL. 31, NO. 6 NOVEMBER 1988/CJS

ings. For example, a much more specif
ic and practical discussion of the train
ing of a surgical investigator would
enhance the book; it should include
such considerations as how to select a
research supervisor, how to select an
area of interest and whether or not a
higher degree should be sought. The
important subject of how to write a
research paper lacks detail; only one
paragraph is devoted to writing a dis
cussion section. There is little or no
instruction on the preparation of tables
and figures. I also found the section on
the role of the surgical investigator
somewhat negative. The categorization
of surgical investigators into “tightrope
walkers, benchmen, or occasional sur
geon-investigators” is not in my view
likely to attract young people to this
endeavour.
These criticisms do not diminish the
considerable value of this book and I
recommend it for the hospital library as

well as the individual surgical laborato
ry.
Steven M. Strasberg, MD, FRCSC
Professor o f Surgery,
Head,
Division o f General Surgery,
M ount Sinai Hospital,
Toronto, Ont.

TOTAL KNEE REVISION ARTHRO
PLASTY. Edited by W. Norman Scott.
223 pp. Illust. Grune & Stratton, Inc.,
Orlando, Fla.; Academic Press Canada,
Don Mills, Ont., 1987. $88.25. ISBN
0-8089-1864-8.

This is a timely book in the sense that
knee revision procedures are becoming
common. Unfortunately, its value is
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Is Incidental Appendectomy a Safe
Practice?
Andrus J. Voitk, MD, MSc, FRCSC; Josiah B. Lowry, MD
In an attempt to determine the safety of appendectomy performed as an incidental
procedure, the authors reviewed 853 operations (458 hysterectomies and 395
cholecystectomies) performed by five surgeons at one hospital between 1981 and
1984 and compared the results in 35% of the patients who underwent incidental
appendectomy with those in the remainder. Factors studied were operative time,
postoperative stay, postoperative fever and leukocytosis, the need for intravenous
fluids, parenteral analgesia and antibiotics, and infectious complications. Most of
these variables differed between individual surgeons, but the addition of incidental
appendectomy did not significantly alter any variable for an individual surgeon or
for the group as a whole. Incidental appendectomy seems to be a safe practice and
one that does not alter the outcome of hysterectomy or cholecystectomy but does
protect against subsequent appendicitis.

Pour tenter d'etablir l’innocuite des appendicectomies effectuees accessoirement a
une autre operation, les auteurs ont passe en revue 853 operations (458
hysterectomies et 395 cholecystectomies) pratiquees par cinq chirurgiens d’un
hopital, entre 1981 et 1984. Ils ont compare les resultats chez 35% de ces patients
qui ont subi une appendicectomie accessoire, avec ceux observes chez les autres
patients. Les facteurs etudies comprennent le temps operatoire, la duree du sejour
postoperatoire, la pyrexie et la leucocytose postoperatoires, le besoin de solutes
intraveineux, d’analgesiques et d’antibiotiques parenteraux, et les complications
infectieuses. On a constate entre les chirurgiens des differences individuelles quant
a la plupart de ces variables, mais l’appendicectomie accessoire n’a modifie aucune
des variables pour aucun des chirurgiens ou pour l’ensemble de ceux-ci. L’appendi
cectomie accessoire semble done etre une pratique sure qui ne modifie en rien les
resultats de l’hysterectomie ou de la cholecystectomie, mais qui protege d’une
appendicite subsequente.

he likelihood of appendicitis
developing decreases with age,
being approximately 20% for those
under 20 years of age, then drop
ping off abruptly to be only about
1% for those 65 years of age and
older.1 However, the death rate
from appendicitis rises with age.2

T

The rate of perforation triples after
60 years of age2 and the likelihood
of death from a perforated appendix
is three times that of an unperfora
ted appendix.3 Thus, although the
disease is less frequent in the elder
ly, its effects are much more seri
ous. In order to avoid the risks of
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appendicitis associated with increas
ing age, appendectomy performed
incidentally at the time of another
surgical procedure should be advo
cated, particularly if it carries no
increased risk to the patient.
To determine if incidental appen
dectomy is associated with undesir
able effects, we decided to review
the results obtained in a small hos
pital where incidental appendecto
my is common. Cholecystectomy
and hysterectomy were standard
and frequently performed opera
tions suitable for the study. In this
setting, incidental appendectomy
carries no monetary reward, as gov
ernment health insurance allows no
additional charge for appendectomy
carried out in the course of other
surgery.

Patients and Method
We reviewed the charts of 853
patients who underwent hysterecto
my (458 patients) or cholecystecto
my (395 patients) at Orillia Soldiers’
Memorial Hospital between 1981
and 1984 inclusive. All participat
ing surgeons claimed to use the
same three criteria for incidental
appendectomy: an uncomplicated
primary operation, a stable patient
with no contraindication to addi
tional surgery and an original inci
sion providing access to the appen
dix without need for enlargement.
For hysterectomy (Table I), done by
two gynecologists and one of the
general surgeons, only elective op
erations on nonpregnant patients
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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30% (138 of 458) with hysterecto
my and 41% (161 of 395) with
cholecystectomy. For the five sur
geons who performed the proce
dures, the incidental appendectomy
rate varied between 12% and 59% (p
< 0.05). There was one death in the
whole group; a nonogenarian man
died of cardiac causes within 48
hours of an emergency cholecystec
tomy without appendectomy. Com
parison of hysterectomy with chole
cystectomy showed close similarity
between the variables studied. With
both operations, no significant dif
ference between appendectomy and
no appendectomy was seen with
respect to any of the variables.
Of the 395 cholecystectomies
112 (28%) were classified as emer
gency. They were associated with a
significantly lower appendectomy
rate than elective cholecystectomies
(22% versus 48%, p < 0.05) (Table
II) and a significantly higher rate of
leukocytosis (37% versus 6%, p <
0.05), use of intravenous fluids
(49% versus 19%, p < 0.05) and
use of antibiotics (53% versus 15%,
p < 0.05). But again, within each
subgroup of emergency and elective
cholecystectomies there was no dif
ference between patients who did or
did not have a concomitant appen
dectomy.
Only infection rates and the inci
dence of postoperative fever were
similar for all surgeons (Table III);

were included; removal of ovaries,
cysts and fallopian tubes were con
sidered part of the procedure, if
carried out. Patients who under
went additional procedures, other
than appendectomy, were rejected.
For cholecystectomy (Table II), per
formed by three general surgeons,
no additional procedures were ac
cepted, but both elective and emer
gency (patients admitted through
the emergency department who had
their operation during the same
admission) procedures were al
lowed. The variables studied are
listed in Tables III and IV. Because
this is a retrospective study, wound
infection is recorded only when it
was listed as a complication in the
discharge summary or progress
notes, or when a procedure was
noted to be draining pus from the
wound. A deep abscess was diag
nosed when it was necessary to
drain pus from the abdominal cavi
ty. The leukocyte count was not
measured in all patients.
Differences between individual
surgeons and variables were
analysed by the x 2 test with Yates’
correction; a p value of less than
0.05 was considered significant.

Findings
The overall rate of incidental ap
pendectomy was 35% (299 of 853),

Table 1- Patients Who Underwent Hysterectomy
With appendectomy

Without appendectomy

Total

1
2
3

102
15
21

201
106
13

303
121
34

Totals

138

320

458

Surgeon

all other variables differed signifi
cantly from surgeon to surgeon,
but no significant difference in any
variable could be detected between
patients who did and did not under
go concomitant appendectomy.
There were no significant differ
ences in the results of the 853
operations. Specifically, the addi
tion of appendectomy did not in
crease the length of hospital stay,
the incidence of fever or leukocyto
sis or the need for intravenous
therapy, antibiotics or parenteral
analgesia. The 10-minute increase
in average operative time was not
significant. The superficial wound
infection rate doubled with appen
dectomy (6 of 291 versus 6 of 562,
p > 0.05); deep abscesses occurred
in three patients after appendecto
my and none in those without.
Total complications from infection
tripled after appendectomy (2 of
291 versus 6 of 562, p > 0.05).

Discussion
Ten series from this decade, re
porting over 1500 patients, did not
show a single death attributable to
incidental appendectomy, nor did
the authors report increased mor
bidity except with respect to wound
infection, where opinions differed.
Cruse4 reported an increased rate of
wound infection after cholecystecto
my when appendectomy was done
incidentally, but Strom and cowork
ers5 were unable to confirm this in a
prospective randomized study. De
spite its apparent safety, incidental
appendectomy does not enjoy uni
versal blessing. Morris and col-

Table II - Patients Who Underwent Cholecystectomy
Surgeon
no.

Elective

Emergency

Totals

Without appendectomy

With appendectomy
Combined

Elective

Emergency

Combined

Elective

Emergency

Combined
193
94
108
395

3
4
5

96
32
8

17
3
5

113
35
13

59
45
43

21
14
52

80
59
95

155
77
51

38
17
57

Totals

136

25

161

147

87

234

283

112
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leagues6 found the observed in
crease in wound infection rate fol
lowing incidental appendectomy to
be statistically insignificant, yet
they advised against the practice.
Nockerts and associates7 also ad
vised against it, at least in the
elderly, as did one-third of the
American Surgical Program direc
tors.8 Among its advocates are
Tranmer and colleagues,9 Shennib
and associates10 and Saade’s
group.11
The variable appendectomy rate
(12% to 59%) between individual
surgeons in our study suggested
that surgeons had used additional
selection criteria to those listed or
that their application had varied
markedly. When we questioned the
surgeons, drawing attention to this
wide variation, one surgeon admit
ted to an underlying wish to finish
the operation quickly and another
had concerns about litigation in the
event of mishap. Not surprisingly,
the incidental appendectomy rate
for both these surgeons was lowest
for the group at 12%. If their rates
were eliminated, the difference lost
its significance.
Clearly, application of the selec
tion criteria favoured the better op
erative candidates for appendecto
my. Thus, the two groups are not
necessarily comparable. The pa
tients who had appendectomy
would be expected to do well, so it
is not surprising that they fared as
well as the others.
This study demonstrates that in
cidental appendectomy, as practised
in the clinical setting using the
selection criteria outlined, seems
safe. To obtain a “true” picture of
the contribution of appendectomy, a
prospective randomized study
would be required with full disclo
sure to the patient. Such a study
would have to eliminate individual
variations of practice by having the
operation totally standardized; post
operative care would also need to be
450

standardized and provided by some
one other than the operating sur
geon. Our study suggests that the
negative contribution of appendec
tomy is so small when measured
against the concomitant primary
operation, that such a complicated
study is not warranted.
Most investigators have failed to
show any significant difference in
patient outcome by the addition of
incidental appendectomy, with the
possible exception of complications
due to infection. In our study, both
superficial and deep infection was
more frequent after incidental ap
pendectomy. Although this differ
ence was not significant, a study
with greater numbers might show
this to be a “true” observation. The
potential risk of infection must be
weighed against the potential gain
when deciding to carry out appen

dectomy at the time of another
procedure.
The most objective variable stud
ied was postoperative fever. Body
temperature was recorded every day
for all patients by a reliable and
disinterested observer (the nurse).
There was no significant difference
in the occurrence of fever between
any of the patients. Despite marked
individual variation in other areas,
fever rates did not vary significantly
between individual surgeons. Leu
kocytosis was a variable that might
be expected to be objective. Howev
er, since it was not measured on all
patients, the difference probably re
flects the degree to which individual
surgeons requested this measure
ment. A difference in operative time
would be expected, and postopera
tive stay also seemed to vary with
the individual surgeon’s routine.

Table III - Maximal Surgeon Variation
Average values
Variable
Incidental appendectomy, %
Average operative time, min
Average postoperative stay, d
Fever, %
Leukocytosis, %
Intravenous fluids > 24 h postop, %
Parenteral analgesia > 48 h postop, %
Antibiotics > 24 h postop, %
Total infection rate (wound and deep
abscess), %

All
surgeons

Lowest
individual

34
74
6.3
42
12
15
23
18
2

12
62
4.7
25
0
7
5
5
0

Highest
individual
59
101
8.1
53
25
47
29
27
5

p value*
<0.05
<0.05
< 0.05
> 0.05
< 0.05
< 0.05
< 0.05
<0.05
> 0.05

‘ Difference between highest and lowest.
Table IV - Comparison of Average Values for All Patients
Average values

Variable
Incidental appendectomy, %
Average operative time, min
Average postoperative stay, d
Fever, %
Leukocytosis, %
Intravenous fluids > 24 h postop, %
Parenteral analgesia > 48 h postop, %
Antibiotics > 24 h postop, %
Wound infection rate, %
Deep abscess incidence, %
Total infection rate (wound and
abscess), %

All
With
Without
patients, appendectomy, appendectomy,
n = 853
n = 291
n = 562
34
74
6.3
42
12
15
23
18
1
0.4
2

100
81
6.3
37
9
15
22
15
2
1
3

0
71
6.3
45
13
15
23
19
1
0
1

p value
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
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Similarly, use of intravenous fluids,
antibiotics and parenteral analgesia
seemed more a function of individu
al practice than operative procedure
or patient need.
Awareness of individual practice
is important in clinical studies. For
example, although the appendecto
my rate for each surgeon perform
ing cholecystectomies was less in
the emergency situation, the differ
ences were not significant. Yet,
when all emergency cholecystecto
mies were compared with all elec
tive ones, the lower appendectomy
rate in the emergency situation was
significant. This can be explained
by the fact that the surgeon with
the lowest appendectomy rate con
tributed over half the emergency
cholecystectomies, whereas the sur
geon with the highest appendecto
my rate contributed over half of the
elective cholecystectomies.
Regardless of significant differ

ences observed between individual
surgeons, the addition of appendec
tomy to hysterectomy or cholecys
tectomy in our study made no sig
nificant difference to any measured
variable for any surgeon and thus
had no significant effect on patient
outcome. It appears to be an effec
tive and safe prophylaxis against
appendicitis, its application seeming
to depend on individual judgement
and training. The only caveat is a
potential increase in infection. De
spite its apparent safety, increasing
litigation in this country may make
this practice less appealing in the
future.
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limited, having been written by the
“cement is best, now and forever”
school of knee replacement.
The quality of the chapters varies.
Some, such as Dohr’s on the mecha
nisms of failure of prostheses, are quite
good. Some contain information that,
while technically correct, is downright
dangerous. Craig, a plastic surgeon, has
written a good chapter on skin grafting
around the knee, but states that “a
lateral or medial parapatellar incision,
even when very long, can safely co-exist
with the midline approach to the knee”.
Early in my experience I tried this and
in two patients lost the skin off the
front of the knees. I believe that the
majority of surgeons doing this proce
dure would advise using the old inci
sion, even if the placement is suboptimal.
Another curious chapter deals with
massive defects in the femur on remov
ing ingrowth-type prosthetic compo
nents. The authors’ technique seems to
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be to lock on a large slap hammer and
batter out the component. If the femo
ral component is well fixed, it is not
surprising that they pull out a lot of
bone, indeed it is surprising that they
don’t pull off the whole distal femur.
Fortunately, in a later chapter, other
authors indicate the appropriate way to
remove these implants.
There is no mention in the book of
stress shielding or stress relief os
teoporosis which is an important factor
in knee revisions. Takedown of a knee
fusion is mentioned briefly, and it is
stated that a constrained prosthesis is
always required. This is definitely not
the case.
Hinges and fixed axis prostheses are
condemned, the preferred alternatives
being a total condylar III or a custom
prosthesis. Custom implants cost at
least $5000. so they really have no
market outside the United States. The
only noncustom prosthesis with huge
stems is the Guepar II hinge. If the

ligaments do not help to stabilize the
knee, then stability comes from the
prosthetic components. The interface
between bone and implant therefore
sees roughly the same loads whether or
not the implant is a true hinge or an
unlinked hinge such as the total condy
lar III. This would seem reasonably easy
to understand, but the authors seem to
have a conceptual block on this subject.
In spite of this book, I recommend that
any surgeon doing a knee revision have
a Guepar II hinge on the back table,
just in case it is needed.
The target audience for this book is
not obvious, except perhaps the ortho
pedic residents in New York and Bos
ton.
Hugh U. Cameron, MB, ChB, FRCSC
Ste. 318,
43 Wellesley St. E,
Toronto, Ont.
M4Y1H1
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Doctor or Mister (the Correct Appellation
of British Surgeons)
Philip Eibel, MD, FRCSC
The form of address for British surgeons — “Mister” instead of “Doctor” — has
mystified other members of the medical profession for years. The author attempts to
show that the designation “Mister” is neither an affectation nor a denigration but a
natural consequence of the history of British barbery, barber-surgery and ultimately
surgery, resulting from the advice and tutelage of King Henry VIII and Parliament.

Le titre do® e aux chirurgiens 1 itanniques, “Monsieur” plutot que “Docteur”,
continue, depuis des annees, ? aisser perplexes les autres membres de la profession
medicale. L’auteur tente de d.montrer que la designation “Mister” n’est pas utilisee
par affectation et qu’elle n’a pas de connotation pejorative, mais qu’elle decoule
plutot de l’Histoire des barbiers, barbiers-chirurgiens et, ultimement, chirurgiens
britanniques, consequence de l’avis et de la tutelle du roi Henri VIII et du
Parlement.

urgeons from the United States
and Canada visiting hospitals in
Great Britain find it difficult to
understand why their British col
leagues are referred to as “Mister”
and not “Doctor”. After many ardu
ous years of study to acquire the
much-coveted fellowship in surgery
it can be disconcerting to address
similarly qualified British colleagues
by the seemingly lowly title of “Mis
ter” . Actually, “Mister” is not a
denigration, and British surgeons
may even be offended if addressed
as “Doctor”. But why the differ
ence from almost universal prac
tice?
Despite personal communication
with the Royal College of Physi
cians and Surgeons of England
(January 1987) and with the Well
come Institute for the History of

S

Medicine (March 1987), I could not
find documentation of the origin of
this British custom. This appella
tion may have arisen from events
that began when surgery and barb
ery were first recognized as arts and
vocations in Britain.
After the dissolution of the
Roman Empire, the little surgery
that continued to be carried out in
Europe was to be found only in
monasteries,1 where monks and
their assistants, the barbers, carried
on the almost forgotten art of sur
gery bequeathed to them by the
Greeks and Romans. In addition to
clipping hair and shaving, barbers
helped the monks with more com
plicated tasks such as blood-letting,
believed to be the origin of the
colours on the barber’s pole — red
stripes representing blood and
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white, the bandages used for
stanching.
In 1123 AD, Pope Calistas II
decreed that monks must not shed
blood. This ruling gave an extraor
dinary boost to the barbers who
now performed, in addition to their
regular chores, more complicated
procedures such as tooth-pulling,
blood-letting and treatment of frac
tures. Because of this, barbers now
became known as barber-surgeons
and, in keeping with the Pope’s
orders, monks ministered only to
the souls of patients; their guiding
principle was Ecclesia abhorret a
sanguine (the Church abhors the
shedding of blood).2 Even so, they
continued for a long time, as ob
servers and advisers, to impart their
superior knowledge of surgery.
Originating at about the same
time as the barber-surgeons was a
more exalted but less numerous
group, the “pure” surgeons. They
were more skilled than the barbers
but were likewise unlettered, manu
al workers. They were apprenticed,
not university trained and, unlike
physicians, could not speak Latin.
Because they had no university de
gree, they could not style them
selves as “Doctors” .
In 1423, an attempt was made to
improve the practice of medicine by
forming a conjoint college of the
university trained physicians and
apprentice-trained surgeons;3 the
barber-surgeons were excluded. The
association survived only 1 year,
probably because of the opposition
of barber-surgeons who were afraid
VOL. 31, NO. 6 NOVEMBER 1988/CJS
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of losing their control of the field of
surgery, or perhaps because of the
tendency of physicians to look
down upon the surgeons.3
In 1493, the surgeons decided to
enter into a working agreement
with the barber-surgeons regarding
their respective spheres of influence
in the practice of surgery and barb
ery.4 However, encroachment on
each other’s territory led to bicker
ing. Surgeons were not above hair
clipping and barbers would occa
sionally dabble in surgery.
In 1540, Henry VIII, by act of
Parliament, completed and extended
the particulars, uniting the two
groups under the name of the
“Masters, Governors, of the Mys
tery and Commonalty of Barbers
and Surgery of London” .5 Hence
forth, by royal edict, the barbers
could engage only in barbery and
the drawing of teeth; surgeons had
to abstain from cutting hair and
shaving. This association was main
tained for over two centuries, until
1745.
The advantages of union were
mutual. The surgeons, who were a
more select body though fewer in
number, helped to raise the prestige
of the barber-surgeons. The latter
group, more numerous and more
affluent, had their own hall (the
Barbers’ Hall), where lectures were
given in anatomy and surgery,46
thus perfecting and advancing the
art of surgery.
King Henry VIII gave each mem
ber of the newly formed group the
right to be addressed as “Master.”
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In time, according to the New En
glish Dictionary on Historical Prin
ciples, “Master” was pronounced
“Mister” .7 Skeat, in his Etymologi
cal Dictionary o f the English Lan
guage8 adds that “ Mister” is a back
formation from “Mistress” , the
feminine for “Master” . It seems,
therefore, that when a British sur
geon is addressed as “Mister” he is
actually being honoured — in reali
ty he is being called “Master” .
The union of barbers and sur
geons lasted until 1745 when the
latter petitioned Parliament to effect
a separation.
From this date, although they
had been instrumental in reviving
and spreading the knowledge of
anatomy and surgery, the place of
barber-surgeons was gradually
taken over by surgeons. The bar
bers and barber-surgeons became
an honourable, benevolent organi
zation to which leading surgeons of
England are now proud to belong.
They hold bimonthly Court dinners
and maintain the traditions of the
old barber-surgeons. Only one-third
of them are members of the medical
profession. They are now a charita
ble foundation, dispensing bursaries
for deserving boys and girls and
pensions to retired barbers and to
nurses in need. They provide study
grants for the history of surgery.
The Cutting Edge,9 a detailed histo
ry of the early surgeons, was writ
ten in 1974 by a non-medical mem
ber, Theodore R. Beck, who is an
architect and antiquarian.
The original beautiful Barbers’

Hall was destroyed by incendiary
bombs in 1940. It contained many
treasures, including the painting by
Holbein of King Henry VIII and the
barber-surgeons. It was rebuilt and
was reopened in 1969 by Her Maj
esty the Queen Mother who grace
fully accepted honorary member
ship in the Worshipful Company of
Barbers.10
With these romantic traditions
stemming from a time when surgery
in Britain was in its infancy, it is
easy to see why British surgeons
adhere tenaciously to the salutation
of “Mister”.
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Progess in Clinical and Biological Re
search, Volume 277. Advances in Urologic Oncology. Edited by Nasser Ja-

vadpour and Gerald P. Murphy. 150 pp.
Illust. Alan R. Liss, Inc., New York,
1988. $48.00 (US). ISBN 0-84515127-4.

Reconstruction Surgery and Trauma
tology, Volume 20. GentamicinPMMA-Chains in Bone and Soft-Tissue
Infections. Edited by H. Eberle. 122 pp.

Illust. S. Karger AG, Basel, 1988.
$73.50 (US). ISBN 3-8055-4603-3.
Revascularization for the Ischemic
Brain. Edited by Donald L. Erickson.

294 pp. Illust. Futura Publishing Co.,
Inc., Mount Kisco, New York, 1988.
$45.00 (US). ISBN 0-87993-320-8.
Vascular and Multi-Infarct Dementia.

Edited by John Stirling Meyer, Helmut
Lechner, John Marshall and James F.
Toole. 276 pp. Illust. Futura Publishing
Co., Inc., Mount Kisco, New York,
1988. $39.00 (US). ISBN 0-87993323-2.
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(for each insertion): $42.00 for the first 40 words or less, additional words 55d each
(additional $16.00 for frame). Special Display under 75 words, 2 lA in. X 2 in., $105.00. $6.00
charge (first insertion only) for CJS box numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario
K1G 0G8.
SURGICAL DIRECTOR OF LIVER TRANS
PLANTATION: BC — the Department of Sur
gery at the University of British Columbia and
the British Columbia Transplant Society are
seeking a surgical director of liver transplanta
tion for a newly established provincial multi
organ transplant program. This is a geographic
full-time tenure track position with salary com
mensurate with faculty rank. This individual
must be fully trained in liver transplantation with
at least one year of post-fellowship experience
in an established program, have a proven re
cord of independent research and possess the
technical, organizational and academic skills
which would enable him/her to develop and
lead an integrated clinical/academic program.
An opportunity exists to oversee the develop
ment of additional programs in intestinal and
multi-visceral transplantation. The British Co
lumbia transplant program is fully funded for
clinical operation and equipped with the neces
sary surgical and laboratory research space. In
accordance with Canadian immigration require
ments, this advertisement is directed to Canadi
an citizens and permanent residents. Starting
date is January 1, 1989. Closing date is De
cember 1st, 1988, or until a suitable applicant
is chosen. Apply, enclosing curriculum vitae to:
Dr. Paul Keown, director, BC Transplant
Society, Room 8, Heather Pavilion, 855
West 12th Ave., Vancouver, BC V5Z 1 M9.
-S88-43
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GENERAL SURGEON: ON - An opportunity
exists for a general surgeon to join the staff of
the Oakville-Trafalgar Memorial Hospital. At
present there are 4 general surgeons in this fully
accredited 330-bed hospital. Please reply to:
Dr. G. Lloyd, Department of Surgery. Oak
ville-Trafalgar Memorial Hospital, 327 Reyn
olds St., Oakville, ON L6J 3L7.
-S88-38
HEAD, DIVISION OF UROLOGY: BC - The
Department of Surgery at the University of
British Columbia is seeking an academic head
for the Division of Urology, University of British
Columbia and Vancouver General Hospital. This
is a geographic full-time tenure track position
with salary commensurate with qualifications
and experience, the successful candidate must
hold FRCSC qualifications with specialty training
in urology and sufficient academic experience
with a background in research. In accordance
with Canadian immigration requirements, priori
ty is given to Canadian citizens and permanent
residents. Other candidates will be considered
if no suitable candidate is found. Starting date is
January, 1989. Closing date is December 1st,
1988, or until a suitable applicant is chosen.
This position is subjected to final budgetary
approval. Apply, enclosing curriculum vitae to:
Dr. A. D. Courtemanche, acting head. De
partment of Surgery, 9 10 W 10th Ave., 3rd
Floor, Vancouver, BC V5Z 4E3.
-S88-42
BIOGRAPHY: - Material for biography of the
late Professor J. C. Grant required. Personal
memoirs, anecdotes, photographs, welcome.

Information treated with discretion and material
returned promptly. Reply to: Dr. Clayton Rob
inson. 8 0 8 - 7 50 W Broadway, Vancouver,
BC V5Z 1 H7.
-S88-39

HAND SURGERY FELLOWSHIP: ON Available, starting July 1, 1989. For infor
mation contact: The office of Dr. J. H.
Roth, (FRCSC), 345 Westminster Ave.,
London, ON N6C 4V3 Tel: (519)
4 3 9 -0 7 0 1 .
-S88-40

GENERAL SURGEON: NT - The board is
seeking a general surgeon to join a medical staff
of seven physicians, to function as a team
member in an isolated location. The Baffin
Regional Hospital is located in Iqaluit (Frobisher
Bay) on Baffin Island. The hospital acts as a
referral centre for 12 outlying health centres in
the eastern arctic and serves a total population
of 10 000. The candidate is required to under
take cesarian sections, general surgery, emer
gency trauma and some general practitioner
clinical sessions. Surgical specialists - ENT,
GYNE, ORTHO visit on a regular basis from
McGill University affiliated hospitals. Candidates
for this position will preferably be FRCSC and
be eligible for licensure in the Northwest Terri
tories. Competitive salary, generous incentive
bonus. Benefits: housing allowance, vacation
travel assistance, paid educational leave, re
location expenses, dental, pension and insur
ance plan. Furnished accommodation. Closing
date to remain open until suitable candidate is
recruited. Please send resume to: Chief Execu
tive Officer, Head office, Baffin Regional
Health Board, Bag 200, Iqaluit, NT XOA
OHO.
-S88-41
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A HELPING HAND FROM
JOHNSON & JOHNSON
Using sterile scissors, cutting gauze sponges and removing loose threads the
sponge may have left in the w ound... not the most convenient use of your time!
Convenience, safety and patient comfort were precisely our main objectives in
designing and developing special pre-cut drain sponges.
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tracheostomy and drain sponges,
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in Canada.
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NU GAUZE* sponges are preferred over ordinary
gauze sponges because they:

• Are more absorbent
• Are virtually lint-free
and non-fraying
• Adhere less to wounds
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• Are softer

rs
PELER VERS LE BAS

PELER VERS LE BAS

PEEt^RlOWN

PEE^^JOWN

PELER VERS LE BAS
PEE^OW ,

j^ o m p r e s s e s

| c o m p r e s s e s p o u r d r a in s

I

NU GAUZE

NU GAU ZE

1 tracheostom y sponge

r

NU GAUZE

■ d ra in gn n n n w s —

iL._
' .

1■

! ,.U,

1:

L"

‘ T r a d e m a r k of
JOHNSON & JOHNSON

polyglyconate monofilament absorbable suture

The multi-faceted
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